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“Rôle de la protéine associée aux microtubules ATIP3 dans la 
migration cellulaire et la formation de métastases du cancer du sein” 
 
 
Le cancer du sein touche une femme sur huit dans le monde et représente un problème 
majeur de santé publique. Alors que la majorité des tumeurs du sein sont aujourd’hui la 
cible de traitement efficaces, il reste une sous-population de tumeurs (dites triple-
négatives) à fort potentiel métastatique qui ne sont pas accessibles aux thérapies ciblées 
et demeurent de mauvais pronostic. L’élucidation des processus impliqués dans la 
progression tumorale et la formation de métastases reste un challenge majeur dans la 
recherche de nouvelles thérapies contre le cancer du sein de mauvais pronostic.  
ATIP3 (AT2-interacting protein 2), produit du gène candidat suppresseur des tumeurs 
MTUS1 (Microtubule-Associated Tumor Suppressor), a été identifiée par le laboratoire 
comme étant un biomarqueur des tumeurs du sein les plus agressives. En effet, les 
résultats précédents de notre équipe ont montré que l’expression d’ATIP3 est diminuée 
dans 85% des tumeurs de haut grade, 83% des tumeurs triples négatives et dans 62% des 
tumeurs métastatiques. Il a également été montré qu’ATIP3 inhibe la prolifération 
cellulaire in vitro, ainsi que la croissance tumorale in vivo. Au niveau moléculaire, ATIP3 a 
été identifiée comme étant une nouvelle protéine associée aux microtubules (MAP) 
localisée au centrosome, le long de microtubules dans les cellules en interphase, au 
fuseau mitotique pendant la division cellulaire et au pont intercellulaire lors de la 
cytokinèse. La localisation cellulaire d’ATIP3, étroitement associée aux microtubules, 
prend toute son importance du fait du rôle de ce cytosquelette dans la division et 
migration cellulaire, deux étapes essentielles du processus tumoral. 
Mon projet de thèse a pour objectif principal d'évaluer le rôle potentiel d'ATIP3 dans la 
migration cellulaire et la formation de métastases tumorales.  
 
Dans un premier temps, les niveaux d’expression d’ATIP3 ont été analysés dans des séries 
de puces à ADN issues de trois cohortes indépendantes de patientes atteintes d’un cancer 
du sein invasif, et les données ont été comparées avec les caractéristiques cliniques des 
patientes. Ces analyses transcriptomiques ont permis de montrer que l’expression d’ATIP3 
est un marqueur pronostic de la survie des patientes et de façon intéressante, qu’ATIP3 
est un nouvel indicateur de la progression métastatique.  
L’effet d’ATIP3 sur la progression des métastases a alors été évalué dans un modèle de 
bioluminescence in vivo, ce qui a permis de montrer que cette protéine est une molécule 
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anti-métastatique qui réduit la progression, le nombre et la taille des foyers 
métastatiques. La colonisation métastatique inclut la migration des cellules cancéreuses à 
travers la matrice extracellulaire (invasion) et l’endothélium vasculaire (extravasation), 
puis leur prolifération au site secondaire. L’évaluation détaillée de ces étapes a montré 
qu’ATIP3 diminue tous ces processus. En ce qui concerne la migration, une réduction de 
vitesse, de la direction de migration et possiblement de la polarité cellulaire, pourraient 
expliquer les effets inhibiteurs d’ATIP3 sur la migration des cellules.  
Comme de nombreuses études ont démontré que la migration et la polarité cellulaires 
dépendent du cytosquelette de microtubules, je me suis intéressée aux effets d’ATIP3 sur 
la dynamique microtubulaire. Des expériences de vidéomicroscopie ont permis de 
montrer que l’extinction d’ATIP3 augmente la dynamique des microtubules en 
incrémentant les épisodes et la vitesse de croissance et en diminuant le temps passé en 
pause et la fréquence des catastrophes. Ces résultats, couplés à des expériences de 
dépolymérisation et de re-croissance ont permis de conclure qu’ATIP3 est une MAP qui 
stabilise les microtubules et diminue leur dynamique pour contrôler la polarité et la 
migration cellulaires. L’ensemble de ces travaux font l’objet d’une publication parue en 
2013 (Molina et al., Cancer Res 73, 2905). 
Dans une seconde partie de mon travail, je me suis intéressée à la protéine EB1 (End-
Binding 1), protéine majeure des bouts croissants des microtubules qui sert de plate-
forme au recrutement de protéines régulatrices appelées +TIP (plus end tracking protein) 
et qui induit la croissance persistante des microtubules en diminuant la fréquence des 
catastrophes. L’analyse de la séquence d’acides aminés d’ATIP3 a révélé que cette 
protéine possède trois motifs consensus potentiels d’interaction à EB1. En utilisant la 
technique de GST pull-down, l’interaction entre ATIP3 et EB1 a été mise en évidence via 
un domaine appelé CN, qui se trouve dans la partie centrale d’ATIP3. Cette interaction est 
directe et fait intervenir un motif protéique un peu atypique (RPLP) sur la séquence 
d’ATIP3. De façon intéressante, nous avons pu montrer que des mutants de délétion 
dépourvus du domaine (ou du motif) d’interaction à EB1 ne sont plus capables de 
délocaliser EB1 de l’extrémité dynamique des microtubules, indiquant que l’interaction 
entre ATIP3 et EB1 est essentielle aux effets d’ATIP3 sur l’accumulation d’EB1 aux bouts 
plus. 
Dans le but de mieux comprendre la fonctionnalité de l’interaction entre ATIP3 et EB1, 
nous avons recherché la présence de complexes moléculaires à l’intérieur de la cellule. De 
façon étonnante, contrairement à la plupart des protéines interagissant avec EB1, ATIP3 
ne s’accumule pas au bout dynamique et reste plutôt localisée au réseau de microtubules. 
Des expériences de PLA (Proximity Ligation Assay) réalisées à l’aide d’anticorps anti-ATIP 
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et anti-EB1 ont montré que l’interaction se produit majoritairement dans le cytoplasme et 
que les complexes ATIP3/EB1 se retrouvent également associés tout le long du 
microtubule.  
Sur la base de ces résultats, un modèle a été proposé. Dans ce modèle, l’interaction entre 
ATIP3 et EB1 dans le cytosol pourrait réduire la concentration d’EB1 disponible à proximité 
du microtubule, avec pour conséquence de limiter sa diffusion dans le cytosol et de 
réduire sa dynamique d’interaction avec les bouts des microtubules. Selon ce modèle, en 
absence d’ATIP3 les protéines EB1 pourraient diffuser librement dans le cytosol et 
s’accumuler en plus grand nombre à l’extrémité du microtubule, avec pour conséquence 
d’augmenter la dynamique microtubulaire. In fine, l’interaction d’ATIP3 avec EB1 pourrait 
ainsi rendre compte des effets anti-prolifératifs, anti-migratoires et anti-métastatiques 
d’ATIP3. 
L’importance clinique de ce modèle en pathologie humaine a été testée en évaluant les 
niveaux d’expression d’ATIP3 et EB1 dans des tumeurs de patientes atteintes d’un cancer 
du sein invasif. Les résultats extraits de l’analyse par puces à ADN ont montré que les 
niveaux relatifs d’expression des protéines ATIP3 et EB1 ont valeur pronostic de la survie 
des patientes. Ainsi, les patientes atteintes de tumeurs ayant des niveaux élevés d’EB1 et 
bas d’ATIP3 présentent un mauvais pronostic clinique par comparaison avec les tumeurs 
ayant des niveaux faibles d’EB1 et ATIP3. D’après notre modèle, une tumeur avec une 
expression élevée d’EB1 et une faible expression d’ATIP3 présenterait un défaut de 
stabilisation d’EB1 dans le cytosol, avec comme conséquence un nombre élevé de 
molécules d’EB1 libres capables de s’accumuler aux bouts plus des microtubules pour 
favoriser la dynamique des microtubules et la progression tumorale. Cette seconde partie 
de mon étude fait l’objet d’un article actuellement en cours de révision (Velot*, Molina* 
et al., first co-authors) 
Dans une troisième partie de cette thèse, je présente les données préliminaires que j’ai 
obtenues, montrant qu’ATIP3 interagit avec d’autres +TIPs telles MCAK (Mitotic 
Centromere-Associated Kinesin) et APC (Adenomatous Polyposis Coli). MCAK est une 
kinésine qui s’associe aux bouts des MTs via EB1 et est impliquée dans la 
dépolymérisation des microtubules, et le contrôle de la dynamique microtubulaire. La 
protéine APC, quant-à elle, est un partenaire majeur d’EB1 qui s’accumule également aux 
bouts plus des microtubules et est impliquée dans la formation de microtubules stables 
lors de la migration cellulaire. La fonction des complexes d’interaction ATIP3/MCAK et 
ATIP3/APC reste encore à déterminer. 
En conclusion, ces travaux de thèse ont permis d’identifier ATIP3 comme étant une 
nouvelle molécule anti-migratoire et anti-métastatique, qui interagit avec EB1 et régule la 
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dynamique des microtubules. A l’avenir il sera nécessaire de clarifier le mécanisme 
d’action par lequel ATIP3 régule la dynamique des MTs en interphase et pendant la 
mitose, et de déterminer si cette régulation est dépendante de l’interaction d’ATIP3 avec 
EB1, MCAK et APC. De plus, le rôle d’ATIP3 sur la polarité devra être approfondi, en 
analysant l’effet de cette protéine sur la dynamique de l’actine ou l’activation des petites 
protéines G (Rho, Rac et Cdc42). Ces travaux devraient permettre de mieux comprendre 
les mécanismes d’action intracellulaires d’ATIP3 et de déterminer comment la perte 
d’ATIP3 est associée à un processus cancéreux, dans le but à terme d’envisager un 
nouveau traitement personnalisé contre les tumeurs de sein métastatiques ayant perdu 
l’expression d’ATIP3. 
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1. Breast Cancer 
 
1.1. Anatomy of the breast 
Mature female breast is mainly composed by glandular tissue, adipose tissue, blood 
vessels, lymphatic vessels, and nerves, all surrounded by a supportive structure of 
connective tissue (Figure 1) (Hassiotou F & Geddes D, 2013). 
Lobules or mammary glands are structures involved in milk production during pregnancy 
and lactation. Several lobules can group together to form lobes, which organize around 
the nipple in a “wheel spoke” shape. Lobes deposit milk into the collecting ducts that go 
through the breast until it opens at the nipple surface (Cooper AP, 1840; Hassiotou F & 
Geddes D, 2013). 
Surrounding the lobes are the fat pad and the connective tissue which bring support to 
the ducts and lobules. Cooper’s ligaments connect the chest wall muscle and the skin 
overlaying the breast to hold the breast and maintain the structural integrity (Cooper AP, 
1840; Hassiotou F & Geddes D, 2013). 
 
Figure 1.  
Schematic representation of the mammary gland (Modified from Mannello F et al. 2008). 
 
1.2. Histology of the mammary gland 
The mammary gland is a complex structure constituted by different cell types which 
generate a network of branching ducts inside the fibrous collagen- and adipose-rich 
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stromal matrix (Figure 2). This structure includes epithelial and endothelial cells as well as 
fibroblasts and adipocytes (Neville MC & Daniel CW, 1987; Schmeichel KL et al. 1998). 
 
Figure 2 
Low magnification of a normal breast tissue. Shown are the ducts, a lobule and the stroma (Modified from Wilson R, 
2006). 
 
1.2.1. Epithelial cells 
Luminal and myoepithelial cells are the two major epithelial cell types present in the 
mammary gland. Luminal cells isolate and line the ductal lumen and alveoli, forming an 
inner continuous layer. These cells are characterized by their cuboidal shape, basoapical 
polarization and by the presence of apical microvilli (Figure 3) (Schmeichel KL et al. 1998; 
Visvader JE, 2009; Vidi PA et al. 2013; Hassiotou F & Geddes D, 2013). On the other hand, 
myoepithelial cells compose the outer or basal layer. They form a discontinuous line 
behind the luminal cells (Figure 3) and have properties of smooth muscle cells (Hassiotou 
F & Geddes D, 2013). 
The mammary gland is involved in milk production and delivery, and these functions are 
accomplished by epithelial cells. Differentiation of luminal cell into lactocytes allows milk 
production during lactation, and contraction of myoepithelial cells allows the milk flow 
into the ducts (Visvader JE, 2009; Vidi PA et al. 2013; Hassiotou F & Geddes D, 2013). 
Epithelial cells (luminal and myoepithelial) express estrogen (ER), progesterone (PR) and 
androgen (AR) receptors at their surface. It has been reported that these three steroid 
hormones play a key role in the development and function of the mammary gland (Li S et 
al. 2010). 
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Figure 3 
The mammary epithelium. (A) Schematic representation of the epithelium (luminal epithelial cells, myoepithelial cells 
and basal membrane) surrounded by the fibrous and fatty stromal compartment. (B) High magnification of a normal 
breast tissue. Shown are the epithelium and stroma. Panel B is from Wilson R, 2006. 
 
Within the basal layer, bi-potent mammary stem cells (MaSC) can be found. MaSC are 
undifferentiated cells which give rise to progenitors that in turn can differentiate into 
luminal and myoepithelial cells (Figure 4) (Prat A & Perou CM, 2009; Visvader JE, 2009; 
Hassiotou F & Geddes D, 2013). It has been suggested that transformation of MaSC at the 
different stages of differentiation can be the origin of each breast cancer molecular 
subtype (Prat A &Perou CM, 2009; Visvader JE, 2009). This will be discussed in chapter 
1.3.4.1. 
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Figure 4  
Human mammary epithelial hierarchy from the mammary stem cell (MaSC) until the latest differentiation stage into 
myoepithelial and luminal cells (From Prat A & Perou CM, 2009). 
 
1.2.2. The mammary stroma 
The mammary stroma is a highly fibrous and complex structure that is separated from the 
epithelial tissue by the basement membrane (BM). The BM is a special form of 
extracellular matrix (ECM) which is mainly composed of collagen IV and laminins, which 
are synthetized by myoepithelial and stromal cells, and connected by nidogen and 
perlecan (Schmeichel KL et al. 1998; Nelson CM & Bissell MJ, 2006; Rowe RG & Weiss SJ, 
2008; Vidi PA et al. 2013). 
The stroma includes (i) an adipose-rich fat pad which mainly gives support to all the other 
stromal components; (ii) blood and lymphatic vessels that provide immune surveillance, 
lymphatic drainage and accomplish an important function during lactation, delivering 
nutrients and removing of the waste metabolites; and (iii) an extracellular matrix-rich 
environment where epithelial cells grow, differentiate and regress (Schedin P & Hovey RC, 
2010). 
The cellular content of the stroma is mainly composed by endothelial cells, pericytes, 
fibroblasts and leukocytes, which will play an important role during cancer progression 
due to cross-talk and close interactions with tumor cells (for review Pietras K & Ostman A, 
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2010). Nevertheless, the interaction of tumor cells with the stroma will not be described 
here. 
 
1.3. Breast Cancer 
1.3.1. Cancer generalities 
Cancer is the leading cause of death worldwide, accounting for 8,2 million of deaths in 
2012 mainly by lung, liver, stomach, colorectal, breast and esophageal cancer (GLOBOCAN 
2012, IARC). 
Cancer is a complex process which can be divided in three phases: tumor initiation, cancer 
progression and metastasis formation. Hanahan D and Weinberg RA (2011) described the 
hallmarks of cancer as eight biological properties that are acquired during the 
development of human tumors. These include sustaining proliferative signaling, evading 
growth suppressors, evading immune destruction, enabling replicative immortality, 
activating invasion and metastasis, inducing angiogenesis, resisting cell death and 
reprogramming of energy metabolism. Underlying these hallmarks are genomic instability 
and inflammation which favor cancer progression (Figure 5). 
 
Figure 5 
Hallmarks of cancer (From Hanahan D and Weinberg RA, 2011). 
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Tumors can initiate at any part of the body. According to this initial location, cancer can be 
classified in five broad categories: Carcinoma (affects epithelial cells and accounts for 85% 
of all cancers), sarcoma (bone, cartilage, fat, muscle, blood vessels, connective or 
supportive tissue), leukemia (blood-forming tissue as the bone marrow), lymphoma and 
myeloma (cells of the immune system) and central nervous system cancer (brain and 
spinal cord) (National Cancer Institute, NIH). 
Metastasis is a fatal complication of cancer and the leading cause of death by this disease. 
It is a multistep process that includes the spreading from the primary site to another 
organ in the body to form a secondary tumor in a tissue-specific manner. The metastatic 
process will be reviewed in chapter 2. 
 
1.3.2. Breast Cancer Epidemiology 
Breast cancer is the most common diagnosed cancer in woman worldwide, being detected 
in 140 of 184 countries during 2012. In this same year, more than 1,5 million (11,9%) of 
new cases were reported and around 520.000 patients died from this disease (Ferlay J et 
al. 2013). According to the IARC last reports in 2008, breast cancer incidence and mortality 
have increased by 20% and 14%, respectively (Figure 6A, 6B) (GLOBOCAN, 2012). 
Increased incidence was higher in developed countries as compared with less developed 
ones. Nevertheless, mortality rates were higher in less developed countries mostly due to 
the late detection and difficulties to access to treatment (Figure 6A, 6B) (GLOBOCAN, 
2012). 
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Figure 6 
Age-standardized incidence (A) and mortality (B) rates for breast cancer in women worldwide in 2012. Color intensities 
indicate incidence (blue) and mortality (red) rates per 100.000 (From GLOBOCAN 2012). 
 
1.3.3. Breast Cancer Classification 
Until 2003, breast cancer classification relied on histological appearance of breast tumors 
and allowed to distinguish between two major groups: in situ carcinomas and invasive 
breast cancer. 
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In situ carcinoma refers to tumors that do not spread to the surrounding tissue and whose 
proliferation does not rip the basal membrane. This type of carcinoma can be, as well, 
subdivided in two: ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). 
DCIS is the most frequent type of in situ carcinomas and makes reference to the presence 
of tumoral cells inside the milk duct (Figure 7A). High grade DCIS could turn into invasive 
breast cancer if left untreated. On the other hand, LCIS (also known as lobular neoplasia) 
refers to the presence of abnormal cells inside the breast lobules or milk glands (Figure 
7B). LCIS is considered as a marker of increased risk of developing invasive breast cancer; 
in fact, women with LCIS have an eightfold to tenfold increased risk of invasive breast 
cancer (Portschy PR et al. 2013). 
 
Figure 7 
Schematic representation of (A) Ductal Carcinoma in situ and (B) Lobular Carcinoma in situ. Invasive ductal and lobular 
breast cancers are also represented (From CancerHelp UK, 2012). 
 
Invasive breast carcinoma refers to the group of malignant epithelial tumors able to 
invade adjacent tissues and with the tendency to metastasize to distant sites. Invasive 
breast carcinoma exhibits a heterogeneous range of morphological phenotypes with 
particular prognosis or clinical characteristics. The 2003 World Health Organization (WHO) 
classification recognized 18 histological types of invasive breast cancer. Within these, 
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invasive ductal and lobular carcinomas are the most prevalent (Weigelt B & Reis-Filho JS 
2009). 
Invasive ductal cancer refers to the uncontrolled proliferation and spread of epithelial cells 
lining the ducts (Figure 7A), and is the most common type of breast cancer (70-80%). In 
contrast, invasive lobular carcinoma (Figure 7B) originates from the epithelial cells inside 
the lobules. It is much less frequent than the ductal (around 10-15%) and is often 
diagnosed in both breasts at the same time. 
Some other types of breast cancer which are less frequent and sometimes classified as 
special breast cancer types (given the particular features of tumor cells) are:  
◦ Inflammatory breast cancer (frequency of 1-4%) in which cancer cells block the 
lymph ducts of the breast, causing tissue inflammation. 
◦ Medullary breast cancer (frequency of 5%) which is characterized by cancer cell 
shape. Tumor cells tend to be bigger and tumoral tissue is clearly isolated from the 
normal tissue when analyzed under the microscope. Women with mutation in the 
BRCA1 gene are more prone to develop this type of cancer. 
◦ Mucinous breast cancer (frequency of 2%) is characterized by the presence of 
malignant cells that “float” in pools of mucus. 
◦ Other, very rare types of cancer include: tubular, adenoid cystic, metaplastic, 
angiosarcoma of the breast, lymphoma of the breast, phyllodes and papillary 
breast cancer.  
At the clinical level breast cancer is not only defined by its morphology. The use of 
predictive biomarkers (known as surrogate markers), such as the expression of estrogen 
receptor (ER), progesterone receptor (PR) and the assessment of HER2 status by 
immunohistochemical methods are currently used.  
 
1.3.4. Breast Cancer Molecular Classification 
Over the last decade, microarray-based gene expression studies demonstrated that breast 
cancer is a heterogeneous disease with different molecular characteristics. One of the 
advantages of molecular classification over the morphological-histological classification is 
that the diagnostic criteria to define the different types are less subjective and can be 
shared across different cancer centers in the world (Rakha EA et al. 2010). 
A key study for detailed molecular classification of breast tumors was performed by Perou 
CM et al. (2000). In this report, Perou CM and collaborators redefined breast cancer as a 
complex disease with specific gene expression profiles. Thus, using tumors with different 
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histopathological characteristics, they were able to describe an “intrinsic gene” list that 
allowed the hierarchical clustering of four breast cancer tumor subtypes: luminal, normal 
breast-like, HER2 and basal-like breast cancer (Figure 8).  
Interestingly, the major molecular subgroups identified by large-scale transcriptomic 
approach (luminal, HER2, basal-like) were very close to those previously classified as 
luminal, HER2 and triple-negative, by means of immunohistochemistry. 
 
 
Figure 8 
Cluster analysis of different breast cancer molecular subtypes. Branches are coloured as: Basal-like, orange; HER2, pink; 
normal breast, green; luminal, blue (Modified from Perou et al. 2000). 
 
One year later, the same group showed that the estrogen (ER)-positive group (luminal 
cluster) could be classified into three distinct subgroups: Luminal A, Luminal B and Luminal 
C (Figure 9) (Sorlie T et al. 2001). Nevertheless a few years later, Sorlie T et al. (2003) 
continued the molecular classification studies of breast cancer using an expanded data 
set, and realized that luminal C was not a true subgroup of this disease but belonged to 
the luminal B subtype. 
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Figure 9 
Hierarchical clustering analysis from gene expression patterns of normal breast and cancerous samples. Branches 
correspond to: Basal-like, red; HER2, pink; Normal breast-like, green; Luminal subtype C, light blue; Luminal subtype B, 
orange; Luminal subtype A, dark blue (Modified from Sorlie T et al. 2001). In 2003, Sorlie T and coworkers indicated that 
Luminal C subtype belonged to Luminal B subtype (purple). 
 
In 2011, the four subtypes defined by gene expression profile studies (Luminal A and B, 
HER2 and basal-like) were included in the St Gallen International Expert Consensus. In 
addition, a concordance between these molecular subtypes and immunohistochemical 
surrogate markers was proposed (Goldhirsch A et al. 2011). 
Thus, knowledge acquired using microarray analysis resulted in better understanding of 
the cellular and molecular heterogeneity of breast cancer. Of importance, the 
classification of breast tumors into distinct subtypes, based on the expression of 
molecular biomarkers, allowed more accurate orientation of patient treatment decisions 
and clinical trial design (Reis-Filho JS et al. 2006) (Table 1).  
Table 1.  
Breast Cancer molecular classification characteristics (Modified from Lam SW et al. 2014).  
Molecular 
Subtype 
Prevalence IHC definition Prognosis Treatment 
  ER PR HER2 Ki-67   
Luminal A 50-60 % + + - Low Good Endocrine 
Luminal B 
(HER2 negative) 
15-20 % + + - High Intermediate Endocrine ± 
chemotherapy 
Luminal B 
(HER2 positive) 
6 % + + + Any Intermediate Endocrine + cytotoxic 
+ anti-HER2 therapy 
HER2-amplified 10-15 % - - + Any Poor Chemotherapy + anti-
HER2 therapy 
Basal-like 10-20 % - - - High Poor Chemotherapy 
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1.3.4.1. Breast cancer molecular subtypes origins 
Prat A & Perou CM (2009) suggested that cancer cells may either be generated by 
transformation of normal mammary stem cells (MaSC) or progenitor cells (Figure 10), or 
result from the acquisition of stem cells-like characteristics by cancer cells.  
Lim E et al. (2009) were the first to propose the human mammary epithelial hierarchy 
(Figure 4) as a framework to understand the cellular origins of the various molecular 
subtypes of breast cancer (Figure 10). Epithelial gene expression signatures established for 
the different mammary epithelial populations have revealed that MaSC signature is most 
concordant with the one of the “normal-like” subtype (Lim E et al. 2009; Visvader EJ 
2009). Surprisingly, the expression profile of basal-like cancers shares a striking similarity 
with the luminal progenitor gene signature and not with the MaSC as expected. While the 
luminal cancer subtypes (Luminal A and Luminal B) where closest to mature ductal cells, to 
date correlation of the HER2 subtype with a specific subpopulation has not been clearly 
defined, but it is presumed that they may derive from a cell with luminal origin (Figure 10) 
(Lim E et al. 2009; Visvader JE, 2009; Visvader JE, 2011; Fu N et al. 2014). 
 
Figure 10 
Human breast epithelial hierarchy at the origin of the different cancer subtypes (From Visvader JE, 2009). 
 
1.3.4.2. Luminal subtype 
Luminal subtype is characterized by the presence of luminal epithelial markers and can be 
divided in three groups: luminal A, luminal B/HER2-negative and luminal B/HER2-positive. 
All three subtypes present a characteristic gene expression profile, prognosis and 
response to appropriate treatment (Sorlie T et al. 2001; Langlands FE et al. 2013; 
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Ignatiadis M & Sotiriou C, 2013; Lam SW et al. 2014). According to the histological 
classification, luminal tumors can be invasive or in situ and be classified as ductal, lobular, 
mixed ductal-lobular, mucinous or tubular carcinomas (Schnitt SJ, 2010; Ignatiadis M & 
Sotiriou C, 2013). 
Luminal A is the most common breast cancer subtype, it represents two-thirds of all 
breast cancer cases and it is characterized by the overexpression of genes related with the 
luminal mammary cells, estrogen receptor (ER) and ER transcription factors (Perou et al. 
2000; Sorlie T et al. 2001; Weigelt B et al. 2010; Lam SW et al. 2014). Luminal A breast 
cancer patients have a 5-year survival of 90% and few lymph node dissemination (O’Brien 
KM et al. 2010). 
The luminal B subtype represents 10-30% of breast carcinomas. Unlike luminal A, luminal 
B is associated with the overexpression of proliferation and cell cycle-related genes. 
Patients with Luminal B tumors present a 5-year survival rate of 50% (Sorlie T et al. 2001; 
Reis-Filho JS et al. 2006; Weigelt B et al. 2010; Lam SW et al. 2014). Two subtypes of 
luminal B tumors have been described according to their HER2 status (HER2 positive and 
HER2 negative). Among them, luminal B/HER2 negative is the most frequent (Lam SW et 
al. 2014). 
Clinically, luminal tumor subtypes are treated using endocrine therapy (Table 1). 
Tamoxifen and aromatase inhibitors (such as letrozole, anastrozole and exemestane) are 
the most commonly used therapies (Ignatiadis M & Sotiriou C, 2013). Hormone treatment 
can be used together with chemotherapy or anti-HER2 therapy according to the luminal 
subtype and high risk patients (Table 1) (Lam SW et al. 2014). 
 
1.3.4.3. HER2 subtype 
This subtype comprises tumors expressing low levels of hormone receptors but 
overexpressing the Erb-B2 oncogene that encodes for the Human Epidermal factor 
Receptor 2 (HER2) (Perou et al. 2000). HER2 is a member of the ErbB receptor tyrosine 
kinases (RTKs) family, with no known ligand but with a high kinase catalytic activity (Rexer 
BN & Arteaga CL, 2012; Langlands FE et al. 2013). 
Amplification of HER2 represents approximately 15% of human breast tumors and is 
associated with an increased risk of metastasis (to the brain, lungs and liver) (Kennecke H 
et al. 2010), high relapse rate, short overall survival and poor patient outcome if not 
treated (Sorlie T et al. 2001; Reis-Filho JS et al. 2006; Rexer BN & Arteaga CL, 2012; Lam 
SW et al. 2014). 
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Several therapeutic strategies have been used to treat HER2 breast tumors. Within those, 
the most commonly used are trastuzumab and lapatinib. Trastuzumab (Herceptin) is a 
humanized monoclonal antibody which targets the extracellular domain of the receptor, 
thereby suppressing HER2 activity by disrupting downstream signaling. In contrast, 
lapatinib is a tyrosine kinase inhibitor that blocks HER2 phosphorylation, thereby inhibiting 
PI3K-Akt and MAPK pathways (Rexer BN & Arteaga CL, 2012; Langlands FE et al. 2013). 
 
1.3.4.4. Basal-like subtype and Triple negative breast cancer (TNBC) 
The basal-like subtype is characterized by the very low or negligible expression of ER, PR 
and no amplification of HER2. Due to the absence of these three receptors, basal-like 
tumors are sometimes referred as triple negative breast cancer (TNBC) (Langlands FE et al. 
2013; Lam SW et al. 2014). Nevertheless, while basal-like denomination is based on 
microarray gene expression analysis, TNBC is according to predictive biomarkers 
classification (ER, PR and HER2 negative). 
Basal-like and TNBC subtypes share a number of characteristics. They are high grade, 
invasive ductal carcinomas, with preference to metastasize to viscera (lungs and brain) 
more than to bones (Foulkes WD et al. 2010). Additionally, both breast cancers are 
associated with an adverse prognosis and by the presence of germline BRCA1 mutations 
(Foulkes WD et al. 2010; Lam SW et al. 2014). 
However, clinical, microarray and immunohistochemical analysis have shown that basal-
like and triple negative subtypes are overlapping but not identical, most of the basal-like 
breast cancer being TNBC (around 60%), and most of the TNBC (approximately 80%) being 
of the basal-like subtype (Weigelt B et al. 2010). 
Triple Negative subtype accounts for 15% of breast cancer cases but is responsible for 25% 
of deaths by breast cancer. Due to its clinical heterogeneity, its highly proliferative and 
metastatic capacities, and the absence of targeted therapies, it remains the subtype with 
the worst prognosis. 
Chemotherapy is the main treatment option for these patients. Chemotherapy targets 
cells that proliferate rapidly, and therefore is more effective on TNBC tumors (29% of 
pathological complete response to anthracycline in TNBC patients versus 10% in HER2, 8% 
luminal B and 6% luminal A) (Carey LA et al. 2007). However, just a small subgroup of 
TNBC patients will benefit from this treatment due to development of tumor drug 
resistance and tumor relapse. 
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1.3.5. Chemotherapy as a treatment for breast cancer 
In addition to TNBC, patients diagnosed for hormone-refractory disease, hormone 
receptor-negative disease and metastatic breast cancer are treated using chemotherapies. 
Chemotherapy can be divided in two groups (DNA-targeting compounds and microtubule-
targeting agents) with different mechanism of action (Fumoleau P & Guiu S, 2012). 
Chemotherapeutic drugs can be applied sequentially or in combination with other active 
cytotoxic agents depending on the patient status, its previous treatments and tumor 
characteristics (Morris PG et al. 2009). 
DNA targeting agents include anthracyclines, gemcitabines and capecitabines. These 
agents induce cancer cell apoptosis through the inhibition of DNA synthesis. Doxorubicin 
is an anthracycline commonly used for several types of cancers due to its high efficacy 
against tumors. This chemotherapy drug intercalates between DNA base pairs causing 
deformation of the double helix, stabilization of the topoisomerase II-DNA complex and 
the induction of double strand breaks (Hortobagyi GN, 1997; Morris PG et al. 2009). 
MTAs (Microtubule Targeting Agents) include vinca alkaloids, colchicinoids, eribulin, 
taxanes and epothilones. These cytotoxic drugs inhibit cell proliferation through the 
modulation of mitotic spindle formation and chromosome attachment, which causes 
mitotic arrest and cell death. Recent observations have shown that MTAs can also have 
anti-migratory and anti-angiogenic properties when used at low concentrations (Yang H et 
al. 2010; Fumoleau P & Guiu S, 2012; Pagano A et al. 2012). MTAs mainly target the 
microtubule cytoskeleton and mitotic spindle that will be reviewed in details in chapter 
3.3. 
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2. Breast Cancer Metastasis 
Cancer metastasis, the ability of tumor cells to disseminate and grow at secondary sites, is 
a fatal complication of breast cancer. Approximately 10-15% of women diagnosed with 
breast cancer develop distant metastasis within 3 years after detection of the primary 
tumor (Weigelt B et al. 2005, Scully OJ et al. 2012). 
Several studies have reported that breast cancer cells can metastasize to different distant 
organs, with preference for the lungs, liver and bones (Figure 11) (Weigelt B et al. 2005). 
 
Figure 11 
Most common metastatic sites of breast cancer cells. Lungs, liver and bones are the organs of preference to metastasize 
(From Weigelt B et al. 2005). 
 
2.1. The metastatic process 
Metastasis is a complex multistep process which mainly depends on cancer cell properties 
and tumor microenvironment (Guise T, 2010). Failure to achieve one of the steps of the 
process will stop it (Poste G & Fidler IJ, 1980). 
The metastatic process (Figure 12) starts with the local invasion of the surrounding tissue 
by cancer cells. As the tumor grows, a higher requirement of oxygen and nutrients will 
activate neoangiogenesis, which in turn will contribute to tumor progression. In highly 
aggressive tumors, metastatic cells will detach from the primary tumor, invade the 
surrounding stroma, migrate until they reach the blood or lymphatic vessels in which they 
enter by intravasation (Hunter KW et al. 2008; Guise T, 2010; Scully OJ et al. 2012). 
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Figure 12 
The metastatic process. Metastasis to a secondary organ is the result of several steps that include tumor growth, 
angiogenesis, invasion of the surrounding tissue, intra and extravasation and final colonization of the new tissue (From 
Nahmias C & Rodrigues-Ferreira S. Accepted, Waiting for Copy Editing). 
 
Even if a large number of cells reach the blood flow, most of them stay quiescent or do 
not survive host defense mechanisms and stressful microenvironments, leading to the 
notion that metastasis is an inefficient process (Chambers AF et al. 2002; Hunter KW et al. 
2008; Scully OJ et al. 2012). However, those few circulating tumor cells (CTC) capable to 
arrest and cross the vasculature endothelium, a process termed extravasation, are 
suitable to grow as a metastasis in a distant organ (colonization) (Hunter KW et al. 2008). 
Interestingly, the organ distribution of full-blown metastasis is not random. In 1889 
Stephen Paget proposed that metastatic cancer cells (or seeds) would only colonize organ 
microenvironments (or soils) that were compatible with their growth (Paget S, 1889). In 
this line of thought, metastatic tropism will depend on the viable premetastatic niche 
within the target organ and on the display of the appropriate functions of the metastatic 
cell to effectively colonize the new organ (Reviewed in Gupta GP & Massagué J, 2006). The 
generation of a viable niche has been extensively studied, however this will not be 
detailed here. 
 
2.2. Tumor cell invasion and migration 
Tumor cell invasion, the first step of the metastatic process, refers to the penetration of 
tissue barriers, such as basement membrane and interstitial stroma, by cancer cells. Cell 
invasion is a heterogeneous, adaptive and cyclic process in which the cell adheres, 
degrades the extracellular matrix (ECM) components and changes its shape to produce a 
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morphological asymmetry resulting in a gain of migratory skills (Friedl P & Alexander S, 
2011).  
Cell migration is an essential process of normal cells during embryogenesis, development, 
tissue regeneration and immune-cell trafficking. Even if the migration process is increased 
and deregulated in cancer, tumor cells use mechanisms that are similar to those that 
occur in normal cells during physiological processes to spread within the tissues (Friedl P & 
Wolf K, 2003). 
Two types of cell migration (single and collective) have been described for cancer cells 
(Figure 13). The way cancer cells migrate depends on the tumor type, its differentiation 
stage and the surrounding microenvironment. Thus, epithelial tumor cells (as breast 
cancer cells) are more prone to migrate in a collective manner, while lymphomas, 
leukaemias and most of the solid stromal tumors (such as sarcomas) spread by single cell 
migration (Friedl P & Wolf K, 2003; Yilmaz M. et al. 2007; Vicente-Manzanares M & 
Horwitz AR, 2011; Friedl P & Alexander S, 2011). 
 
Figure 13 
Different types of cell migration. Tumor cells can migrate alone (single mesenchymal or amoeboid cell migration, left 
side) or grouped (collective coordinated or cohort cell migration, right side) (From Yilmaz M. et al. 2007). 
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2.2.1. Collective Cell Migration 
Collective cell migration refers to the movement of a coherent cell group of up to several 
hundred cells. This migration type contributes to numerous normal processes including 
embryological development, development of glands and ducts of mammary tissue, 
formation of blood vessels by endothelial cells, lung formation and wound healing. 
Additionally, it has been described that multicellular structures of cancer epithelial cells 
(such as acini, cords, glands or cell strands) can penetrate the surrounding stroma as 
elongated strands of connected tumor cells (Hegerfeldt Y et al. 2002; Friedl P & Wolf K, 
2003; Friedl P & Gilmour D, 2009; Friedl P et al. 2012). 
Collective migration models stand for a structure where there is a leader cell (or several 
cells) at the migration front and follower cells behind. Considering that leader cells must 
pull the inner and trailing cells behind, collective migration depends on the strongly cell-
cell adhesions provided by cell junctions (Hegerfeldt Y et al. 2002; Friedl P & Wolf K, 2003; 
Friedl P & Gilmour D, 2009; Friedl P et al. 2012). Thus, the leading cell will have one or 
several actin-rich protrusions, that will generate adhesive traction for forward movement, 
and matrix degradation activity to create a zone that guides the group (Wolf K et al. 2007). 
On the other hand, follower cells do not associate with the ECM directly, but will contact 
neighboring cells and intercellular matrix present along cell-cell junctions (Figure 14) 
(Friedl P et al. 2012). 
 
Figure 14 
Collectively migrating cells form two major zones: zone 1, in which a leader cell generates a proteolytic track at the front 
of the migrating group, and zone 2, in which the subsequent cells then widen this track (From Friedl P & Alexander S, 
2011). 
 
  
36 
Various subtypes of collective migration have been stratified according to the degree of 
cell-cell adhesion and the multicellular morphology. In fact, depending on cell-cell 
adhesion, cell-matrix adhesion, proteolysis and the type of tissue encountered, the size 
and shape of a collective invasion structure (and mostly its front) can vary. According to 
this, invading cell groups include strands of one or two cells in diameter, broad compact 
masses and masses that can form luminal structures (Figure 15). 
 
 
 
 
 
 
Figure 15 
Schematic diagram of collective cancer cell migration (Modified from Friedl P et 
al. 2012). 
 
Collective cancer cell migration can be classified in coordinated and cohort migration 
(Figure 13 and Figure 15). Coordinated migration consists in the sheet-like movement of 
tumor cells without detaching from the primary tumor. Contrariwise, cells that migrate in 
cohort detach from the primary site generating nests of migrating cells that can be 
detected at any stage of the metastatic process (Friedl P & Wolf K, 2003). Both subtypes of 
collective migration have been observed in invasive breast epithelial cancers (Friedl P et 
al. 1995; Nabeshima K et al. 1999; Nabeshima K et al. 2000). 
Breast cancer cells can also migrate in a “chain manner” or multicellular streaming. In this 
type of migration, a leader cell directs the migration of a stream of followers through the 
matrix (Friedl P & Wolf K, 2003; Vicente-Manzanares M & Horwitz AR, 2011; Friedl P & 
Alexander S, 2011). It has been reported that chains of tumor cells can align between 
stromal fibers, a characteristic that improves the penetration mechanisms and thus, is 
associated with high metastatic capacity and poor prognosis (Friedl P & Wolf K, 2003; 
Bacac M & Stamenkovic, 2008; Roussos ET et al. 2011). Tumor cells sometimes follow 
nerve trajectories (perineural migration) and cancer-associated fibroblasts (CAFs) (Friedl P 
& Wolf K, 2003; Choi YP et al. 2014). 
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2.2.2. Single Cell Migration 
The single cell migration process includes several steps that imply changes in cell 
morphology and stiffness (Figure 16). First, the cell has to polarize and elongate. A 
pseudopod is then formed, via the extension and ruffling of the leading edge which is 
mainly composed by an actin-rich lamellipodia. After protrusion formation, cell leading 
edge binds to the ECM substrate. Subsequently, cell contracts in order to allow the 
forward movement of the entire body and the trailing edge. Finally, disassembly of 
adhesion contacts at the trailing edge allows cell displacement (Friedl P & Wolf K, 2003). 
 
Figure 16 
Single cell migration involves five molecular steps that change the cell shape, its position, and the tissue structure 
through which it migrates (From Friedl P & Alexander S, 2011). 
 
Two types of single cell migration (mesenchymal and ameboid) have been described 
(Figure 13). Mesenchymal migration is characterized by the presence of fibroblast-like 
shape, increased cell invasiveness, increased cell-stroma interaction and decreased cell 
proliferation. This migration mechanism is dependent on ECM adhesion proteins, as well 
as on the activation of proteins involved in the matrix degradation (reviewed in Yilmaz M. 
et al. 2007, Friedl P & Alexander S, 2011).  
In contrast, in the amoeboid phenotype, cells are more deformable due to weak 
interactions between the cell membrane and the matrix. The absence of mature adhesion 
contacts make these cells faster than mesenchymal migrating cells (10 to 30-fold higher 
velocities). Therefore, more than grip, the amoeboid cells have to adapt their morphology 
to preformed matrix structures in order to glide through (Friedl P & Wolf K, 2003; Yilmaz 
M. et al. 2007). 
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3. Microtubule (MT) Network 
 
The eukaryotic cell cytoskeleton is a network composed of proteinaceous fibers and is 
required for the majority of essential cellular functions such as cell motion, cell division, 
intracellular transport and maintenance of cellular shape. It is a complex and often highly 
dynamic structure built of three major components: microtubules (MT), actin and 
intermediate filaments (IF) (Figure 17). 
 
Figure 17 
Microtubules, actin and intermediate filaments are the principal components of eukaryotic cell cytoskeleton (From 
Tobin & Dusheck, 2001). 
 
Actin cytoskeleton is composed of semi-flexible filaments able to arrange in a variety of 
architectures, generating cellular organizations including branched or cross-linked 
networks in the lamelipodium, parallel bundles in filopodia and anti-parallel structures in 
contractile fibers (Blanchoin L et al. 2014). Intermediate filaments (IF) are assembled from 
a diverse group of fibrous proteins (such as vimentin and keratin) with intermediate size 
between actin and microtubules. IFs are elastic non-polarized fibers, expressed in a cell 
type-specific manner (Yi H & No Ku, 2013). Microtubules (MTs) are the subject of this third 
chapter: its organization, functions and the proteins capable to interact with them in 
order to regulate their dynamics will be described below. 
 
3.1. Microtubule organization 
Microtubules are cylindrical hollow tubes of 25 nm of diameter and variable length. They 
are composed of αβ tubulin heterodimers that are organized head-to-tail to form a 
polarized protofilament. Thirteen of these filaments will interact laterally to subsequently 
form the MT lattice (Figure 18) (Amos L & Klug A, 1974; Brinkley WBR, 1997; Desai A & 
Mitchison TJ, 1997; Valiron O et al. 2001). 
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Figure 18 
Microtubule structure. (A) Representation of the head-to-tail interactions of αβ dimers to form a linear protofilament. 
(B) Thirteen linear protofilaments associate laterally to form a MT polymer. 
 
Each tubulin monomer can be divided into three functional domains: the N-terminal 
domain containing the GTP-binding site, an intermediate domain containing the taxane-
binding site in β-tubulin, and the C-terminal domain which contains the binding surface for 
motor proteins (Figure 19) (Nogales E et al. 1998). 
 
Figure 19 
Ribbon diagram of the tubulin dimer showing α-tubulin with bound GTP (top), and β-tubulin containing GDP and taxane 
(TAX) (bottom). Green arrow indicates the direction of the protofilament and MT axis (Modified from Nogales E et al. 
1998). 
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Even if α- and β-tubulin are similar, there are two unambiguous ways to distinguish them: 
(i) β-tubulin binds to taxanes, and (ii) β-tubulin monomer contains an exchangeable (E) 
GTP site, while the α-tubulin monomer has the non-exchangeable (N) site, always filled 
with GTP (Spiegelman BM et al. 1977; Hyman AA et al. 1992; Valiron O et al. 2001). 
The denomination of E site on β-tubulin monomer owes to the possibility of binding GTP 
or GDP. During or after αβ tubulin dimers addition to the protofilament, GTP hydrolyzes to 
GDP and the latter gets locked in the protofilament during MT growing. After 
depolymerization, the GDP-β tubulin exchanges to GTP in solution (Hyman AA et al. 1992).  
MTs display an intrinsic polarity, generated by the head-to-tail assembly of tubulin dimers, 
with one end growing at three times the rate of the other (Summers K & Kirschner MW, 
1979). The faster growing and more dynamic extremity is termed the plus-end and the 
slower growing extremity, the minus-end (Allen C & Borisy GG, 1974). Experiments using 
GTP-coated fluorescent beads showed that GTP specifically binds to the plus-ends, 
indicating that β-tubulin monomer is exposed toward the plus end, while the α-tubulin 
monomer is directed to the minus end (Mitchison TJ, 1993). This observation was further 
confirmed when beads coated with anti-α-tubulin antibodies were shown to bind the 
minus end of MTs (Fan J et al. 1996). 
MT minus-ends are usually capped by centrosomal proteins. From the centrosome or 
MTOC (for MicroTubule Organizing Center), MTs grow out and their plus-ends explore the 
cytoplasmic space, often interact with the cell cortex and work as a search-and-capture 
tool (Mimori-Kiyosue Y & Tsukita S, 2003; Honoré S et al. 2005; Bornens M, 2008). The 
polarity of MTs is important to the function of motor proteins, kinesins and dyneins, which 
use ATP hydrolysis to transport various cargos along MTs (Desai A & Mitchison TJ, 1997).  
MTs within cells can be found in two states: (i) transiently unstable, as the radial array in 
interphase cells, the bipolar spindle during mitosis and meiosis, the parallel array in 
polarized cells and the linear array in neuronal extensions, or (ii) highly stable, like in the 
centrioles, basal bodies and axonemes of cilia and flagella (Brinkley WBR, 1997). 
 
3.2. Microtubule dynamics 
Microtubules are dynamic polymers that cannot be understood in terms of the classical 
polymerization theory of Oosawa F (1970), where subunit exchange at polymerization 
state was limited to the slow association-dissociation of tubulin dimers at MT ends. Rather 
they present a non-equilibrium dynamic behavior which allows the organization and rapid 
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remodeling of the cytoskeleton, allowing MTs to search in the three-dimensional space 
(Kirschner M & Mitchison T, 1986; Holy TE & Leibler S, 1994).  
In order to explain what MT dynamics means, several studies were performed in vitro and 
in vivo. Some of these studies and the important concepts are listed below. 
 
3.2.1. MT dynamics in vitro 
The characterization of the dynamic properties of MTs began when, in 1972, Weisenberg 
RC discovered that pure tubulin self assembles and disassembles in the presence of GTP. 
Later on, observation of continuous incorporation of tubulin into MT, when polymer 
length is constant, led to the concept of treadmilling (Margolis RL & Wilson L, 1978; 
Margolis RL & Wilson L, 1998). Treadmilling is defined as the unidirectional flux of tubulin 
subunits from one polymer end to another. This concept indicates that a treadmilling MT 
might have a constant assembly rate of tubulin subunits at one end, with a balanced loss 
at the opposite end (Margolis RL & Wilson L, 1998). 
A few years later, in 1984, the observation of a population of fixed MTs by Mitchison and 
Kirschner led to the discovery of a new MT dynamic mechanism termed dynamic 
instability (Mitchison T & Kirschner M, 1984). In this process MTs switch between 
continuous phases of polymerization and depolymerization. Soon after, a large number of 
studies using differential interference contrast (DIC) microscopy confirmed this concept 
and dynamic instability became the predominant mechanism to explain MT dynamics 
(Horio T & Hotani H, 1986; Cassimeris LU et al. 1987; Hotani H & Horio T, 1988; Walker RA 
et al. 1988; Gelfand VI & Bershadsky AD, 1991; Erickson HP & O’Brien ET, 1992). 
To date, MT dynamic instability is described as a three-state model that includes MT 
growing, MT pause and MT shrinking (Figure 20). MT growing or polymerization stands for 
the elongation of the lattice in a GTP-tubulin concentration dependent manner. This 
elongation was described by Chrétien D et al. (1995) as the extension of protofilaments 
rather than the helical subunit addition (Figure 20, upper panel).  
During or soon after polymerization, GTP hydrolyzes to GDP, a process not required for 
further polymerization but essential for dynamic instability (Hyman AA et al. 1992; Caplow 
M et al. 1994). In fact, Caplow M and coworkers (1994) showed that the free energy 
released after GTP hydrolysis is store in the MT lattice as a mechanical strain and might 
destabilize the MT network. Unstable GDP-microtubules undergo catastrophe, releasing 
the energy that in turn promotes and maintains rapid depolymerization. Additionally, 
Melki R et al. (1989) provided a model where GTP hydrolysis causes a change in tubulin 
conformation, having GTP-tubulin with a “straight” conformation and GDP-tubulin with a 
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“curved” conformation. Curved protofilaments peel outwards and promote MT 
depolymerization. 
 
 
 
 
Figure 20 
MT dynamics in vitro and in vivo. Microtubules can polymerize (upper panel), stay in pause (middle panel) or 
depolymerize (lower panel). Cryoelectron microscopy pictures are from Chrétien D et al. 1995 (growing), Janosi IM et al. 
2002 (pause) and Warner FD & Satir P, 1973 (shrinking). 
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This unstable “curved” lattice promotes the disassembly of the polymer. During MT 
shrinking, GDP-tubulin is released from the MT end. Cryoelectron microscopy studies 
revealed that depolymerizing ends contain highly curved protofilaments (Figure 20, lower 
panel) (Mandelkow EM & Mandelkow E, 1985; Mandelkow EM et al. 1991; Tran PT et al. 
1997) suggesting that the driving force for MT depolymerization is the curling up of 
protofilament ends. 
Finally, MTs can undergo pause moments, where MTs do not grow nor shrink (Figure 20, 
middle panel). Pauses were described by Keller PJ et al. (2007) as stochastic events that 
were not so commonly seen in vitro (Walker RA et al. 1988; Shelden E & Wadsworth P, 
1993). Chrétien D et al. (1995) described MT pause as the moment when protofilament 
sheets close to form the cylindrical shape of MTs. This process could occur at a variable 
rate and as MTs cannot stay in this close shape for long time, it would finish by the 
induction of depolymerization. 
Four parameters have been proposed to describe MT dynamic instability: growth rate, 
shrinking rate and frequencies of catastrophes (transition from polymerization to 
depolymerization) and rescues (transition from depolymerization to polymerization) 
(Figure 21). 
 
Figure 21 
MT dynamic instability is characterized by continuous cycles of polymerization, where GTP-tubulin is added to the plus 
end of the MT, and depolymerization, where GDP-tubulin is rapidly released from the lattice. Catastrophe and rescue 
transitions are indicated as red arrows. 
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The growth velocity depends on the soluble tubulin concentration, on the rate constant 
for GTP-tubulin association, the temperature and the presence of MAPs. In contrast, the 
shortening rate does not depend on tubulin concentration but it depends on temperature 
and presence of MAPs. The catastrophe (or rescue) frequency is calculated as the number 
of catastrophes (or rescues) observed during the total time the MT spends in growing 
state. Erickson HP and O’Brien ET (1992) showed that in vitro catastrophe frequencies 
were lower than rescue frequencies in both the plus and minus ends. Nevertheless, these 
MT dynamic instability parameters can vary according to tubulin concentration and 
polymerization buffer composition. 
All MT dynamic instability parameters can be visualized and determined on kymographs 
(Smal I et al. 2009). Kymographs are graphical representations of spatial position over 
time (Figure 22). 
 
Figure 22 
Kymograph representation showing different phases of MT dynamic instability. The spatial axis shows a MT visualized 
with mCherry-α-tubulin in red and its growing end stain with EB3-GFP in green (From Akhmanova A & Steinmetz MO, 
2008). 
 
In vitro minus-ends are able to assemble and disassemble pure tubulin and thus exhibit 
dynamic instability as the plus-ends but with slower rate constants (Walker RA et al. 
1988). 
 
3.2.2. MT dynamics in vivo 
Current models of MT dynamics accept both treadmilling and dynamic instability as 
intrinsic properties of MTs that coexist in cells. Treadmilling have been reported in the 
mitotic spindles even if the MT ends are anchored at the spindle poles and kinetochores 
(Rodionov VI & Borisy GG, 1997; Waterman-Storer CM & Salmon ED, 1997; Margolis RL & 
Wilson L, 1998). 
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MT dynamic instability in vivo shares most characteristics with the in vitro model, except 
that cellular MTs have higher assembly rates (up to 10 times faster), more transition 
frequencies (Cassimeris L, 1993) and more frequent pause events (Keller PJ et al. 2007). 
Moreover, MT dynamics in vivo can vary according to regulatory signals (interphase versus 
mitosis) (reviewed in McNally FJ, 1996), cell type (Bré MH et al. 1990; Bass PW et al. 
1991), measured zone inside the same cell (Komarova YA et al. 2002b), and differentiation 
stage (Bulinsky JC & Gundersen GG, 1991). 
The most important function of MTs is their participation in mitosis, as segregation of 
chromosomes towards cell poles during anaphase requires regulated and coordinated 
MTs dynamics. However, MT dynamic instability in living cells also allows MT spatial 
organization, rapid remodeling of the cytoskeleton and cell shape (Figure 23A). 
Additionally, this permits MTs to search and find specific targets (search-capture model) 
and guides MTOC movement (Figure 23B). 
 
Figure 23 
MT dynamic instability allows cytoplasm and cell shape remodeling (A) and interphase centrosome positioning to a 
specific cortical site (B) (From Desai A & Mitchison TJ, 1997). 
 
But MT dynamics not only depends on tubulin polymerization/depolymerization. Dynamic 
instability is also regulated by tubulin post-translational modifications and by microtubule-
associated proteins (MAPs). Of importance, microtubule-targeting agents (MTAs) also act 
by modulating MT dynamic instability parameters. 
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3.3. Microtubule-targeting agents (MTAs) 
Microtubule-targeting agents constitute a class of chemotherapeutic drugs that target 
microtubules and disrupt the normal function of the mitotic spindle to cause cancer cell 
death by mitotic arrest. Microtubule targeting agents (MTA) can be classified in 
microtubule (MT)-stabilizing and destabilizing drugs according to their effects on MT 
dynamics (Figure 24). 
 
Figure 24 
Effect of Microtubule Targeting Agents (MTAs) on microtubule dynamics. MTAs can destabilize (left side) or stabilize 
(right side) the MTs in order to induce cancer cell apoptosis. 
 
Some representatives of MT-destabilizing agents are the vinca alkaloids, the colchicinoids, 
and eribulin (Figure 24). The vinca alkaloids (vincristine, vinblastine, vinorelbine) prevent 
MT polymerization by binding to β-tubulin subunits, which causes a metaphase arrest. 
These agents also decrease polymerization and depolymerization velocities and increase 
the percentage of time MTs spend in an attenuated or paused phase (Himes RH, 1991; 
Jordan MA et al. 1992; Morris PG et al. 2009; Fojo AT & Adelberg DE, 2010). Vinka 
alcaloids are currently used in clinics, however, an inconvenient reported for these 
cytotoxic agents is the sensitivity to cancer cells resistance pumps (Fumoleau P & Guiu S, 
2012). 
Binding of colchicine to tubulin induces a conformational change in the tubulin that locks 
the colchicine in a complex where it can poorly dissociate. Colchicine depolymerizes MTs, 
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inhibits MT polymerization and increases the time MTs spend in pause state (Reviewed in 
Fojo AT & Adelberg DE, 2010). 
Eribulin is a destabilizer molecule which acts through the suppression of microtubule 
growth (with no effect in the shortening) and sequestration of tubulin into nonproductive 
aggregates. Thus, tubulin retention impedes mitotic spindle formation inducing a mitotic 
blockage (Cortes J et al. 2012; Scarpace SL, 2012).  
The second group of MTAs is the MT-stabilizing agents. MT-stabilizing agents are mainly 
composed by Taxanes and epothilones (Figure 24). Taxanes bind tubulin to inhibit MT 
depolymerization, enhance MT assembly, and thereby bundling and stabilizing MTs 
(Morris PG et al. 2009; Fojo AT & Adelberg DE, 2010; Pagano A et al. 2012). Paclitaxel and 
Docetaxel are widely used for the treatment of metastatic breast cancer. Nevertheless, 
two complications are associated with taxane use: toxicity (neurotoxicity and 
hematopoietic toxicity) and acquired tumor resistance (Morris PG et al. 2009). 
Epothilones treatment is frequently used in taxane-resistant and taxane-insensitive 
tumors. Epothilones and ixabepilones are natural antibiotics that bind to microtubules in 
the taxane-binding site and are involved in tubulin polymerization, MT bundling and the 
inhibition of depolymerization (Morris PG et al. 2009; Fojo AT & Adelberg DE, 2010; 
Pagano A et al. 2012).  
 
Even if these agents are used to impede tumor progression, the risk of treatment 
resistance and patient relapse along with the acute and long-term side effects of the 
chemotherapy, have created an urgent need to understand how endogenous factors 
modulate MT dynamics in order to target them as tools against cancer. 
 
3.4. Microtubule post-translational modifications 
The MT network is composed by sets of dynamic and stable MTs. Stable MTs can 
incorporate several post-translational modifications mostly in the C-terminal tail of both, 
α- and β-tubulin. As these tails are located on the outside of the microtubule, they are 
therefore well positioned to influence interactions with other proteins (Westermann S & 
Weber K, 2003; Verhey KJ & Gaertig J, 2007). 
MT post-translational modifications are conserved throughout evolution and are thought 
to act (individually or in combination) to regulate specific MT based functions (Hammond 
JW et al. 2008). Some of these modifications are described in Table 2 and in Figure 25 and 
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include acetylation, detyrosination, polyglutamylation, polyglycylation and 
phosphorylation.  
Acetylation occurs in lysine 40 of α-tubulin; it is a very common modification that can be 
found on stable MTs in most cell types (Hammond JW et al. 2008). It has been reported 
that acetylated MTs are more resistant to depolymerization by nocodazole but are not 
protected against cold depolymerization (Piperno G et al. 1987). 
Detyrosination involves the removal of the C-terminal tyrosine of α-tubulin in MTs, 
generating a detyrosinated tubulin (also known as Glu-tubulin) which has been observed 
in long-lived MTs (Westermann S & Weber K, 2003; Verhey KJ & Gaertig J, 2007). Removal 
of the preceding glutamate residue in Glu-microtubules results in Δ2-tubulin. This type of 
tubulin is found in neurons and axonemes, where MTs are also highly polyglutamylated 
(Lafanechère L & Job D, 2000) 
Polyglutamylation and polyglycylation are post-translational modifications in which 
glutamate and glycine side chains of variable length are added to glutamate residues in 
the C-terminal tails of both α and β-tubulin. Glycylation is mostly found in axonemes of 
motile cilia and flagella, whereas, glutamylation is present on MTs in neurons, centrioles, 
mitotic spindle and cilia (Westermann S & Weber K, 2003; Verhey KJ & Gaertig J, 2007). 
Tubulin modifications can have different biological roles. For example, decreased MT 
acetylation increases cell motility (Hubbert C et al. 2002); polyglycylation and 
polyglutamylation are important for axonemal structure, ciliary motility and cytokinesis 
(reviewed in Verhey KJ & Gaertig J, 2007); and deregulation in the 
tyrosination/detyrosination cycle result in spindle orientation defects  (Peris L et al. 2006). 
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Figure 25 
Tubulin post-translational modifications. The C-terminal tails of α and β tubulin can be modified by different enzymes in 
order to polyglycylate, detyrosinate, polyglutamylate or acetylate (From Janke C & Bulinski JC, 2011). 
 
Finally, MT modifications are linked to MT dynamics regulation: they work as a readable 
code for the recruitment of MAPs and motor proteins (reviewed in Janke C & Kneussel M, 
2010; Wloga D & Gaertig J, 2010). 
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Table 2 
Tubulin post-translational modifications (Modified from Westermann S & Weber K, 2003; Verhey KJ & Gaertig J, 2007). 
Modification Description Site Proposed Function Comments 
Acetylation 
 
Addition of acetyl 
group 
Lys40 of α-tubulin 
Regulation of cell 
motility, binding of 
MAPs to microtubules 
Marker for 
stable MTs 
Detyrosination 
 
Removal of tyrosine 
C-terminal tail of α-
tubulin 
Crosstalk to 
intermediate filaments; 
differentiation 
Reversible 
∆2 Tubulin 
 
Removal of 
penultimate 
glutamate from 
detyrosinated 
tubulin 
C-terminal tail of α-
tubulin 
Removing tubulin from 
tyrosination cycle; 
marking MTs for 
polyglycilation 
Marker for 
stable MTs 
Polyglutamylation 
 
Addition of one or 
more glutamates as 
a side chain 
C-terminal tail of α- 
and β-tubulin 
Centriole maturation 
and stability; flagellar 
and cilliary motility; 
regulation of 
interaction with MAPs 
Up to 20 side-
chain residues 
Polyglycylation 
 
Addition of one or 
more glycines as a 
side chain 
C-terminal tail of α- 
and β-tubulin 
Essential in 
Tetrehymena for: 
axonemal organization, 
cilliary motility, 
cytokinesis (severing of 
MTs) 
Up to 30-40 
side-chain 
residues 
Phosphorylation 
 
Addition of 
phosphate 
Ser172/441/444 of 
β-tubulin, unknown 
sites of α-tubulin 
Neuronal 
differentiation? 
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3.5. Microtubule-regulating proteins 
MTs are controlled by factors that regulate different parameters of their dynamics. These 
factors can act directly or indirectly through the action of other proteins (Lyle K et al. 
2009a; Lyle K et al. 2009b).  
All MTs regulators are Microtubule-Associated Proteins (MAPs) able to interact with 
tubulin or MTs in vitro or in vivo. A particular group of MAPs that act predominately at the 
MT growing end are the plus-end tracking proteins (+TIPs) that will be reviewed below in 
chapter 3.6. MT-regulating proteins can be classified in two main groups: proteins that 
stabilize MTs and proteins that destabilize them. 
 
3.5.1. Microtubule-stabilizing proteins 
MTs can be stabilized by different ways: by promoting polymerization, by preventing 
catastrophes, by rescuing depolymerizing MTs, by decreasing shrinking velocity, by 
bundling or by capping MTs. According to these characteristics, a large number of proteins 
are able to stabilized MTs and can be grouped in five categories: (i) classical MAPs, (ii) MT 
assembly promoters, (iii) MT stabilizers with mitosis-specific functions, (iv) MT stabilizers 
through cell cortex interaction, and (v) other MT-stabilizing proteins (Lyle K et al. 2009a; 
Lyle K et al. 2009b). 
The first proteins reported as MT stabilizing factors were the classical MAP proteins. The 
MAP family of proteins has been extensively studied and is mainly composed by MAP1 
(MAP1A and MAP1B), MAP2 and Tau (which are highly abundant in neurons) and MAP4 
(non-neuronal cells) (Desai A & Mitchison TJ, 1997). It has been reported that MAP1A, 
MAP1B, MAP2 and Tau are able to (i) reduce catastrophe frequencies, (ii) increase rescue 
frequencies and therefore they are able to (iii) reduce tubulin turnover rates and (iv) 
increase steady state tubulin. Additionally, these proteins can inhibit protofilament 
peeling and thus depolymerization induction (Drechsel DN et al. 1992; Pryer NK et al. 
1992; Dehmelt L & Halpain S, 2005). Contrariwise, MAP4 is able to increase rescue 
frequencies without changing catastrophe frequency (Ookata K et al. 1995). 
The group of MT assembly promoters is mainly composed by MAPs that accumulate at the 
MT growing end, i.e. +TIPs. End-binding proteins (EBs), chTOG, CLIPs proteins and CRMP-2 
are some examples of assembly promoters and are implicated in the promotion of rescue 
frequencies and in accelerating MT polymerization (Lyle K et al. 2009a). This group of 
proteins will be reviewed in detail in chapters 3.6 and 3.7. 
MT stabilization also includes its capping at both ends, the plus-ends and the minus-ends. 
During mitosis, MTs can be captured at spindle poles by NuMA (Nuclear protein that 
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associates with the Mitotic Apparatus), RHAMM (Receptor for Hyaluronan-Mediated 
Motilty), TACC (Transforming Acidic Coiled-Coil) proteins and TPX2 (Targeting Protein for 
Xklp2). All these proteins play a role organizing the MTs at the polar region of the mitotic 
spindle (Gaglio T et al. 1995; Maxwell CA et al. 2003; Fant X et al. 2004; Barros TP et al. 
2005). In addition, proteins that capture MTs at kinetochores near the chromosomes 
includes the kinesin-7 CENP-E (CENtromere-associated Protein E) and NuSAP (Nucleolar 
Spindle-Associated Protein) (Yao X et al. 2000; Putkey FR et al. 2002; Raemaekers T et al. 
2003; Manning AL & Compton DA, 2008), which have a relevant function in chromosome 
alignment at metaphase. Finally, some other MT-stabilizing proteins with mitosis-specific 
functions are Astrin, which localizes at spindle poles and kinetochores of bioriented 
chromosomes and functions to crosslink and stabilize MTs, and HURP (Hepatoma 
UpRegulated Protein), that is located at kinetochores fibers and contributes to 
chromosome alignment (Manning AL & Compton DA, 2008). 
Representatives of the MT stabilizers through cell cortex interaction are APC 
(adenomatous polyposis coli), CLASPs (CLIP-associating protein) and the spectraplakins 
MACF/ACF7 (Microtubule-Actin Crosslinking Factor) which mediate interactions with 
cortical sites, Golgi and actin, respectively. These proteins and some stabilizers involved in 
MT capture will be described in chapter 3.6. 
The last group of MT stabilizers includes some miscellaneous proteins such as CLAMP 
(CaLponin-homology And Microtubule-associated Protein) (Dougherty GW et al. 2005), 
VHL (von Hippel–Lindau) (Hergovich A et al. 2002; Thoma CR et al. 2010), YB-1 (Chernov 
KG et al. 2008), BPAG1 (Bullous Pemphigoid Antigen-1) (Yang Y et al. 1999), the formins 
Dia1 and Dia2 (Palazzo AF et al. 2001b; Gundersen GG et al. 2004; Wen Y et al. 2004; 
Bartolini F & Gundersen GG, 2010), MAP6/STOP (Guillaud L et al. 1998; Bosc C et al. 2003), 
tektins which crosslink and stabilize axoneme MTs in cilia and flagella (Steffen W & Linck 
RW, 1988; Tanaka H et al. 2004; Amos LA, 2008), MURFs (MUscle-specific RING-Finger 
proteins) that stabilize MTs in striated muscle (Spencer JA et al. 2000), Lis1 and 
Doublecortin that stabilize MTs during neuronal migration (Sapir T et al. 1997; Gleeson JG 
et al. 1999; Coquelle FM et al. 2002; Fourniol F et al. 2013), VAPs (Vesicle-Associated 
membrane Protein) that stabilize presynaptic MTs, the kinesin-5 Eg5, the MAP65 and 
DDA3 that are involved in MT bundling by crosslinking antiparallel MTs  (Manning AL & 
Compton DA, 2008; Lyle K et al. 2009b). 
 
3.5.2. Microtubule-destabilizing proteins 
The difference in the catastrophe frequencies between free tubulin and tubulin in living 
cells suggests the presence of factors involved in the depolymerization of MTs. These 
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cellular factors would modulate MT dynamics in vivo, by promoting MT disassembly and 
increasing tubulin turnover. MT-destabilizing proteins include microtubule-associated 
proteins, microtubule-severing proteins and microtubules plus-ends tracking proteins 
(+TIPs). 
It is now clear that the oncoprotein 18 (Op18)/stathmin is a catastrophe inducer, but its 
mechanism of action is still controversial. Some experimental observations stand for a 
hijacker effect of Op18/stathmin over tubulin dimers: as the oncoprotein is able to 
interact with free tubulin dimers it could reduce the available free tubulin concentration 
and thus induce MT depolymerization (Belmont L et al. 1996; Howell B et al. 1999a). Other 
studies suggest that Op18/stathmin may be a catastrophe promoting factor at the plus 
ends by promoting GTP hydrolysis without having an effect on MT growth rate (Howell B 
et al. 1999a; Howell B et al. 1999b). An interesting study showed that it was possible to 
dissociate the tubulin-sequestering and MT catastrophe-promoting activities in vitro by 
controlling the pH at which experiments were performed. At pH 6.8, Op18/stathmin acts 
through tubulin sequestration, and at pH 7.5 it acts as a catastrophe promoter (Howell B 
et al. 1999b). 
Other MT disassembly promoters are the kinesin-8 KIF18A and the kinesins-13 KIF2A, 
KIF2B and KIF2C (MCAK). These kinesins are able to induce conformational changes in 
both the plus-ends and minus-ends that will trigger catastrophe (reviewed in Mayr MI et 
al. 2007 and Ems-McClung SC & Walczak CE, 2010). MCAK is the most studied MT 
depolymerase and will be described in more detail in chapter 3.6. 
The last proteins that induce MT disassembly are the MT-severing proteins katanin, 
spastin and fidgetin. These three proteins are able to cleave the MT lattice, releasing free 
ends that will depolymerize. MT-severing proteins function to control the number and 
length of MTs, which is necessary for the assembly and dynamics of the mitotic spindle 
(McNally FJ et al. 1996; Zhang D et al. 2007). Indeed, katanin severs MTs near the plus-
ends and helps depolymerization of MTs near the chromosome attachment site for 
continued movement of chromosomes towards spindle pole in late anaphase. In contrast, 
spastin and fidgetin sever MTs near the minus-ends to cause active depolymerization and 
to fasten chromosome movement towards the spindle pole (Ghosh DK et al. 2012). 
 
3.6. Microtubule plus-ends tracking proteins (+TIPs) 
Microtubule plus-end tracking proteins (+TIPs) belong to a class of MAPs that accumulate 
at the growing end of the MTs (Schuyler SC & Pellman D, 2001). When fused with a 
fluorescent tag, +TIPs appear as comets at the plus-ends which move throughout the cell 
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as the MTs grow to then disappear when MTs undergo catastrophe (Howard J & Hyman 
AA, 2003).  
Since 1990 when CLIP170, the first MT plus-end tracking protein, was reported (Rickard JE 
& Kreis TE, 1990) a large number of proteins have been identified as +TIPs including 
motor, non-motor, MT polymerases, depolymerases, regulatory and adaptor proteins. 
Although these proteins are functionally diverse and structurally unrelated, they are often 
highly conserved in eukaryotes and associate preferentially with the growing and not the 
shrinking MT end (Mimori-Kiyosue Y et al. 2000; Schuyler SC & Pellman D, 2001; 
Akhmanova A & Steinmetz MO, 2008). 
+TIPs are able to participate in MT dynamics regulation and in the coordination of cell 
architecture through their interaction with different proteins and/or cell structures. 
 
3.6.1. Structural +TIPs classification 
+TIPs are a very heterogeneous group of proteins that differ in structure, function, size 
and plus-end tracking mechanism. Structural classification will be the subject of this part 
of the chapter and includes: End-Binding family of proteins, Cytoskeleton-associated 
proteins Gly-rich (CAP-Gly) proteins, proteins that contain basic and Ser-rich sequence 
(SxIP) and MT motor proteins (Figure 26) (Akhmanova A & Steinmetz MO, 2008). 
 
Figure 26 
Structural classification of plus-end tracking proteins. Four groups of +TIPs have been described according to the 
structural elements that are involved in tracking the MT plus-end (Modified from Akhmanova A & Steinmetz MO, 2008). 
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End-binding (EB) family proteins are small globular dimers that contain highly conserved 
N- and C-terminal domains. The N-terminal domain is responsible for the binding to MTs 
(Hayashi I & Ikura M, 2003) while in the C-terminal region a coiled-coil domain allows the 
dimerization of EB monomers (Honnappa S et al. 2005). EBs are considered as the core of 
+TIP network, as they are able to interact with almost all CAP-Gly and serine-rich proteins. 
The specific details of EB proteins and their interactions will be discussed below (chapter 
3.7). 
 
The cytoskeleton-associated proteins Gly-rich (CAP-Gly) domain is a specialized module of 
approximately 80 residues that is highly conserved in eukaryotes (Riehemann K & Sorg C, 
1993). This domain can be found in single or multiple copies and is involved in protein-
protein interactions, in particular with α-tubulin monomers, dimers, MTs and EB proteins 
by the recognition of a C-terminal EEY sequence motif (Steinmetz MO & Akhmanova A, 
2008). 
CAP-Gly proteins include some +TIPs such as the cytoplasmic linker proteins (CLIPs) and 
the large subunit of the dynactin complex p150
glued
. In these proteins the CAP-Gly domains 
are located in the N-terminal part and will interact with the C-terminal EEY motif on MTs 
and EB proteins (Honnappa S et al. 2006; Ligon LA et al. 2006; Mishima M et al. 2007). 
CLIP170 was the first protein where the interaction between a CAP-Gly domain and MTs 
was shown (Pierre P et al. 1992) and also the first protein for which MT plus-end tracking 
behavior was described (Perez F et al. 1999). CLIP proteins contain two similar CAP-Gly 
domains surrounded by serine and basic residues rich regions in the N-terminal part, 
which contribute to MT interaction (Hoogenraad CC et al. 2000). CLIP170 is involved in MT 
dynamics in interphase and during mitosis (Arnal I et al. 2004; Tanenbaum ME et al. 2006) 
and in the recruitment of the MT minus-end-directed motor dynein to the MT growing 
end (Lomakin AJ et al. 2009). 
 
The largest group of +TIPs are enriched in basic and serine residues. These regions, which 
are predicted to be flexible, often mediate interactions with MTs and EB proteins 
(Steinmetz MO & Akhmanova A, 2008; Kumar P & Wittmann T, 2012). Inside this region 
there is a small 4-residue motif SxIP (Ser-x-Ile-Pro) which is implicated in the targeting of a 
large number of +TIPs to the growing MT end in an EB1-dependent manner. This 
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conserved motif is now considered as a microtubule tip localization signal (MtLS) 
(Honnappa S et al. 2009). 
Representative examples of this group of +TIPs are the adenomatous polyposis coli (APC), 
the mitotic centromere-associated kinesin (MCAK), TIP150, the MT-actin crosslinking 
factor (MACF or ACF7), the stromal interaction molecule 1 (STIM1), the CLIP-associating 
proteins (CLASPs), p140Cap, DDA3, RhoGEF2, Navigators, melanophilin and CDK5RAP2. I 
will review here a few SxIP-containing +TIPs that will be of relevance for this work. 
APC is a highly conserved multidomain tumor suppressor implicated in the regulation of 
the Wnt signaling pathway (Mimori-Kiyosue Y & Tsukita S, 2001). Considering the different 
subcellular localizations of APC (Bienz M, 2002), it has been linked to multiple processes as 
cell migration, cell adhesion, chromosome segregation, spindle assembly, neuronal 
differentiation and apoptosis (Hanson CA & Miller JR, 2005; Aoki K & Taketo MM, 2007). 
Biochemical studies have mapped the EB1-APC interaction to a basic, serine-rich sequence 
of 39 residues in the APC C-terminal domain, termed APCp1 (Honnappa S et al. 2005) 
which contains one SxIP motif that allows tip tracking in living cells through interaction 
with EB1 (Berrueta L et al. 1998; Morrison EE et al. 1998; Mimori-Kiyosue Y et al. 2000). 
MCAK was initially identified as a member of the KinI subfamily of kinesins and was 
classified as a MT depolymerase that induces conformational changes at the MT plus-end 
(Desai A et al. 1999). Later on, the kinesin nomenclature was standardized and MCAK 
(KIF2C) was grouped as a member of the kinesin 13 family along with mammalian KIF2A 
and KIF2B (Lawrence CJ et al. 2004; Moores CA et al. 2006). This family has a particular 
characteristic because rather than walk along MTs (as other kinesins), they use ATP 
hydrolysis to depolymerize MTs from both ends (Desai A et al. 1999; Hunter AW et al. 
2003; Helenius J et al. 2006). MCAK is a homodimeric molecule with a motor domain 
located in the central part of the protein, which is involved in MT depolymerization in vitro 
and in vivo (Maney T et al. 2001; Newton CN et al. 2004; Ogawa T et al. 2004; Moores CA 
et al. 2006). In spite of being a MT depolymerase, MCAK is able to track MT plus-ends in 
living cells (Moore AT et al. 2005) by one-dimensional diffusion (Helenius J et al. 2006) or 
by its association with EB proteins via its basic/serine rich region and the SxIP motif 
located in the N-terminus of the protein (Lee T et al. 2008). 
TIP150 was identified in silico as a +TIP candidate with an EB1-binding domain rich in 
serines, prolines and basic residues. Further experiments showed that it binds EB1 and 
tracks growing MT plus-end via an SxIP motif located in the C-terminal part of the protein. 
TIP150 also binds to MCAK and knockdown experiments suggested that TIP150 could play 
a role in targeting MCAK to the plus-end (Jiang K et al. 2009). Recently, a role has been 
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attributed to TIP150-EB1 interaction in the dynamic regulation of kinetochore MTs and 
chromosome alignment during metaphase (Ward T et al. 2013). 
 
The last group of +TIPs comprises the motor proteins kinesins and dyneins. In eukaryotes, 
these motor proteins are essential partners of MTs during interphase and mitosis, and can 
accumulate at the MT plus-end through the association with other +TIPs (Akhmanova A & 
Steinmetz MO, 2008). 
Kinesins were first described in neurons as plus-end directed motors needed for axonal 
transport (Vale RD et al. 1985). Later studies involved kinesins in the organization of the 
MT cytoskeleton in interphase, directional organelle movement and cell division (Wade 
RH, 2009). 
Cytoplasmic dynein is a large multisubunit complex whose activity in vivo requires the 
dynactin complex (Wade RH, 2009). Dynein has relevant roles in minus-end transport of 
cargoes along the MTs, formation and orientation of the mitotic spindle and MT array, and 
in nuclear positioning (reviewed in Wu X et al. 2006). In mammalian cells, dynein has been 
observed at the MT plus-ends showing comet-like structures that co-localize with EB1 
(Vaughan KT et al. 1999; Kobayashi T & Murayama T, 2009). It has also been proposed 
that dynein is targeted to MT growing ends by dynactin or by LIS1, which both require 
CLIP170 for efficient plus-end accumulation (Akhmanova A & Steinmetz MO, 2008). 
 
3.6.2. Plus-end tracking mechanisms 
+TIPs can target MT growing ends in two ways, either directly by association with tubulin 
or MTs, or indirectly, through other factors (Figure 27). It has been described that some 
+TIPs (e.g. CLIP170, APC) tip track the MT plus-end using different mechanisms (Folker ES 
et al. 2005; Kita K et al. 2006). 
Different plus-end tracking mechanisms can be classified in four groups: end recognition, 
copolymerization, directed transport and hitchhiking (Figure 27). Within these groups a 
sub-classification can be done. Indeed, the end recognition mechanism can be divided 
according to the binding kinetics in slow (treadmilling) and fast exchange, and the directed 
transport can be motor-based or by one-dimensional diffusion. 
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Figure 27 
Mechanisms of MT plus-end tracking. +TIPs can (A) recognize a specific structure at the growing end of the MT (right 
diagram) and get released after tubule closure (left diagram) or (B) can bind the plus-ends by co-polymerization with 
tubulin dimers, by hitchhiking, by lateral diffusion or by kinesin-based transport (Modified from Akhmanova A & 
Steinmetz MO, 2008). 
 
The end recognition model stands for the identification of a specific characteristic in the 
structure of the growing end that is different from the lattice. In accordance, +TIPs could 
recognize the GTP cap, the tubulin sheets, the individual protofilaments or some hidden 
sites at the inner side of MTs (Figure 27A) (Akhmanova A & Steinmetz MO, 2008). Once 
the +TIPs bind the MT plus-ends, its turnover can be slow (treadmilling), meaning that the 
+TIP binds the MT plus-end and only dissociates when the MT lattice becomes mature 
(Carvalho P et al. 2003). Alternatively, +TIPs can be highly dynamic and bind/unbind 
repeatedly the same MT close to its tip, which allows several binding events on a single 
binding site. Some examples are EB1, EB3 and CLIP170 (Bieling P et al. 2008; Dragestein 
KA et al. 2008). 
Besides interacting with MT growing ends, some +TIPs can bind tubulin dimers and 
oligomers and thus, be copolymerized with tubulin. This is the case for mammalian CLIPs, 
which can co-polymerize with tubulin and are then released from the mature lattice 
(Figure 27B) (Diamantopoulos GS et al. 1999; Folker ES et al. 2005). 
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+TIPs can also move along the MT lattice until they reach the growing end in two ways, 
either by associating with motor proteins or by one-dimensional diffusion (Figure 27B). In 
the motor-based transport, growing end movement is driven by a plus-end directed 
kinesin, in an ATP-dependent manner; nevertheless, it should be noted that reaching the 
growing end does not imply an accumulation mechanism per se. That is why +TIP 
accumulation requires that kinesin moves faster that MT polymerization. An example of 
motor-based transport is APC that can be transported to the MT growing end by kinesin 2 
(Jimbo T et al. 2002).  
The MT lattice diffusion, unlike motor transport, implies +TIP targeting to the plus-end 
without energy consumption (Cooper JR & Wordeman L, 2009). This type of movement 
has been reported for some kinesins including Eg5 (Kwok BH et al. 2006) and CENP-E (Kim 
Y et al. 2008) and some MAPs as MCAK (Helenius J et al. 2006) and Tau (Konzack S et al. 
2007). 
Most of the +TIPs accumulate at the plus-end by hitchhiking on EB proteins through CAP-
Gly domains or SxIP motifs (Figure 27B). This indicates that hitchhikers do not interact (or 
less efficiently) with tubulin or MTs and are mostly transported to the growing end. Some 
examples of these hitchhikers +TIPs are MCAK, APC, MACF/ACF7, CLASPs, STIM1 and 
CLIP170 proteins (Carvalho P et al. 2003). Of note, CLIP170 and MCAK can also track MT 
plus-ends autonomously as mentioned before. 
 
3.6.3. +TIPs functions 
Being located at the growing end of the MTs allows +TIPs to control microtubule 
dynamics, the anchoring of MTs to other cellular structures and the transport of 
molecules (Akhmanova A & Steinmetz MO, 2008). 
Even if they can interact and co-localize at the plus-end, +TIPs effects on MT dynamics can 
be different and sometimes opposed. +TIPs can induce MT growth, MT shrinkage or MT 
stabilization. 
Binding of +TIPs to MT plus-ends can cause MT stabilization by the reduction of 
catastrophe frequencies and the promotion of rescues and pauses states. CLIP170 is 
involved in MT stability as it has been described as a rescue factor in mammalian cells 
(Komarova YA et al. 2002a). Similarly, proteins with basic and serine rich regions, such as 
CLASPs, MACF/ACF7 and APC are MT stabilizing factors which act by preventing MT 
catastrophes and promoting rescues and pauses (Mimori-Kiyosue Y et al. 2005; Kita K et 
al. 2006; Akhmanova A & Steinmetz MO, 2008; Al-Bassam J et al. 2010) 
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The kinesin 13 MCAK is considered a potent MT depolymerizer able to induce 
conformational changes in order to bend and peel off tubulin individual protofilaments 
(reviewed in Hunter AW et al. 2003; Moores CA & Milligan RA, 2006 and Ems-McClung SC 
& Walczak CE, 2010). 
EB proteins are able to make MTs more dynamic and promote MT polymerization by 
increasing MT rescue frequencies and decreasing depolymerization and pausing in vivo 
(Nakamura M et al. 2001; Komarova YA et al. 2009). EB1 implication in MT dynamics will 
be reviewed in the next chapter. SLAIN2 can also promote MT polymerization during 
interphase through the interaction with other +TIPs (van der Vaart B et al. 2011). 
Besides regulating MT dynamics, +TIPs have been reported to be involved in the 
attachment of MTs to other cellular structures like the kinetochores or the plasma 
membrane (Gundersen GG et al. 2004; Lansbergen G & Akhmanova A, 2006). This often 
requires the combined effect of several +TIPs. For example, APC together with IQGAP1 
and mDia1 attach MT growing ends to the cell cortex (Watanabe T et al. 2004; Wen Y et 
al. 2004) and CLIP170 also seems to target cortical cell sites in a complex with IQGAP1 
(Fukata M et al. 2002). 
+TIPs can also facilitate MT-intracellular membranes binding. For example STIM1 
participates in the MT growth-dependent extension and remodeling of endoplasmic 
reticulum tubes through the interaction with EB1 (Grigoriev I et al. 2008). Dynamic MT 
plus-ends are also implicated in remodeling of focal adhesions and in the formation of cell 
contacts and gap junctions (Akhmanova A & Steinmetz MO, 2008). 
During mitosis, one of the most important functions of the MT growing ends is to capture 
chromosomes and ensure their correct segregation. Indeed, most of the +TIPs are able to 
localize to mitotic kinetochores where they can mediate the interface between MTs and 
chromosomes. From this position, +TIPs can participate in mitotic spindle assembly, 
spindle orientation and positioning, and MT-kinetochore attachment (Maiato H et al. 
2004a; Maiato H et al. 2004b). For example, CLASPs are essential for the assembly and 
maintenance of the mitotic spindle (Maiato H et al. 2002), whereas MCAK, which localizes 
at the centromeres, is necessary for correct chromosome position at the metaphase plate 
(Walczak CE et al. 2002) and serves as a correction mechanism through the 
depolymerization of MTs when they are incorrectly attached (Ohi R et al. 2003). 
Many +TIPs are present at the spindle pole and the centrosomes (EBs, MCAK, APC, 
CLASPs, dynein) where they can have a role in MT anchoring and nucleation or in the 
stabilization of MT minus-ends (Yan X et al. 2006; Fong KW et al. 2008). +TIPs can also 
crosslink MT and actin cytoskeletons, interact with actin motors and modulate actin 
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dynamics (Kodama A et al. 2003; Wu XS et al. 2005; Moseley JB et al. 2007; Tsvetkov AS et 
al. 2007). 
Finally, +TIPs are involved in cargo transport from the periphery to the minus-end through 
dyneins (Vaughan PS et al. 2002; Lomakin AJ et al. 2009) and in the plus-end transport 
along the MT lattice to organize the array as for the mitotic spindle formation (Goshima G 
et al. 2005). 
 
3.7. End-binding protein 1 
EB1 is the leading member of the family of End Binding proteins. This family also 
comprises EB2 (RP1) and EB3 (EBF3). EB proteins are evolutionary conserved and in 
mammals are encoded by the MAPRE gene family (Su LK & Qi Y, 2001). EB1 and EB3 are 
ubiquitously expressed, but EB3 is especially abundant in the central nervous system 
(Nakagawa H et al. 2000), whereas expression levels of EB2 differ in various cell lines (Su 
LK & Qi Y, 2001). 
EB proteins contain two highly conserved domains connected by a linker sequence (Figure 
28). The N-terminus of the EBs consist of a calponin homology (CH) domain, which is 
necessary and sufficient for binding to MTs and recognizing their growing ends (Hayashi I 
& Ikura M, 2003). The C-terminal domain (EB1c), contains a coiled-coil motif responsible 
for protein dimerization (Su LK & Qi Y, 2001). This motif partially overlaps with the end 
binding homology (EBH) domain, which is involved in the interaction with EB binding 
partners (Akhmanova A & Steinmetz MO, 2008). An acidic tail at the C-terminus contains a 
highly conserved EEY sequence motif, similar to those found in α-tubulin and CLIP170 
(Komarova Y et al. 2005; Honnappa S et al. 2006), that is implicated in the interaction with 
other proteins (Honnappa S et al. 2005; Hayashi I et al. 2005). 
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Figure 28 
EB1 protein structure. (A) Schematic representation of EB1. Calponin homology (CH), coiled coil and EB homology (EBH) 
domains are represented. Amino acids are shown on the bottom (Adapted from Buey RM et al. 2011). (B) Structural 
organization of homodimeric end-binding proteins. The structures of the CH and EBH domains are shown. The EEY 
sequence motifs are also shown. Dashed, curved lines show the linker segments (From Akhmanova A & Steinmetz MO, 
2008). 
 
EB1 and EB3 are able to interact with a large number of proteins (Bu W & Su LK, 2003). 
EB2 is also able to interact with some EB1/EB3 partners (Bu W & Su LK, 2003) although 
with lower affinity, mainly due to the presence of fewer acidic residues contained in its C-
terminal tail. The N-terminal region of EB2 is also different from EB1/EB3 proteins and 
contains an extension of approximately 40 amino acids. The residue difference is critical 
for MT binding and reduces EB2 accumulation at the MT plus-ends (Komarova YA et al. 
2009). 
EB1 was initially discovered as an APC-interacting partner by yeast two-hybrid screen (Su 
LK et al. 1995). Later studies published in 1998 showed that EB1 was associated with the 
MTs and often concentrated at their tips (Morrison EE et al. 1998). But it was in 2000 that 
Mimori-Kiyosue Y and collaborators demonstrated, using time-lapse videomicroscopy of 
EB1-GFP construct, that EB1 was localized at the end of growing MTs independently of 
APC. 
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Later after, the “EB1 boom” started and several studies about its structure, its relation 
with MTs and other +TIPs filled the journals pages. After Mimori-Kiyosue Y et al. work in 
2000, the pursuit of how EB1 was able to bind the growing ends of MTs began. Bieling P 
and coworkers (2007) showed, using an in vitro model, that EB1 could track autonomously 
the tip of the MT by fast exchange, meaning that EB1 associates and disassociates from 
the plus-end in a dynamic way. 
Besides binding APC via its C-terminal portion, EB1 also binds to multiple partners 
(through the same domain) and works as a scaffold protein that brings different proteins 
to the MT growing end (Jiang K et al. 2012). EB1 is thus considered as the “key stone” or 
core component of +TIP network. Two major binding regions have been described: the 
EBH domain that is recognized by the SxIP-containing proteins (Honnappa S et al. 2009) 
and the EEY motif which in turn is recognized by the CAP-Gly proteins (Bieling P et al. 
2008). 
In 2012, the analysis of a large number of SxIP binding partners of EB1 by Jiang K and 
coworkers led to the outstanding discovery that not all the proteins that interact with EB1 
are tip trackers. Using GST pull-down and mass spectrometry they found that some 
proteins were membrane-associated as AMER2 (plasma membrane) and Syntabulin 
(mitochondria membrane); some were actin-binding proteins (GAS2L1); small GTPases 
(RasL11B); or kinases as MARK1, TTBK1 and TTBK2. Surprisingly, they also found two 
proteins (namely, tastin and DDA3) that in addition to tracking the growing end, were able 
to track shrinking MTs. 
EB1 localizes at the growing ends of MTs in interphase and during mitosis (Figure 29) and 
from this strategic position it has a role in controlling MT dynamics in vitro and in vivo, by 
promoting MT polymerization (Tirnauer JS & Bierer BE, 2000; Vitre B et al. 2008; 
Komarova Y et al. 2009). However, its precise influence on dynamic instability parameters 
(in vitro and in vivo) is still controversial. The first evidence for a role of EB1 in controlling 
MT dynamics, in particular by promoting MT growth, was done studying EB1 yeast 
homologues (Mal3 and Bim1) (Tirnauer JS & Bierer BE, 2000). These results were 
confirmed in Drosophila cells. EB1 was shown to stimulate catastrophes and rescues, 
making MTs more dynamic, while it decreased the time spent pausing (Rogers SL et al. 
2002). Conversely, in Xenopus extracts, it was demonstrated that EB1 stimulated MT 
polymerization, MT rescues and inhibited catastrophes, suggesting a stabilizer role for EB1 
(Tirnauer JS et al. 2002b). Later in 2006, using mouse fibroblasts Kita K and coworkers 
showed that depletion of EB1 promoted MT pausing and decreased the time MT spend in 
growth (Kita K et al. 2006). Finally, using CHO-K1 cells it was shown that EB1 and EB3 
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promote persistent MT growth by suppressing catastrophes, with little effect on MT 
growth rate or rescues (Komarova Y et al. 2009). 
 
Figure 29 
Localization of EB1 (green) in an interphase cell (left panel) and in a mitotic cell (right panel). Red stain corresponds to β-
tubulin (From Akhmanova A & Steinmetz MO, 2008). 
 
EB1 also accumulates at MT plus-ends at the interface between kinetochores and growing 
MTs, suggesting that it could have a role in the dynamic behavior during mitosis (Tirnauer 
JS et al. 2002a; Mimori-Kiyosue Y & Tsukita S, 2003). In addition, it was shown that EB1 
may partially depends on APC interaction to regulate spindle dynamics and chromosome 
alignment (Green RA et al. 2005), and may also be implicated in spindle positioning by the 
stabilization of astral MTs (Toyoshima F & Nishida E, 2007). 
The accumulation and tip tracking characteristics of EB1 at the MT growing end can be 
considered as a useful tool for the measurement of dynamic instability parameters, as 
have been described in different studies (Piehl M & Cassimeris L, 2003; Salaycik KJ et al. 
2005; Long JB et al. 2013; Lowery LA et al. 2013).  
EB1 can also be found localized at other cellular structures such as the centrosomes and 
the cilia, where it may play a role in MT anchorage (Berrueta L et al. 1998; Louie RK et al. 
2004) and primary cilia assembly (Schroder JM et al. 2007). In addition, EB1 together with 
its partners can link MT plus-ends with other structures such as actin (through MACF/ACF7 
(Kodama A et al. 2003)), the cell cortex (through CLASPs (Mimori-Kiyosue Y et al. 2005)), 
melanosomes (through melanophilin and myosin Va (Wu XS et al. 2005)) and the 
endoplasmic reticulum (through STIM1 (Grigoriev I et al. 2008)). 
Overexpression of EB1 has been associated with hepatocellular (Fujii K et al. 2005; Orimo 
T et al. 2008), gastric (Nishigaki R et al. 2005), oesophageal (Wang Y et al. 2005), breast 
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(Dong X et al. 2010) and in early colorectal (Stypula-Cyrus Y et al. 2014) carcinomas. It 
would be interesting to investigate if the oncogenic functions of EB1 are related with its 
effects on MT dynamics and/or with the interaction with other +TIPs. Overexpression of 
EB1 could be implicated in the deregulation of MT-mediated cell activities such as cell 
division and cell migration, which lead to cancer progression. 
 
3.8. Microtubules in cell migration 
The cell cytoskeleton plays an essential role in cell migration. The participation of the actin 
network has been studied extensively (reviewed in Carlier MF & Pantaloni D, 2007), but is 
not the goal of this chapter. This last chapter will rather summarize current knowledge on 
the role of MTs in cell migration. 
According to the cell type, MTs can be dispensable or not for cell migration. For example, 
in small cells as fish keratocytes, hematopoietic cells, T lymphocytes and neutrophils, 
migration is possible even in the absence of MTs. In contrast, in fibroblasts, epithelial cells 
and neurons a disrupted MT network implicates problems in cell adhesion turnover, actin 
dynamics, membrane trafficking and thus directed cell migration (Kaverina I & Straube A, 
2011 and Etienne-Manneville S, 2013). 
MTs act as spatiotemporal coordinators of cell migration due to their involvement in the 
turnover and distribution of adhesion complexes and the localization and activation of 
Rho GTPases. And the most important function of MTs during migration is related to the 
establishment and maintenance of cell polarity to promote a persistent and directed cell 
migration (Gundersen GG & Bulinski JC, 1988; Etienne-Manneville S, 2013). 
Cell polarity accounts for the asymmetrical distribution of signals, molecules and 
arrangement of actin and MT cytoskeletons, in order to distinguish a front (named leading 
edge) that is characterized by the local activation of Cdc42 and Rac GTPases (Ridley AJ et 
al. 2003), and by the presence of a lamellipodial protrusion which indicates the migration 
direction. There is also a rear (known as trailing edge) that is located in the opposite 
direction of the lamellipodium and is characterized by the local activation of RhoA GTPase 
(Figure 30) (reviewed in Watanabe T et al. 2005; Kaverina I & Straube A, 2011 and Etienne-
Manneville S, 2013). 
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Figure 30 
Cell polarity is intrinsic to a migrating cell. Asymmetric distribution of cellular organelles allows the distinction of a 
leading edge (right side) and a trailing edge (left side). N: nucleus, MTOC: centrosome (From Watanabe T et al. 2005). 
 
A key feature of cell polarity is the differential distribution of MT network and MT 
dynamics between the leading and the trailing edge. Even if the lamellipodium is mainly 
composed by actin filaments, some MTs (around a dozen), known as pioneer MTs, can 
enter into the protrusion to contribute to pushing forces, cellular trafficking and signaling 
(Figure 31) (Watanabe T et al. 2005; Etienne-Manneville S, 2013). 
Several studies have reported that different activities occur at the front and at the rear of 
a migrating cell. At the leading edge, MTs are captured and stabilized at cortical and 
adhesion sites (Fukata M et al. 2002; Krylyshkina O et al. 2003; Watanabe T et al. 2004; 
Mimori-Kiyosue Y et al. 2005; Manneville JB et al. 2010). They are post-translationally 
modified (acetylation) enabling the binding of motors that will crosslink the different 
cytoskeleton filaments (Figure 31A) and will transport factors associated with cell 
protrusion (membrane vesicles, membrane-associated signaling molecules such as Rac 
and Cdc42) (Figure 31B) (Etienne-Manneville S, 2013). Of note, +TIP complex formation at 
the cell cortex, such as EB1-APC, EB1-CLASP, EB1-MACF/ACF7, CLIP170-IQGAP, APC-IQGAP 
(Fukata M et al. 2002; Kodama A et al. 2003; Watanabe T et al. 2004; Wen Y et al. 2004; 
Drabek K et al. 2006) and inactivation of Op18/Stathmin at the leading edge (Niethammer 
P et al. 2004; Wittmann T et al. 2004) will lead to MT stabilization. 
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Figure 31 
MT in cell protrusions. MT can bind actin and intermediate filaments through different crosslinkers (A). MTs functions in 
cellular trafficking (B) and signaling (C) are shown (From Etienne-Manneville S, 2013). 
 
MTs also possess signaling properties that will promote cell migration through the 
activation/deactivation of Rho GTPases (Figure 31C) that in turn will impact on actin 
polymerization (reviewed in Watanabe T et al. 2005; Kaverina I & Straube A, 2011 and 
Etienne-Manneville S, 2013). One of the first studies to demonstrate the effect of MTs on 
actin polymerization at the leading edge was performed by Waterman-Storer CM et al. 
(1999). In their study, they showed that MT polymerization activates Rac1 to promote 
protrusion formation in nocodazole washout experiments. Later studies showed that MT 
growth towards the leading edge also activates Asef, a Rac GEF, which interacts with APC 
at the tips of the protrusions to induce membrane ruffles (Kawasaki Y et al. 2000; 
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Kawasaki Y et al. 2003). Some other Rac/Cdc42 effectors (TIAM1, TIAM2/STEF, IQGAP1, 
Trio and GEF H1 ) can be found at the leading edge and interact with either MTs, MAPs or 
+TIPs to induce actin polymerization (reviewed in Watanabe T et al. 2005; Kaverina I & 
Straube A, 2011 and Etienne-Manneville S, 2013). 
On the other hand, at the trailing edge MT are more dynamics, Op18/Stathmin is still 
activated (Niethammer P et al. 2004) which means more catastrophe events (Salaycik KJ et 
al. 2005). Additionally, MT depolymerization induces RhoA activation (Ren XD et al. 1999) 
which is implicated in the maturation and dissociation of adhesion complexes at the 
trailing edge together with the assembly of contractile actin and myosin in the rear part of 
the cell (Watanabe T et al. 2005). 
Various MAPs have been involved in the regulation of cell polarity through their effects on 
MT dynamics, mostly at the leading edge. For example, down-regulation of EB1 results in 
decreased lamellipodium formation, cell velocity and cell directionality in melanoma cells 
(Schober JM et al. 2009). EB1 is also implicated in MT stabilization at the front edge 
together with APC and downstream RhoA and mDia (Wen Y et al. 2004). Additionally, 
CLASPs, CLIP170 and MACF (ACF7) are also able to stabilize MTs and therefore increase 
directional cell migration (Akhmanova A et al. 2001; Kodama A et al. 2003; Drabek K et al. 
2006; Nakano A et al. 2010). 
Besides MT organization, some other characteristics of cell polarity during migration 
include nucleus, centrosome (MTOC) and Golgi repositioning (Figure 32). The position of 
the centrosome is controlled by signaling pathways downstream Cdc42 and by the action 
of dynein and dynactin that will act in MT pulling forces from the plus-end to the minus-
end (Palazzo AF et al. 2001a; Etienne-Manneville S & Hall A, 2001; Tzima E et al. 2003). 
Nuclear positioning depends on cell type and physiological context (Dupin I & Etienne-
Manneville S, 2011) but is mostly driven by actin retrograde flow (Gomes ER et al. 2005). 
Nucleus is pushed toward the rear of the cell, behind the centrosome, and in that way the 
nucleus-centrosome axis is defined parallel to the migration direction. 
Finally, the MTOC positioning affects the localization of the Golgi complex. These two 
cellular organelles are maintained in close proximity by dynein (Sütterlin C & Colanzi A, 
2010) and are involved in MT nucleation. 
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Figure 32 
Cell polarization during migration (From Etienne-Manneville S, 2013). 
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4. ATIP3 a novel therapeutic target against breast cancer 
 
In this last chapter of the manuscript I will present MTUS1, a candidate tumor suppressor 
gene located at chromosome position 8p22, a region frequently lost in a large number of 
human cancers. I will describe MTUS1 gene’s major product ATIP3, its main characteristics 
and functions.  
 
4.1. MTUS1, a candidate tumor suppressor gene 
Before being designated as a Microtubule Tumor Suppressor gene 1 (MTUS1), this gene 
was named GK1 (Kinjo T et al. 2000), MTSG1 (Seibold S et al. 2003), ATIP (Nouet S et al. 
2004) and finally MTUS1 (for mitochondrial tumor suppressor 1) (Di Benedetto M et al. 
2006a). 
GK1 was described for the first time by Kinjo T et al. (2000). Through large-scale 
sequencing of genomic DNA from human chromosome 8p22-p21.3, this group isolated a 
new gene that encoded a 1270 amino-acid protein. In silico analysis revealed that the 
gene product contained putative leucine-zipper domains and a mitochondrial targeting 
motif. Immunofluorescence stain confirmed the co-localization of GK1 with the 
mitochondria. 
Then in 2003, with the aim to identify new molecular regulators of carcinogenesis Seibold 
S et al. reported a new potential tumor suppressor gene located in a position frequently 
lost in several types of human cancers: 8p21.3-22. In their study, immunofluorescence and 
western blot analysis demonstrated a mitochondrial localization of the mature protein, 
and BrdU proliferation assays showed a reduction in the compound incorporation when 
the gene product was expressed. According to the functional data and intracellular 
localization, they named this gene MTSG1: mitochondrial tumor suppressor gene 1. 
One year later, Nouet S et al. (2004) while investigating for new interacting partners of the 
angiotensin II AT2 receptor, using yeast two-hybrid assay, found a new protein that they 
called ATIP (for Angiotensin II AT2 receptor-Interacting Protein). They also found that this 
ATIP protein was a gene product out of four (ATIP1, ATIP2, ATIP3 and ATIP4), generated by 
alternative splicing of the ATIP gene. Interestingly, they showed that all these ATIP 
proteins shared the C-terminal sequence where the AT2 binding domain was present. 
Later studies from the same group (and then confirmed by Yu J et al. 2009) reported the 
exon/intron organization of human MTUS1 (mitochondrial tumor suppressor gene 1) 
(Figure 33) (Di Benedetto M et al. 2006a): MTUS1 comprises 17 coding exons distributed 
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over 112 kb, with three different gene promoters (Yu J et al. 2009), three 5’ UTR 
(untranslated regions) and ATG initiating codons located at exons 8, 1 and 5, that generate 
the three major ATIP transcripts: ATIP1, ATIP3 and ATIP4, respectively. They also 
described that exons 9 to 17 are common to all ATIP members and encode a large and 
highly conserved coiled-coil domain involved in the dimerization of ATIP proteins that is 
now considered as the “ATIP-signature”. 
 
Figure 33 
Structural organization of MTUS1 and MTUS1 gene products (ATIPs) (From Rodrigues-Ferreira S & Nahmias C, 2010). 
 
A number of studies have shown that MTUS1 expression levels are reduced in breast 
(Rodrigues-Ferreira S et al. 2009), pancreas (Seibold S et al. 2003), ovary (Pils D et al. 
2005), colon (Lee S et al. 2006; Zuern C et al. 2010), head-and-neck (Ye H et al. 2007; Ding 
X et al. 2012), bladder (Xiao J et al. 2012; Rogler A et al. 2014) and gastric carcinomas (Li X 
et al. 2014). At the genomic level, a mutational analysis of MTUS1 gene in a series of 51 
primary hepatocellular carcinomas (HCC) and 51 HCC cell lines led to the identification of 
five nucleotide sequence variations (in the exonic sequence) that were absent in non-
tumoral control DNA (Di Benedetto M et al. 2006b). Some of these variations (four) were 
also found (along with nine single-nucleotide sequence variants) in an analysis performed 
in 41 head and neck squamous cell carcinoma cell lines (Ye H et al. 2007). Additionally, in a 
case-control study Frank B et al (2007) showed that deletion of the entire exon 4 of the 
MTUS1 gene was associated with a decreased risk for familial breast cancer. All these data 
together support the notion of MTUS1 as a tumor suppressor gene. 
Genomic sequence comparison reveals the presence of a human paralog MTUS2 
(chromosome position 13q12) which presents similar genomic organization as MTUS1. 
This gene can generate two proteins by alternative splicing (CAZIPa or TIP150 (Jiang K et 
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al. 2009) and CAZIPb) which are structurally similar to ATIP3 and ATIP1, respectively. 
Additionally, CAZIP proteins share their C-terminal portion (coiled-coil domains) and differ 
in the N-terminal part, similar to ATIP proteins (Du Puy L et al. 2009). Amino acid sequence 
comparison of the C-terminal region revealed a 35% identity between coiled-coil domains 
of CAZIPs and ATIPs (Rodrigues-Ferreira S & Nahmias C, 2010). Indeed, this region is highly 
conserved among mammals (86 to 96% amino acid sequence identity between human, 
canine, bovine, murine and rat sequences) (Di Benedetto M et al. 2006a). 
The Xenopus ortholog of MTUS1 encodes for a protein structurally similar to ATIPs 
proteins. ICIS (Inner Centromere kin-I Stimulator) contains two coiled-coil domains, one of 
them located at the C-terminal portion of the protein, which presents 60% identity with 
ATIPs C-terminus (Di Benedetto M et al. 2006a). ICIS has been identified as an inner 
centromere protein which acts as a scaffold protein to bring two depolymerizing kinesins 
(MCAK and KIF2A) at the kinetochore during mitosis in order to ensure proper 
chromosome segregation (Ohi R et al. 2003; Knowlton AL et al. 2009). 
 
4.2. A family of ATIP proteins 
The family of angiotensin II AT2 receptor-interacting proteins is composed by three major 
proteins (ATIP1, ATIP3 and ATIP4) which share the same C-terminus but differ in their N-
terminus and therefore in their length (Figure 33). In 2006, a study performed by Di 
Benedetto M and co-workers analyzed the tissue distribution of each ATIP transcript in a 
large number of human normal tissues by means of real-time quantitative RT-PCR. 
Consistent with the different promoter use, ATIP1, ATIP3 and ATIP4 show different tissue 
distribution in normal human tissues (Figure 34). Of note, two ATIP3 variants (ATIP3a and 
ATIP3b) showing similar tissue distribution have been described and will be presented 
below in more details. 
ATIP3 is the major transcript expressed in almost all tissues, except for the brain. In 
contrast, ATIP1 is mainly expressed in central nervous system tissues, in female 
reproductive tissues (placenta, breast, ovary and uterus), thyroid and heart. Finally, ATIP4 
mRNA is exclusively detected in the brain and most specifically in the cerebellum and the 
fetal brain. 
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Figure 34 
Quantitative RT-PCR of total ATIP transcripts in human normal tissues (From Di Benedetto M et al. 2006). 
 
ATIP1 was the first characterized member of ATIP proteins. The 5’ UTR and initiating 
codon of ATIP1 are contained in exon 8 (the only N-terminal exon of ATIP1 protein). The 
first 40 amino acids of exon 8 also contain a mitochondrial targeting signal (Seibold S et al. 
2003). To date, ATIP1 is the only ATIP member in which it has been shown an interaction 
with AT2 receptor in eukaryotic cells (Nouet S et al. 2004; Wruck CJ et al. 2005; Li JM et al. 
2007). ATIP1 interacts with AT2 in the absence of ligand angiotensin II and is involved in 
AT2R activation and in the transport of the receptor to the cell membrane (Wruck CJ et al. 
2005). Additionally, ATIP1-AT2 interaction contributes to AT2 effects on neuron 
differentiation (Li JM et al. 2007), vascular remodeling (Fujita T et al. 2009), vascular 
senescence (Min LJ et al. 2012) and adipose function (Jing F et al. 2013) (Figure 35).  
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Figure 35 
A family of multifunctional ATIP proteins with diverse subcellular locations (From Rodrigues-Ferreira S & Nahmias C, 
2010). 
 
ATIP3 is the major and the longest MTUS1 gene product. It includes three alternative 
splice variants: ATIP2, ATIP3a and ATIP3b. ATIP3a is characterized by the presence of 
exons 1, 2, 4, 6 and 7. Of these, exon 1 contains the initiating codon, exon 4 contains a 
polyproline-rich motif (PRPLP) that usually participate in interaction with both SH3 and 
WW domains (but to date it has not been demonstrated for ATIP3), exon 6 contains a 
second polyproline-rich motif (PPKP) and is always joined to exon 7 that harbors a nuclear 
localization signal (Di Benedetto M et al. 2006a). 
On the other hand, ATIP3b differs from ATIP3a by the absence of exon 4 indicating that 
these two proteins may interact with distinct intracellular partners and exhibit different 
cellular functions. Finally, and although ATIP2 contains the same exons that ATIP3a, it also 
uses exon 3 that contains an in-frame stop codon that potentially translates a truncated 
protein that does not contain the coiled-coil region (Di Benedetto M et al. 2006a). ATIP2 is 
hardly expressed in normal tissues (Figure 34), suggesting that its expression may be 
regulated by a mechanism of nonsense-mediated decay. 
  
75 
Up to now, cDNA cloning and functional characterization of ATIP4 have not been 
undertaken. Nevertheless, due to its restricted expression in the brain and the presence of 
a membrane spanning domain located in exon 5, it may be possible that ATIP4 mediates 
AT2R functions in the brain (Di Benedetto M et al. 2006a; Rodrigues-Ferreira S et al. 2013). 
 
4.3. ATIP3, A TIP top protein down-regulated in Breast Carcinoma 
While several studies have demonstrated down-regulation of MTUS1 gene in various 
types of cancers, Rodrigues-Ferreira S et al (2009) were the first to provide evidence that 
ATIP3, and not ATIP1 or ATIP4, was the major MTUS1 gene product whose expression is 
decreased in human breast cancer as compared to normal tissue. 
Indeed, Affymetrix DNA array conducted in a series of 151 invasive ductal breast 
carcinomas, further validated by real-time RT-PCR analysis using specific primers for 
different ATIP variants, revealed that MTUS1, and more specifically ATIP3, is down-
regulated in 85% of high grade tumors (grade III); in 83% of triple negative breast cancer, 
as well as in 62% of metastatic tumors (Figure 36) (Rodrigues-Ferreira S et al. 2009).  
 
Figure 36 
ATIP3 down-regulation in invasive breast carcinoma. MTUS1 levels are decreased in high histological grade (A), triple 
negative (TN) (B) and metastatic tumors (C). Real-time RT-PCR using ATIP3 specific primers indicate that this is the 
MTUS1 transcript down-regulated in breast cancer (D) (From Rodrigues-Ferreira S et al. 2009). 
 
At the functional level, different in vitro experiments (clonogenicity, MTT and BrdU assays) 
showed that re-expression of ATIP3 into ATIP3-deficient breast cancer cells lines (MCF7 
and MDA-MB-231) reduces cell proliferation whereas ATIP3-silencing in ATIP3-positive 
MDA-MB-468 cells leads to increased cell proliferation. Interestingly, time-lapse 
videomicroscopy of HeLa-H2B stable clones expressing ATIP3 revealed that decreased cell 
proliferation was due to an extension of the time spent in mitosis. Indeed, time 
  
76 
measurements of all mitosis phases indicated that ATIP3 expressing cells spent more time 
in metaphase than cells lacking the protein (Figure 37) (Rodrigues-Ferreira S et al. 2009). 
 
 
Figure 37 
ATIP3 delays mitosis (A) and more specifically delays the time to achieve metaphase (B) (From Rodrigues-Ferreira S et al. 
2009). 
 
On the other hand, in vivo experiments showed that ATIP3 also reduces tumor growth 
(incidence and size) after subcutaneous injection of MCF7 breast cancer cells expressing or 
not ATIP3 into immunodeficient mice (Rodrigues-Ferreira S et al. 2009). All these results 
indicate that ATIP3 is a novel biomarker for breast tumor of poor prognosis and an 
interesting therapeutic target for aggressive breast cancer. 
 
4.4. ATIP3 is a novel Microtubule-associated protein 
At the molecular level, ATIP3 decorates the microtubule (MT) cytoskeleton and the 
microtubule organizing center (MTOC) in interphase, the mitotic spindle during cell 
division and the intercellular bridge during cytokinesis (Figure 38). Co-sedimentation 
assays on cells expressing GFP or GFP-ATIP3 confirmed that ATIP3, and not GFP, 
associated with microtubules (Rodrigues-Ferreira S et al. 2009). 
Due to its association to MTs, in 2010 the nomenclature committee of the National Center 
for Biotechnology Information (NCBI) changed the name of MTUS1 gene to Microtubule-
associated TUmor Suppressor 1. 
  
77 
 
Figure 38 
ATIP3 associates with microtubules during interphase and mitosis (From Rodrigues-Ferreira S et al. 2009). Scale Bar, 10 
µm 
 
Overexpression of GFP-ATIP3 in a large number of cell lines (SKMES, HeLa, RPE1, MDA-
MB-231 and MCF7) led to the formation of bundles, suggesting that ATIP3 may induce MT 
stabilization. 
 
4.5. A functional family of Microtubule-Associated Proteins in cancer 
As state by Kaverina I and Straube A (2011) “the loss of microtubule-associated proteins 
and subsequent alteration of interphase microtubule dynamics stimulate uncontrolled 
motility in cancer cells that is associated with invasiveness and poor prognosis in cancer 
patients.” 
Additionally, a large number of studies have shown that loss of microtubule-associated 
proteins cause the stabilization of microtubule-kinetochore attachment errors during 
mitosis which will result in chromosome mis-segregation, aneuploidy and chromosomal 
instability (CIN) (Reviewed in Thompson SL et al. 2010). 
Besides ATIP3, a number of MAPs have been reported to display tumor suppressor 
functions, suggesting the existence of a functional superfamily of “Microtubule-Associated 
Tumor Suppressor Proteins (MATSP)” (Table 3). At the molecular level, these MATSPs can 
either stabilize or promote MT assembly. Representatives of this group of proteins are the 
RAS Association domain Family 1A (RASSF1A), the von Hippel–Lindau (VHL), the 
neurofibromatosis 2 (NF2) protein Merlin, the cylindromatosis tumor suppressor CYLD, 
the Adenomatous Polyposis Coli (APC), the Breast Cancer 1 (BRCA1), the leucine zipper 
putative tumor suppressor 1 (LZTS1) and the Fragile Histidine Triad (Fhit).  
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Table 3 
“Microtubule-Associated Tumor Suppressor proteins” (MATSP) characteristics. 
Protein 
Name 
Related-Cancer Inactivated by 
Subcellular 
localization 
Effect on MT References 
CYLD 
Skin appendages tumors or 
cylindromas, familial trichoepithelioma 
and Brooke-Spiegler syndrome 
Gene mutations 
MT network 
Midbody 
- Stabilization: 
- Promotes MT assembly and decreases 
depolymerization velocity 
- Promotes stability of astral MTs 
Bignell GR et al. 2000; Stegmeier F et al. 2007; Gao J et al. 
2008; Steinmetz MO & Akhmanova A, 2008; Massoumi R, 
2011 ; Li D et al. 2014; Yang Y et al. 2014 
Merlin 
Tumors in central and peripheral 
nervous system, colorectal cancer, 
melanoma and renal carcinoma 
Gene mutations 
and protein 
inactivation by 
phosphorylation 
MT network 
Mitotic Spindle 
- Stabilization: 
- Decreases tubulin turnover, growth and 
shrinkage rates, catastrophe frequencies 
- Inhibits GTP hydrolysis  
Xu HM & Gutmann DH, 1998; Muranen T et al. 2007; Cooper 
J & Giancotti FG, 2014; Smole Z et al. 2014 
RASSF1A Several carcinomas and solid tumors 
Promoter 
hypermethylation 
MT network 
Mitotic Spindle 
MTOC 
- Stabilization: 
- Decreases catastrophes, MT polymerization 
and depolymerization rates 
- Increases rescue frequency, pause events 
and MT lifetime 
- Bundles MTs  
- Decreases MT outgrowth towards cell cortex 
- Protect from depolymerization 
Liu L et al. 2003; Rong R et al. 2004; Dallol A et al. 2004; 
Dallol A et al. 2005; Richter AM et al. 2009 ; Arnette C et al. 
2014 
VHL 
Haemanglioblastomas and clear-cell 
RCC 
Gene mutations 
and promoter 
hypermethylation 
MT network 
Mitotic Spindle 
Primary cilia 
- Stabilization: 
- Blocks tubulin turnover, inhibits GTP activity, 
inhibits catastrophes, increases rescue 
frequency 
- Protect from depolymerization 
Hergovich A et al. 2002; Lolkema MP et al. 2004; Nyhan MJ 
et al. 2008; Thoma CR et al. 2009; Thoma CR et al. 2010; 
Haddad NM et al. 2013 
APC 
Sporadic Colorectal and familial 
adenomatous polyposis 
Gene mutations 
MT network/ 
MT growing end 
- Stabilization: 
- Protects from depolymerization 
- Interacts with other +TIPs (EB1, Amer2, 
KIF17, IQGAP and mDia) 
Nagase H & Nakamura Y, 1993; Munemitsu S et al. 1994; 
Smith KJ et al. 1994; Su LK et al. 1995; Polakis P, 1997; 
Mimori-Kiyosue Y et al. 2000; Goss KH & Groden J, 2000; 
Zumbrunn J et al. 2001; Nakamura M et al. 2001; Watanabe 
T et al. 2004; Wen Y et al. 2004; Jaulin F & Kreitzer G, 2010; 
Pfister AS et al. 2012 
BRCA1 
Breast, ovarian, gastric, non-small cell 
lung cancer 
Gene mutations 
MTOC 
Mitotic Spindle*  
Spindle Poles* 
Midbody* 
- Stabilization: 
- Decreases MT outgrowth towards cell cortex 
- Decreases growth and shrinkage rates, and 
MT dynamicity 
Hsu LC & White RL, 1998; Russell PA et al. 2000; Lotti LV et 
al. 2002; Lynch HT et al. 2008; Rosell R et al. 2009; Wei J et 
al. 2011; Foulkes WD & Shuen AY, 2013; Sung M & 
Giannakakou P, 2014 
LZTS1 
Gastric, ovarian, breast, lung, oral 
squamous cell carcinomas, bladder, 
prostate, esophageal cancers, uveal 
melanoma and kidney 
Gene mutations 
and promoter 
hypermethylation 
MT network 
- MT assembly dependent on MAP (mitogen-
activated protein) 2 
Ishii H et al. 1999; Ishii H et al. 2001; Vecchione A et al. 2001; 
Vecchione A et al. 2002; Ono K et al. 2003; Nonaka D et al. 
2005; Onken MD et al. 2008 ; Chen L et al. 2009; Califano D 
et al. 2010 
Fhit 
Ovarian, prostate, non-small cell lung 
cancer and primary breast cancer 
Promoter 
hypermethylation 
MT network - MT assembly 
Chaudhuri AR et al. 1999; Yang Q et al. 2002 ; Wali A, 2006; 
Wali A, 2010 
* Reported only in one paper Lotti LV et al. 2002
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A large number of studies have reported the inactivation, down-regulation or mutation of 
the genes encoding for these MAPs in several solid tumors (Table 3 for references). Of 
note, two of these proteins (APC and BRCA1) have been extensively studied and to date 
are considered masterpieces in the colorectal and breast/ovary cancer field, respectively. 
Six tumor suppressors have been shown to stabilize MTs either in vitro or in cell-based 
assays. For most of these proteins, few studies are available to explain the mechanism of 
MT stabilization.  
CYLD decorates the MT network to stabilize MTs by promoting their assembly and 
decreasing MT depolymerization velocity. This protein also decorates the midbody (known 
to be composed of stable MTs) and the astral MTs highlighting its role during mitosis 
(Stegmeier F et al. 2007; Gao J et al. 2008; Steinmetz MO & Akhmanova A, 2008; Li D et al. 
2014; Yang Y et al. 2014).  
Merlin has been described as a protein that binds MTs, anchors the actin cytoskeleton, 
controls cell proliferation, cell adhesion and epithelial polarization (Xu HM & Gutmann DH, 
1998; Muranen T et al. 2007). Its effects on MT dynamic instability parameters include 
decrease on tubulin turnover, as well as reduction of growth and shrinkage rates and 
catastrophe frequencies. These effects together with the inhibition of GTP hydrolysis 
make of this protein as a potent MT stabilizer (Muranen T et al. 2007; Smole Z et al. 2014). 
RASSF1A associates with interphase MTs, mitotic spindle and the MTOC. It bundles and 
stabilizes MTs through the reduction of catastrophes and MT polymerization and 
depolymerization rates. RASSF1A also increases the rescue frequencies, the percentage of 
time spent in pause and MT lifetime. Additionally, reduces MT regrowth and protects MTs 
from induced depolymerization (Liu L et al. 2003; Rong R et al. 2004; Dallol A et al. 2004; 
Arnette C et al. 2014). At the functional level, RASSF1A reduces cell migration, cell polarity 
and prevents CIN (Rong R et al. 2004; Dallol A et al. 2005; Arnette C et al. 2014). 
VHL accomplishes important roles in the renal epithelium. It has been described as a MAP 
that binds MTs in interphase and mitosis and associates with the primary cilia. It 
stabilization effects include inhibition of tubulin turnover and GTP activity, decrease of 
catastrophes, increase of the rescue frequency, as well as protection from 
depolymerization (Hergovich A et al. 2002; Lolkema MP et al. 2004; Thoma CR et al. 2010). 
Similar as RASSF1A, VHL prevents cell migration, CIN and spindle misorientation (Thoma 
CR et al. 2009). 
APC has been involved in a large number of functions as cell proliferation and survival 
preventing CIN and spindle misorientation, and in the promotion of cell migration (Polakis 
P, 1997; Watanabe T et al. 2004; Wen Y et al. 2004; Pfister AS et al. 2012). APC binds 
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directly the MTs or indirectly via EB1 (Munemitsu S et al. 1994; Smith KJ et al. 1994; Su LK 
et al. 1995; Mimori-Kiyosue Y et al. 2000; Zumbrunn J et al. 2001; Nakamura M et al. 
2001). APC is able to stabilize MTs mostly through the interaction with other +TIPs such as 
IQGAP (Watanabe T et al. 2004), mDia and EB1 (Wen Y et al. 2004), KIF17 (Jaulin F & 
Kreitzer G, 2010) and Amer2 (Pfister AS et al. 2012).  
BRCA1 has been shown to stabilize MTs but its mechanism remains controversial. Unlike 
the other MATSPs, BRCA1 does not localize at the MT lattice and rather regulates MT 
stability from the MTOC (Lotti LV et al. 2002; Sung M & Giannakakou P, 2014). BRCA1 
decreases MT outgrowth towards the cell cortex, as well as growth and shrinkage rates 
(Lotti LV et al. 2002; Sung M & Giannakakou P, 2014). 
Other members of the MATSPs family have been shown to promote MT assembly. LZTS1 
and Fhit are reported as MAPs that bind assembled MTs and tubulin, and function to 
promote MT assembly (Chaudhuri AR et al. 1999; Ishii H et al. 2001). Nevertheless, the 
mechanism of action has not been elucidated for any of the two proteins. 
 
It may be interesting to investigate if members of the MATSP superfamily can interact 
with each other and function in a concerted and cooperative way to regulate 
tumorigenesis. Interestingly, van der Weyden L and coworkers (2008) showed that 
cooperation between inactivation of RASSF1A and APC results in accelerated intestinal 
tumorigenesis, through the interfering of β-catenin pathway. It would now be of interest 
to evaluate whether these tumor suppressors may also coordinately regulate cancer 
progression by a mechanism involving their effects on MT dynamics.  
Finally, ATIP3 being part of the functional superfamily of MATSP, the question can be 
raised of whether ATIP3 may regulate some parameters of MT dynamic instability and/or 
cooperate with other members of the superfamily to exert its tumor suppressor effects. 
Based on these observations, my PhD project aims at elucidating the effects of ATIP3 on 
the regulation of MT dynamic instability, with possible consequences on cancer cell 
migration, and metastasis (Article 1). Additionally, the search for ATIP3 interacting 
partners that may contribute to the effects of ATIP3 on dynamic instability and/or cell 
migration shall constitute the second objective of this work (Article 2 and Unpublished 
results). 
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II. RESULTS 
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ARTICLE 1: 
ATIP3, a Novel Prognostic Marker of Breast Cancer Patient Survival, 
Limits Cancer Cell Migration and Slows Metastatic Progression by 
Regulating Microtubule Dynamics 
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Previous data from the laboratory identified a new microtubule-associate protein named 
ATIP3, encode by the candidate tumor suppressor gene MTUS1, whose expression is 
down-regulated in 48% of invasive breast carcinoma and 62% of metastatic tumors. 
Additionally, that ATIP3 re-expression at normal levels in breast cancer cell lines 
significantly reduced cancer cell proliferation in vitro and tumor growth in vivo. 
Based on these results, the aim of the first part of my PhD work, which was published in 
the Cancer Research Journal, was to elucidate whether ATIP3 was involved on breast 
cancer metastasis, and if ATIP3 may represent a new biomarker for breast cancer 
metastasis. As mentioned in the introduction cancer metastasis is a multistep process that 
involves cancer cell migration and invasion, followed by extravasation and colonization. 
Thus, we wonder how does ATIP3 could alter the metastatic process and through which 
mechanism. 
Using the DNA microarray data from three independent cohorts (Institut Curie, Institut 
Gustave Roussy and the Kaplan-Meier plotter database) of breast cancer patients with 
known clinical data, the prognostic value of ATIP3 as a marker for metastatic progression 
and overall survival was evaluated. Comparison of MTUS1 probeset intensities with 
clinicopathologic data of the patients showed that low expression levels of ATIP3 
significantly decrease the overall probability of survival and the relapse-free survival of 
breast cancer patients when compared with patients expressing normal levels of ATIP3. 
Additionally, when compared the percentage of patients with metastatic disease surviving 
after 5 years, those expressing low levels of ATIP3 had a reduced survival percentage than 
the ATIP3-normal expression group. Of note, this difference (and overall survival 
difference) was no longer found in non-metastatic patients. These results suggest that 
ATIP3 is an important prognostic marker of clinical outcome for patients with metastatic 
disease. 
Given the association of low ATIP3 and metastatic patients’ outcome, the effects of ATIP3 
on metastatic progression were then evaluated. Using an in vivo experimental mouse 
model of metastasis, D3H2LN highly invasive breast cancer GFP and GFP-ATIP3 stable 
clones (expressing luciferase) were injected intracardiacally into nude mice to elucidate 
the late steps of the metastatic process. The metastatic dissemination was followed by 
intravital bioluminescence imaging every 2 days during 24 days. Quantification of photon 
number/s showed that mice injected with GFP-ATIP3-expressing cells presented a delay in 
metastasis time course, a decrease in the number of metastasis per mouse and a 
reduction in the number of large metastatic foci (at the end of the experiment) when 
compared with GFP-expressing mice. Altogether these data indicate a strong effect of 
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ATIP3 in the metastatic progression and suggest a role for this protein in metastatic 
growth and colonization in vivo. 
To investigate the effect of ATIP3 on the colonization step, extravasation, invasion and 
migration experiments were performed using Boyden chambers. Different conditions 
were tested, where the upper chambers were either plated with HCMEC/D3 cells or 
coated with collagen I or no coated, before D3H2LN GFP and GFP-ATIP3 stable clones 
were seeded above. Re-expression of ATIP3 revealed a markedly reduction in migration 
(included the transendothelial migration or extravasation). These results were confirmed 
using MDA-MB-468 cells that express endogenous levels of ATIP3. Migratory behavior was 
increased followed ATIP3 down-regulation, suggesting that loss of ATIP3 allows the 
acquisition of a promigratory phenotype that may be more prone to develop distant 
metastasis.  
Directional migration was then evaluated through a wound-healing experiment in ATIP3-
expressing cells in which ATIP3-specific siRNAs were transfected. In accordance with 
Boyden chamber results, silencing of ATIP3 increased directional cell migration. These 
results were confirmed using breast cancer (D3H2LN and MCF7) stable clones expressing 
GFP or GFP-ATIP3. Indeed, expression of ATIP3 significantly reduced wound closure. 
Wound-healing time-lapse videomicroscopy using D3H2LN GFP and GFP-ATIP3 stable 
clones was performed to follow the migration process. Cell tracking analysis revealed that 
ATIP3 expression impairs cancer cell velocity and directionality, effects that explain the 
reduction of cell migration induced by ATIP3. 
It has been shown that ATIP3 is a microtubule-associated protein (MAP) that reduces cell 
proliferation and migration, suggesting that the effect of ATIP3 on essential cell process is 
due to the possible regulation of microtubule (MT) dynamic instability parameters. 
Nocodazole incubation at 37°C during 1h and nocodazole washout experiments were 
performed to analyze the effect of ATIP3 on MT depolymerization and MT regrowth, 
respectively. Results shown that in ATIP3-expressing cells, nocodazole (1µmol/L) 
incubation did not depolymerize all the MTs. Of note, anti-acetylated tubulin staining 
revealed that the remaining MTs were stable MTs which were post-translationally 
modified. On the other hand, ATIP3-silencing induces a high decrease on MT density and 
few stable acetylated MTs remained, indicating that ATIP3 stabilizes MTs and protects 
them from depolymerization. The same experiment was performed in MCF7 breast cancer 
cell line stably expressing GFP and GFP-ATIP3 and incubated with nocodazole (10 µmol/L). 
ATIP3 re-expression in MCF7 breast cancer cell line increases stable MTs, while GFP-
expressing cells did not. 
  
87 
RPE1 cells were used to evaluate the effect of ATIP3 in MT regrowth. GFP and GFP-ATIP3 
were transiently transfected for 24h and MTs were depolymerized with nocodazole 
(10µmol/L) at 4°C. Nocodazole washout showed that ATIP3 expression significantly 
delayed MT regrowth, strongly suggesting an effect of ATIP3 in MT dynamics. 
EB1 accumulation at the MT plus-ends was then used as an indicator of MT dynamics. 
RPE1 cells were transiently transfected for 24h with mCherry-ATIP3 construct and stained 
with an anti-EB1 antibody. Immunofluorescence images indicated that ATIP3 expression 
lead to a significant reduction of EB1 comet size that was not associated with a reduction 
of EB1 expression. Similar results were obtained in ATIP3-expressing HeLa cells 
transfected with ATIP3-specific siRNA. Silencing of the protein resulted in a significant 
increment of EB1 comet size and fluorescence intensity at the MT growing ends that was 
not the case for control siRNA transfected cells. These results indicate that loss of ATIP3 
may increase MT dynamics. 
Soon after, the role of ATIP3 on MT dynamic instability parameters was elucidated by TIRF 
time-lapse videomicroscopy using EB1-GFP as plus-end marker. HeLa cells were co-
transfected with siRNAs (control or ATIP3-specific) and EB1-GFP during 48h. Tracking 
results revealed that loss of ATIP3 leads to an increase of MT growth episodes and growth 
rate, and a decrease of the time spent in pause and catastrophe frequency. These results 
confirm the role of ATIP3 in MT dynamic instability. 
We then hypothesize that MT stabilization and decreased growth could impair MT correct 
anchoring at the cell cortex during migration. To test this hypothesis, D3H2LN cells 
transiently transfected with GFP or GFP-ATIP3 were grown until confluence before being 
scratched and kept at 37°C for 90 minutes. In GFP-expressing cells, MT were radially 
organized toward the cell periphery with the MT plus-ends close to the cell margin; 
instead, in ATIP3-expressing cells MTs bend before reaching the cell edge and 
consequently MT plus-end did not anchor the cell cortex. This difference in MT 
polarization was traduced in a defect of cell polarity in ATIP3-positive cells in respect with 
GFP cells. This indicates that ATIP3 impairs MT dynamics, MT polarization and therefore 
cell polarity and cell migration. 
Cleavage of ATIP3 into three domains (D1, D2 and D3) allows the characterization of the 
full length protein. Transfection of GFP-D1, GFP-D2 and GFP-D3 into RPE1 cells followed by 
immunostaining using anti-GFP, anti-tubulin and anti-EB1 antibodies was performed. 
Immunofluorescence images shown that the central D2 was the only able to associate to 
MTs and to impair EB1 comet accumulation at the plus-ends. Interestingly, D2 also retain 
the functional properties of the full-length protein, reducing cell proliferation and cell 
migration and directionality. Thus, D2 recapitulates the functional characteristics of ATIP3. 
  
88 
To conclude, in this study ATIP3 was identified as an important indicator of metastatic 
progression that regulates early (tumor growth) and late (colonization) stages of cancer 
development through its ability to regulate MT dynamics. Additionally, the functional 
domain of the protein was characterized, and termed D2, which is of highly importance 
for the future targeted therapeutic approaches against breast tumors that have lost ATIP3 
expression. 
 
   
2013;73:2905-2915. Published OnlineFirst February 8, 2013.Cancer Res 
 
Angie Molina, Lauriane Velot, Lydia Ghouinem, et al. 
 
Progression by Regulating Microtubule Dynamics
Survival, Limits Cancer Cell Migration and Slows Metastatic 
ATIP3, a Novel Prognostic Marker of Breast Cancer Patient
 
Updated version
 
10.1158/0008-5472.CAN-12-3565doi:
Access the most recent version of this article at:
 
Material
Supplementary
 
http://cancerres.aacrjournals.org/content/suppl/2013/02/08/0008-5472.CAN-12-3565.DC1.html
Access the most recent supplemental material at:
 
 
 
 
 
Cited Articles
 
http://cancerres.aacrjournals.org/content/73/9/2905.full.html#ref-list-1
This article cites by 35 articles, 6 of which you can access for free at:
 
 
 
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
 
Subscriptions
Reprints and 
 
.pubs@aacr.org
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
 
Permissions
 
.permissions@aacr.org
To request permission to re-use all or part of this article, contact the AACR Publications Department at
on May 25, 2014. © 2013 American Association for Cancer Research. cancerres.aacrjournals.orgDownloaded from 
Tumor and Stem Cell Biology
ATIP3, a Novel Prognostic Marker of Breast Cancer Patient
Survival, Limits Cancer Cell Migration and Slows Metastatic
Progression by Regulating Microtubule Dynamics
Angie Molina1,2,3, Lauriane Velot1,2,3, Lydia Ghouinem1,2,3, Mohamed Abdelkarim4,7,
Benjamin Pierre Bouchet10, Anny-Claude Luissint1,2,3, Imene Bouhlel1,2,3, Marina Morel1,2,3,
Elene Sapharikas1,2,3, Anne Di Tommaso1,2,3, St ephane Honor e8, Diane Braguer8, Nadege Gruel5,
Anne Vincent-Salomon5, Olivier Delattre5, Brigitte Sigal-Zafrani5, Fabrice Andr e9, Benoit Terris1,2,3,6,
Anna Akhmanova10, M elanie Di Benedetto4,7, Clara Nahmias1,2,3, and Sylvie Rodrigues-Ferreira1,2,3
Abstract
Metastasis, a fatal complication of breast cancer, does not fully beneﬁt from available therapies. In this
study, we investigated whether ATIP3, the major product of 8p22MTUS1 gene, may be a novel biomarker and
therapeutic target for metastatic breast tumors. We show that ATIP3 is a prognostic marker for overall
survival among patients with breast cancer. Notably, among metastatic tumors, low ATIP3 levels associate
with decreased survival of the patients. By using a well-deﬁned experimental mouse model of cancer
metastasis, we show that ATIP3 expression delays the time-course of metastatic progression and limits the
number and size of metastases in vivo. In functional studies, ATIP3 silencing increases breast cancer cell
migration, whereas ATIP3 expression signiﬁcantly reduces cell motility and directionality. We report here
that ATIP3 is a potent microtubule-stabilizing protein whose depletion increases microtubule dynamics. Our
data support the notion that by decreasing microtubule dynamics, ATIP3 controls the ability of microtubule
tips to reach the cell cortex during migration, a mechanism that may account for reduced cancer cell motility
and metastasis. Of interest, we identify a functional ATIP3 domain that associates with microtubules and
recapitulates the effects of ATIP3 on microtubule dynamics, cell proliferation, and migration. Our study is a
major step toward the development of new personalized treatments against metastatic breast tumors that
have lost ATIP3 expression. Cancer Res; 73(9); 2905–15.  2013 AACR.
Introduction
The occurrence of distant metastasis is a dreadful compli-
cation of breast cancer and a leading cause of death by
malignancy in women worldwide. Metastasis is a multistep
process that involves cancer cell migration and invasion across
the extracellular matrix to reach the blood ﬂow, followed by
extravasation and colonization of secondary organs (1). Among
millions of invasive cancer cells that reach the blood circula-
tion, only few will establish at distant sites and grow as
metastases (2–5). Breast cancer metastases can remain latent
for several years following primary tumor removal, and the
identiﬁcation ofmolecularmarkers thatmay predict the risk of
metastasis occurrence, and/or progression is of invaluable help
for the follow-up of the patients and choice of therapeutic
options (5, 6). Over the past decade, extensive studies have led
to the classiﬁcation of breast tumors into distinct molecular
subtypes, allowing subsequent development of efﬁcient tar-
geted treatments for a majority of primary tumors (7–9).
However, available therapies have limited effect on cancer
metastasis and new genetic determinants contributing to
essential steps of the metastatic process need to be
characterized.
Microtubule-targeting drugs such as taxanes are used for
standard ﬁrst-line treatment of breast cancer metastasis, and
new microtubule-targeting agents, such as epothilones and
eribulin, are under clinical evaluation (10). Microtubules are
polarized and highly dynamic structures that rapidly switch
between periods of polymerization (growth) and depolymer-
ization (shrinkage) at the plus ends, a process termed dynamic
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instability (11–13). The extent and rate of microtubule growth,
as well as transitions between growth and shrinkage, are
parameters of dynamic instability that can be measured by
tracking end-binding proteins at the microtubule plus ends
(13–15). Dynamic instability is essential for the microtubule
plus ends to explore the cytosol and ensure cytoskeleton
reorganization during cell division and migration. Targeting
the expression or activity of metastasis genes that regulate
microtubule dynamics represents a promising option for can-
cer therapy.
ATIP3 is a microtubule-associated protein encoded by 8p22
candidate tumor suppressor gene MTUS1 (16–18). We have
previously shown that ATIP3/MTUS1 levels are signiﬁcantly
downregulated in 47.7% of invasive breast carcinomas and
62.4% ofmetastatic tumors (19). Restoring ATIP3 expression at
normal levels in breast cancer cells signiﬁcantly reduces cancer
cell proliferation in vitro and tumor growth in vivo (19).
However, effects of ATIP3 on breast cancer metastasis have
not yet been evaluated.
In this study, we investigated whether ATIP3 may represent
a new biomarker and therapeutic target for breast cancer
metastasis. We present evidence that low ATIP3 levels corre-
late with the decreased probability of survival among patients
with breast cancer metastasis, and that ATIP3 expression into
ATIP3-deﬁcient cancer cells markedly impairs the establish-
ment of metastatic foci in vivo. Loss of ATIP3 increases breast
cancer cell migration and alters microtubule dynamics. We
show that ATIP3 associates with microtubules through a
central basic domain that retains the functional properties of
the full-length protein. Our study thus identiﬁesATIP3 as a new
promising therapeutic target against metastatic breast tumors
of poor prognosis.
Materials and Methods
Breast tumor samples and gene arrays
Microarray data for a series of 150 inﬁltrating ductal primary
breast carcinomas and 11 normal breast tissues from the
Institut Curie (Paris, France) and clinical data for the patients
were described elsewhere (19, 20). Gene expression proﬁles
from an independent cohort of 162 invasive breast carcinomas
were obtained from patients included in the prospective
database of the Institut Gustave Roussy (IGR; Villejuif, France)
between 1984 and 1994. This study was approved by the
Institutional Review Boards of the IGR. Data have been sub-
mitted to the Array Express data repository at the European
Bioinformatics Institute (Saffron Walden, United Kingdon;
http://www.ebi.ac.uk/arrayexpress/) under accession number
E-MTAB-1389. MTUS1 gene expression in a meta-analysis of
2,898 patients with breast cancer with known clinical outcome
was retrieved from Kaplan–Meier plotter database (21, 22).
Cell lines, plasmid constructs, and transfections
Human breast cancer cell linesMDA-MB-468 andMCF7 and
stable clones were described previously (19). MDA-MB-231-
Luc-D3H2LN breast cancer cells (designated D3H2LN)
obtained from Caliper Life Science (Xenogen) were derived
from an in vivo-selected metastatic subclone of MDA-MB-231
cells expressing luciferase and grown as described (23). HeLa
cells were provided by Dr. Mounira Amor-Gueret (Institut
Curie, Orsay, France). RPE-1 [human telomerase reverse tran-
scriptase (h-TERT)-immortalized, retinal pigment epithelial]
cells were from Dr. Franck Perez (Institut Curie, Paris). MRC5-
SV lung ﬁbroblasts were grown in Dr. A. Akhmanova's labo-
ratory as described (24). All cells were used at passages 2 to 20
after thawing and grown as described by the provider. Cells
were routinely authenticated by morphologic observation and
tested for absence of mycoplasma contamination using
MycoAlert Assay detection kit (Lonza).
Plasmid constructs are described in the Supplementary
Methods. Transfections using ATIP3-speciﬁc siRNAs (si#1 and
si#2) were conducted as described (19) and veriﬁed by immu-
noblotting using anti-MTUS1 polyclonal antibodies (ARP-
44419, Aviva Systems).
Intracardiac experimental mouse model of metastasis
Experimental metastasis was conducted as described
(23, 25, 26) following intracardiac injection of stable
ATIP3-negative [WT (wild-type), GFP] or positive (Cl3, Cl6)
D3H2LN cell clones. All injected cells showed similar via-
bility as measured by Annexin V apoptosis kit (Beckman
Coulter). The experiment was carried out with the approval
of the Departement d'Experimentation Animale, Institut
d'Hematologie, Hopital St-Louis ethical committee, and was
conducted twice (9 mice per group).
Clonogenicity, cell migration, and adhesion assays
Analyses of colony formation, Boyden chambers chemo-
taxis, transendothelial migration, wound healing, and cell
adhesion were conducted as described (23). Time-lapse
videomicroscopy analyses of cell motility are described in
the Supplementary Methods. For cell polarity measure-
ments, transiently transfected D3H2LN were allowed to
migrate for 90 minutes and analyzed using bright ﬁeld
microscopy. Polarized cells were identiﬁed on the basis of
nucleus position and cytoplasm extension at the leading
edge.
Immunostaining, ﬂuorescence microscopy, analysis of
microtubule dynamics
Cells were plated on glass coverslips and transfected for 24
hours (plasmids) or 72 hours (siRNA), ﬁxed in ice-cold
methanol for 5 minutes, and incubated for 1 hour at room
temperature with anti-a-tubulin clone F2C (27), monoclonal
anti-g-tubulin (Sigma), anti-end-binding 1 (EB1; clone 5; BD
Biosciences), or anti-acetylated tubulin (clone 6-11B-1; Sigma).
Secondary antibodies and ﬂuorescence images capture are
described in the Supplementary Methods.
Linescan analyses of a-tubulin and EB1 ﬂuorescence inten-
sity were done (ImageJ) on a 6 mm line along the length of
microtubule tip. At least 10 microtubules per cell in 4 separate
cells were measured. EB1-comet maximal intensity was
obtained by subtracting the intensity value of the EB1-dot
(100 a.u.) to the maximal staining intensity.
Analyses of microtubule stability, regrowth, and microtu-
bule dynamic instability are described in the Supplementary
Methods.
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Statistical analysis
Statistical analyses were done using JMP-7 and GraphPad
Prism softwares. Overall survival (OS) curves were plotted
according to the method of Kaplan–Meier and compared by
the log-rank test. Data in bar graphs (mean þ/ SD) were
analyzed using 2-tail unpaired Student t test. Dot plot analyses
were done using Mann–Whitney test. P < 0.05 was considered
statistically signiﬁcant.
Results
ATIP3 is a prognostic marker of poor outcome in
metastatic breast cancer
The prognostic value of ATIP3 as a marker for metastatic
progression and OS was evaluated in 3 independent cohorts of
patients with breast cancer. Comparison ofMTUS1 Affymetrix
probeset intensities with clinicopathologic data of the patients
in a panel of 150 invasive breast carcinomas (Supplementary
Table S1) showed that the overall probability of survival is
strongly reduced in patients with tumors expressing low as
compared with normal ATIP3 transcript levels (Fig. 1A and
Supplementary Fig. S1A). Relapse-free survival (RFS) of the
patients was also signiﬁcantly reduced in low ATIP3-expres-
sing tumors (Supplementary Fig. S1B). Similar results were
obtained by analyzing MTUS1 levels in an independent cohort
of 162 patients with breast cancer (Fig. 1B and Supplementary
Table S2) and in a meta-analysis of 2,898 patients with breast
cancer (Fig. 1C and Supplementary Fig. S1C and S1D). Of note,
correlation between ATIP3 expression and OS of the patients
was independent of the estrogen receptor (ER) status of the
tumor (Fig. 1D).
Tumors were then classiﬁed according to their metastatic
properties and MTUS1 probeset intensities were compared
with the probability of patient survival. As shown in Fig. 1E, the
percentage of patients withmetastatic disease surviving after 5
years was markedly reduced when tumors expressed low
ATIP3 (6.25%) compared with normal ATIP3 levels (31.6%),
whereas in patients with nonmetastatic tumors, 5-year sur-
vival (Fig. 1E and Supplementary Fig. S1E) and OS rates (Fig. 1F
and H) were independent of the levels of ATIP3. Within
patients with metastatic disease, OS rates (Fig. 1F and H and
Supplementary Fig. S1E) and survival time (Fig. 1G and I) were
also reducedwhen tumors expressed low levels of ATIP3. Thus,
ATIP3 expression is an important indicator of clinical outcome
for patients with metastatic breast tumors. Correlation
between low ATIP3 levels and reduced survival rates among
patients with advanced breast cancer suggests major effects of
ATIP3 on metastatic progression.
ATIP3 limits breast cancer metastatic colonization in
vivo
In vivo effects of ATIP3 on the metastatic potential of breast
cancer cells were evaluated using a well-deﬁned experimental
mouse model of metastasis monitored by intravital biolumi-
nescence imaging (23, 25, 26). Highly metastatic, ATIP3-neg-
ative, D3H2LN breast cancer cells were transfected with either
GFPorGFP-ATIP3, and independent stable cell clones (Cl3 and
Cl6) expressing moderate levels of ATIP3 were selected (Fig.
2A, left). All cell clones exhibited similar levels of luciferase
activity (Fig. 2A, right). Metastatic cancer cells were injected
intracardiacally into the bloodstream of nude mice to reca-
pitulate the late, rate-limiting, steps of the metastatic process,
and examinemetastatic dissemination to various organs while
avoiding any effect of ATIP3 on primary tumor growth. Four
groups of 18 mice were analyzed in two independent experi-
ments. For each animal, the total number of metastatic foci
and the number of photons/s were quantiﬁed every 2 days for
24 days (Supplementary Table S3). As shown in Fig. 2B, the
time-course of metastasis formation was markedly delayed in
mice injected with ATIP3-positive as compared with ATIP3-
negative cell clones. The number of cancer cells growing at
secondary sites increased exponentially from day 17 after
injection of ATIP3-positive clones, as compared with day 10
for mice injected with control cells (Fig. 2B). As shown in Fig.
2C, the number of mice developing metastasis was strongly
diminished upon ATIP3 expression. Importantly, the number
of detectable metastases per mouse was also signiﬁcantly
reduced at all times in the presence of ATIP3 (Fig. 2D). At day
24, the number of mice invaded with large metastases reached
13 of 18 (72.2%) in the control group as compared with 2 of 18
(11.1%) following injection of ATIP3-positive cells (Fig. 2E and
F), indicating a prominent effect of ATIP3 on cancer cell
growth and colonization at secondary sites. Accordingly, on
day 24, the total number of photons/s per mouse was 50- and
25-fold lower following injection with Cl3 and Cl6 clones,
respectively, compared with WT (Supplementary Fig. S2A).
For ethical reasons, mice had to be sacriﬁced at day 24,
therefore OS of the two groups of mice could not be quantiﬁed.
Furthermore, ex-vivo and histologic analysis of metastatic
nodules (Supplementary Fig. S2B) conﬁrmed that biolumines-
cent signals indeed correspond to metastases of human tumor
cells having inﬁltrated mouse tissues. Metastases were mainly
detected in the bones, the lungs, and the brain, which are the
most frequent sites of metastatic dissemination of human
breast tumors. No preferential location of metastatic nodules
in ATIP3-positive versus ATIP3-negative cell types could be
observed. Altogether, these results identify ATIP3 as a potent
antimetastatic molecule, and support a role for ATIP3 in
metastatic growth and colonization in vivo.
ATIP3 impairs breast cancer cell proliferation and
migration
Metastatic colonization involves cancer cell migration, inva-
sion through the extracellular matrix, and proliferation at the
secondary site. As expected from our previous studies (19), cell
proliferation was signiﬁcantly reduced in ATIP3-positive
clones Cl3 and Cl6 as compared with control (Supplementary
Fig. S3A). In addition, Boyden chambers assays of chemotaxis
and invasion revealed more than 90% reduction in the promi-
gratory properties of Cl3 compared with GFP (Fig. 3A). Similar
effects were observed using stably transfected MDA-MB-231
cells (Supplementary Fig. S3B). Conversely, ATIP3 silencing in
metastaticMDA-MB-468 breast cancer cells expressing endog-
enous ATIP3 induced a 2- to 2.5-fold increased chemotactic
migration (Fig. 3B), suggesting that cancer cells having lost
ATIP3 may acquire a promigratory phenotype and may be
more prone to develop distant metastasis.
Antimetastatic Effects of ATIP3 in Breast Cancer
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The ability to migrate through a monolayer of endothelial
cells (transendothelialmigration)was signiﬁcantly reduced (58
 16%) in Cl3 compared with control (Fig. 3C). Adhesion of
clones Cl3 and Cl6 to endothelial cells was signiﬁcantly ele-
vated (3-fold and 2.8-fold, respectively) compared with WT
(Fig. 3D), suggesting that increased tumor-endothelial cell
adhesionmay account for reduced transendothelial migration.
Cell adhesion to collagen I was also increased in Cl3 (1.85-fold)
and Cl6 (1.93-fold) compared with WT (Fig. 3E). Altogether,
these data indicate that ATIP3 concomitantly increases cell
adhesion and limits cell migration.
The consequences of ATIP3-silencing on cancer cell motility
were analyzed in HeLa cells that express endogenous ATIP3
and are well suited for analyses of wound closure. As shown
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Figure 1. Low levels of ATIP3 predict poor outcome amongmetastatic tumors. A, OS curves for patients from the Institut Curie cohort, with tumors expressing
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Kaplan–Meier plotter. The best performing threshold was used as a cutoff. D, OS curves from patients expressing normal or low ATIP3 as in A,
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in Fig. 3F, ATIP3 silencing in HeLa cells increased (1.84- to 2.6-
fold) directional migration. Conversely, stable ATIP3 expres-
sion into D3H2LN (Cl3 and Cl6, Fig. 3G) and MCF7 cells
(Supplementary Fig. S3C) signiﬁcantly reduced wound closure.
Time-lapsemicroscopy (SupplementaryMovies S1 and S2) and
tracking of D3H2LN-migrating cells further indicated that
stable ATIP3 expression impairs both cancer cell velocity
(0.34 mm/s and 0.55 mm/s for Cl3 and GFP clones, respectively;
ref. Fig. 3H) and directionality (Fig. 3I). Similar results were
obtained (Supplementary Fig. S3D and S3E) by analyzing cell
tracking following transient transfection of GFP or GFP-ATIP3
into D3H2LN cells (Supplementary Movies S3 and S4). Of
note, the number of GFP-ATIP3–positive cells reaching the
wound edge was reduced compared with GFP-expressing
cells. GFP-ATIP3 expressing cells were overtaken by nontrans-
fected cells reaching the border of the wound (Supplementary
Fig. S3F), further conﬁrming the inhibitory effect of ATIP3 on
cancer cell migration.
ATIP3 alters microtubule dynamics
We hypothesized that ATIP3, being closely associated with
microtubules (19),may limit cell proliferation andmigration by
Figure 2. ATIP3 expression slows
metastatic progression in vivo. A,
characterization of stably
transfected D3H2LN cell clones.
Left, immunoblots of nontransfected
(WT) and GFP-ATIP3-expressing
D3H2LN clones (Cl3, Cl6) using anti-
GFP antibodies, reprobed with anti-
a-tubulin (a-tub) antibodies. Right,
measurement of luciferase activity
per cell (n ¼ 3). B, number of
photons/s per mouse (n ¼ 9) at days
6 to 24 following tumor cell
inoculation. C, left, representative
pictures of bioluminescence (5/9
mice) at day 17 following intracardiac
injection. Scale is on the right. Right,
number of mice with at least one
detectable metastasis at day 17.
D, total number of metastastic sites
per mouse at indicated days after
inoculation of control (Ctrl, WT and
GFP, n ¼ 18) and ATIP3 positive
(ATIP3, Cl3 and Cl6, n ¼ 18) cells.
  ,P < 0.01,    ,P < 0.001. E, number
of mice with large metastases at
different times after inoculation as in
D. F, representative pictures (day 24)
as in C.
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regulating microtubule dynamics. We ﬁrst analyzed the con-
sequences of ATIP3 depletion on the sensitivity of microtu-
bules to nocodazole that prevents repolymerization of dynam-
ic microtubules. Stable microtubules that are not affected by
nocodazole treatment are typically stained by anti-acetylated
tubulin. As shown in Fig. 4A, ATIP3-silenced HeLa cells were
highly sensitive to nocodazole. The number of cells retaining
stable microtubules was decreased by 51% 10 and 53% 14
following transfection of siRNA#1 and siRNA#2 compared with
control. Conversely, stable transfection of GFP-ATIP3 into
MCF7 cells signiﬁcantly increased thenumber of cells retaining
stable, nocodazole-resistant, microtubules as assessed by anti-
acetylated tubulin labeling (Fig. 4B) and immunoblotting (Fig.
4C). ATIP3 expression also signiﬁcantly delayed microtubule
regrowth following nocodazole washout (Fig. 4D). At 5 min-
utes, microtubule length around the centrosome was reduced
by 57  20% in GFP-ATIP3 compared with GFP-transfected
clones, supporting the notion that ATIP3 may impair micro-
tubule dynamics.
The effects of ATIP3 on microtubule dynamic instability
parameters were further analyzed by measuring EB1 protein
accumulation at the microtubule plus tips (13–15, 28, 29) in
RPE-1 epithelial cells and lung ﬁbroblasts (MRC5-SV), which
have a sparse microtubule array and are well suited for
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cancer cell migration. A, Boyden
chamber migration of stable
D3H2LN cell clones across ﬁlters
coated (coll) or not (no coll) with
collagen I. Results (percent) are
mean  SEM (n ¼ 3). Right,
representative picture of cells
migrating to the bottom of the well.
B, Boyden chamber assay using
ATIP3-positive (WT and siCtrl) and
ATIP3-negative (si#1 and si#2)
MDA-MB-468 cells. Results are
shown as in A. Top, immunoblots
of MDA-MB-468 cells after siRNA
silencing [anti-MTUS1, reprobed
with anti-a-tubulin (a-tub)
antibodies]. Right, representative
pictures of the lower face of the
ﬁlter. C, transendothelial migration,
mean  SEM (n ¼ 3). D and E,
cancer cell adhesion (meanSEM,
n ¼ 3) to endothelial cells (D) and
collagen (E). F, migration of ATIP3-
positive (siCtrl) and ATIP3-silenced
(si#1, si#2) HeLa cells (n ¼ 3). Left,
representativepictures ofwoundat
times T0 and T22. Right,
quantiﬁcation (percent) of wound
closure at T22. Results are mean
SEM (n ¼ 2). Top, immunoblots of
siRNA-transfected HeLa cells as in
B. G, directional migration of
stably transfected D3H2LN clones
(n ¼ 4). Left, representative
pictures of wound at times T0 and
T7. Right, quantiﬁcation of wound
closure at T4 and T7. Results are
mean  SD (n ¼ 3). H and I, cell
tracking of D3H2LN stable clones
during wound closure. H, cell
velocity scattered dot plot. I,
diagrams of migration trajectories
(12 hours). Number of cells is under
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(Dir) is inside the graph. A, B, F, and
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"", P < 0.001; """, P < 0.0001.
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distinguishing individualmicrotubule tips. As shown in Fig. 5A,
ATIP3 expression in RPE-1 cells led to a signiﬁcant reduction in
the number and size of EB1 comets that rather appeared as
dots. Decreased accumulation of EB1 at microtubule plus ends
was not associated with decreased EB1 expression (Supple-
mentary Fig. S4A). In ATIP3-depleted HeLa cells, signiﬁcantly
more EB1 comets of increased length and intensity were
detected compared with control cells (Fig. 5B), suggesting that
ATIP3 silencing increases microtubule dynamics. Time-lapse
total internal reﬂection ﬂuorescence (TIRF) videomicroscopy
analysis of EB1-GFP comets (Supplementary Movie S5) and
subsequent microtubule-tips tracking indicated that microtu-
bule growth episodes were signiﬁcantly longer in ATIP3-
silenced HeLa cells compared with control (Fig. 5C). ATIP3
depletion increased microtubule growth rate and decreased
the time spent in pause aswell as the frequency of catastrophes
(Fig. 5C), accounting for increased microtubule dynamics.
Conversely, videomicroscopy of EB3-GFP comets following
expression of mCherry-ATIP3 in MRC5-SV cells (Supplemen-
tary Movie S6), and corresponding kymographs (Supplemen-
tary Fig. S4B), indicated that ATIP3 expression decreases
microtubule dynamics and reduces the rate of microtubule
growth.
Microtubule stabilization and decreased growth rate at
the cell periphery should be responsible for an inhibition of
microtubule targeting and capture at the cell cortex (30). As
shown in Fig. 5D, in migrating D3H2LN cells, microtubules
projected radially toward the cell periphery and microtubule
plus ends were close to the cell edge (mean distance 1.43 
0.7 mm), whereas in the presence of ATIP3, microtubules
Figure 4. ATIP3 reduces
nocodazole sensitivity and
microtubule outgrowth. A,
immunostaining (anti-a-tubulin
(a-tub) and anti-acetylated tubulin
[Ac-tub antibodies] of ATIP3-positive
(siCtrl) and -negative (si#1) HeLa
cells incubated without (0) or with
1 mmol/L nocodazole (Nz). Right,
immunoblots of HeLa cells after
siRNA silencing (anti-MTUS1,
reprobed with antitubulin
antibodies). Bottom, quantiﬁcation
(%) of cells retaining stable
microtubules, mean  SEM (n ¼ 3).
B, immunostaining of stable MCF7
clones incubated with or without 10
mmol/L nocodazole, as in A. Right,
quantiﬁcation as in A,meanSEM (n
¼ 3). C, immunoblot analysis of
acetylated-tubulin (Ac-tub) and ezrin
content in stably transfected MCF7
clones, either nontreated (!) or
treated with DMSO (D) or increasing
concentrations of nocodazole. Right,
quantiﬁcation of the ratio between
Ac-tub and ezrin intensity. D,
microtubule regrowth in transiently
transfected RPE-1 cells (n ¼ 4).
Shown is a-tubulin staining at
indicated times after nocodazole
(10 mmol/L) washout. Right,
quantiﬁcation of microtubule density
at 4 mm around the centrosome,
mean  SD (n ¼ 4 to 10 cells).
", P < 0.05; "", P < 0.001. Scale bar,
10 mm.
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were bended and more than 50% of microtubule tips did not
reach the cell margin (mean distance 2.31 1.2 mm). Of note,
reduced ability of microtubules to reach the cell cortex in
migrating ATIP3-positive cells was accompanied by a 34%
decrease in cell polarity (Fig. 5E). Taken together, these
results suggest that ATIP3-dependent regulation of micro-
tubule dynamics results in decreased ability of microtubules
to reach the cell cortex, which contributes to reduced cell
polarity and migration.
Microtubule-binding domain D2 recapitulates the
functional effects of ATIP3
The ATIP3 polypeptide was cleaved into 3 fragments des-
ignated D1, D2, and D3 (Fig. 6A), which were fused to GFP and
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Figure 5. ATIP3 regulates
microtubule dynamics. A,
immunostaining (anti-EB1, anti-
mCherry antibodies) of RPE-1 cells
transiently transfected with
mCherry-ATIP3 (Ch-ATIP3). Insets,
EB1 comet-like structures in
ATIP3-negative (1) and positive (2)
cells. Distribution of EB1 (black),
a-tubulin (dashed) andATIP3 (gray)
at the microtubule tip (linescans)
and quantiﬁcation of comets
intensity (scattered dot plot).
Number of comets analyzed is
under brackets. Shown is 1
experiment out of 5. B, EB1
localization in siRNA-silenced
HeLa cells. Insets, EB1 comet-like
structures in ATIP3-positive (1) and
ATIP3-negative (2) cells.
Distribution of EB1 (black) and
a-tubulin (dashed) at the
microtubule tip (linescans).
Quantiﬁcation of comets intensity
as in A. Shown is 1 experiment out
of 3. C, time-lapse images of
siRNA-silenced HeLa cells
expressing EB1-GFP. Arrowhead
indicates theposition of EB1comet
over time (in seconds). Parameters
of microtubule dynamics (EB1-
GFP comets) in siRNA-transfected
HeLa cells (n ¼ 100 comets) are
shown in scattered dot plot and
histograms. D, immunostaining
[anti-a-tubulin (a-tub) and anti-
GFP] of transfected D3H2LN in
migration. Arrows indicate the
direction of migration. Cell margin
(black line) is visualized by bright
ﬁeld microscopy. Insets show
microtubule array at the cell border
of ATIP3-negative (1, 2) and
GFP-ATIP3-positive (3, 4) cells.
Right, immunoblots (anti-GFP,
antitubulin) of transiently
transfected D3H2LN cells. Bottom
left, quantiﬁcation of microtubules
reaching given distance from the
cell cortex in GFP- and GFP-
ATIP3- expressing cells. Bottom
right, mean distance between
microtubules and cell cortex.
Number of microtubules analyzed
is under brackets. E, quantiﬁcation
(percent) of polarizedD3H2LNcells
during migration. Number of
cells is under brackets. !, P < 0.05;
!!, P < 0.001, !!!, P < 0.0001.
A, B, C, and D, scale bar, 10 mm.
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expressed in RPE-1 cells (Fig. 6B). As shown in Fig. 6C, the GFP-
D1 fusion protein did not associate withmicrotubules and was
rather diffuse in the cytosol. Accordingly, GFP-D1 expression
hadno signiﬁcant effect on the number, size, or intensity of EB1
comets (Fig. 6D). In contrast, GFP-D2 clearly colocalized with
the microtubule cytoskeleton and centrosome in living cells
(Fig. 6C). As for GFP-ATIP3, GFP-D2 was entirely retrieved in
the pellet fraction in microtubule cosedimentation assays
(Supplementary Fig. S5A). Of interest, upon expression of
GFP-D2, accumulation of EB1 as comet-like structures at the
microtubule plus ends was strongly impaired (Fig. 6E), indi-
cating that expression of theD2domain is sufﬁcient to stabilize
microtubules. Expression of GFP-D3 (Fig. 6C) led to the
formation of large aggregates containing tubulin, probably
due to oligomerization of coiled-coil motifs present in the
C-terminal region of ATIP3 (31). Because of these aggregates,
functional properties of GFP-D3 could not be evaluated
further.
Altogether our results identify D2 as the ATIP3 domain able
to associate with microtubules and suppress their dynamics.
Of importance, the D2 domain also retained the ability of
ATIP3 to inhibit cell proliferation (91.6% inhibition for GFP-D2
and GFP-ATIP3 compared with GFP; ref. Fig. 7A). In wound
healing assays, cells expressing GFP-D2 showed reduced cell
migration and directionality (Fig. 7B). Cell tracking of transient
transfectants (Supplementary Movie S7) indicated that similar
to GFP-ATIP3, GFP-D2–positive cells mostly remained at the
back of the wound and were overtaken by untransfected cells
(Fig. 7C and Supplementary Fig. S5B). Thus, the microtubule-
binding domain D2 is sufﬁcient to recapitulate the functional
features of ATIP3.
Discussion
We report here that ATIP3 is an important prognostic
marker for survival of the patients with breast cancer, inde-
pendently of the ER status of the tumor. Using 3 different
patient cohorts, we show that among metastatic breast
tumors, low ATIP3 levels correlate with reduced probability
for overall survival of the patients, suggesting that ATIP3 may
be an important indicator of metastatic progression.
Figure 6. The D2 region of ATIP3
decorates and stabilizes
microtubules. A, scheme of ATIP3
regions D1, D2, and D3. Amino acid
numbering is according to accession
number NP_001001924. B,
immunoblots (anti-GFP, antitubulin)
of RPE-1 cells transfected (24 hours)
with GFP-D1, GFP-D2, and GFP-D3.
C, immunostaining (anti-GFP,
antitubulin) of RPE-1 cells transiently
transfected as in A. D, anti-EB1
immunostaining of GFP-D1–
transfected RPE-1 cells. Insets show
EB1 comets in GFP-D1-negative (1)
and GFP-D1-positive (2) cells.
Distribution of EB1 (blue), a-tubulin
(pink), and GFP-D1 (green) at the
microtubule tip (linescans) and
quantiﬁcation of comets intensity
(scattered dot plot). Number of
comets is under brackets. E, GFP-
D2-transfected RPE-1 cells stained
with anti-EB1 antibodies and
analyzed as in D. , P < 0.0001.
B, C, and D, scale bar, 10 mm.
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Examination of ATIP3 levels in breast tumors may contribute
to identify a population of patients at high risk of fatal
complication, who should be the subject of careful medical
follow-up.
Using a bioluminescence-based experimental mouse model
for cancer metastasis (23, 25, 26), we showed that restoring
ATIP3 expression into highly metastatic ATIP3-deﬁcient
D3H2LNbreast tumor cells signiﬁcantly delays the time-course
ofmetastasis and reduces the number of detectablemetastases
per mouse at all times examined. ATIP3 expression in cancer
cells also strongly reduces the size of metastatic foci as well as
the number of mice fully invaded with large metastases. These
observations, together with above mentioned results on
human patients, suggest that ATIP3 may have a prominent
effect on metastatic colonization.
Essential steps of metastatic progression include the ability
of cancer cells to reach a secondary organ and grow in the new
microenvironmental context (3–5). This requires active cell
migration and proliferation, two important biologic processes
that are signiﬁcantly increased in breast cancer cells following
ATIP3 silencing. By promoting dual effects on cancer cell
proliferation and migration, ATIP3 likely regulates both early
(tumorigenic) and late (metastatic) stages of cancer develop-
ment. Beneﬁcial actions of ATIP3 on a wide range of cancer-
related processes, including invasion, transendothelial migra-
tion, cell migration, and proliferation may explain its potent
anti-metastatic effects in preclinical studies.
Other studies have shown that the MTUS1 gene encoding
ATIP3 is signiﬁcantly downregulated in various types of can-
cers including from the pancreas (32), ovary (33), head-and-
neck (34, 35), colon (36), and bladder (37). Low MTUS1 levels
were also correlated with reduced overall survival of the
patients with bladder cancer (37) and oral tongue squamous
cell carcinomas (35), highlighting the potential importance
of ATIP3 as a new prognostic marker in a variety of solid
tumors.
At themolecular level, we show that ATIP3 is amicrotubule-
associated protein with potent microtubule-stabilizing effects.
We propose that by stabilizing microtubules, ATIP3 decreases
their dynamics therefore leading to impaired ability of micro-
tubule tips to reach the cell cortex during migration. Micro-
tubule dynamics at the cell cortex is essential for generating a
polarized microtubule array, required for cell polarity and
migration (30). Reduced microtubule dynamics may thus
represent a major mechanism accounting for anti-migratory
and anti-metastatic effects of ATIP3 in breast cancer. Accord-
ingly, loss of ATIP3 leads to increasedmicrotubule growth rate,
less time spent in pause, and decreased frequency of cata-
strophes. Alteration of microtubule dynamics parameters in
ATIP3-depleted cells may explain uncontrolled cancer cell
motility that is associated with increased metastasis and poor
prognosis in patients with ATIP3-negative breast cancer. The
association of ATIP3 with the microtubule lattice involves an
internal basic region designated D2 whose expression is suf-
ﬁcient to recapitulate all effects of the full-length protein on
microtubule stabilization, as well as cell proliferation, motility,
and directional migration. The microtubule-binding D2 region
thus represents the functional domain of ATIP3. Further
characterization of this domain and identiﬁcation of intracel-
lular interacting partners may help deciphering the molecular
mechanisms by which ATIP3 limits breast cancer cell migra-
tion and hence, metastasis. Our study paves the way to the
design of peptides or small molecules able to mimic the effects
of ATIP3, which is a prerequisite for the development of
targeted therapy. These may be particularly beneﬁcial to the
subset of breast tumors that have lost ATIP3 expression and
are prone to metastasize.
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Supporting Information Materials and Methods 
 
Plasmids constructs and transfections 
EB1-GFP and EB3-GFP plasmids were described previously (1). mCherry-ATIP3 plasmid was 
obtained by subcloning the full-length cDNA insert (3.8 Kb) of GFP-ATIP3 (2) into the XhoI-
KpnI cloning sites of pmCherry-C1 vector (Clontech, CA, USA). Plasmids encoding GFP-
fused ATIP3 regions D1, D2 and D3 (410, 464 and 396 amino acids, respectively) were 
obtained by PCR-amplification of full-length ATIP3 sequence using specific oligonucleotides : 
5’-CCGCTCGAGCCATGACTGATGATAATTC AGATG-3’ (sense) and  
5’-CGGGGTACCTCATCCAAATGACGAGCCCACCTTTTG-3’ (antisense) for D1;  
5’-CCGCTCGAGGACTGACTTGGGATGCAAATGAT-3’ (sense) and  
5’-CGGGGTACCTCATGCATTAAGAGCTGTAAATAA-3’ (antisense) for D2;  
5’-CCG CTCGAGCAGTTGAAAAGAGCAGGCAAAAG-3’ (sense) and  
5’-CGGGGTACCTCAT CTGGGTGAAATGCTGGG-3’ (antisense) for D3.  
Resulting cDNA insert fragments (1230 bp, 1395 bp and 1188 bp for D1, D2 and D3, 
respectively) were subcloned into the XhoI and KpnI sites of the pEGFP-C1 vector (Clontech, 
CA, USA) so that the first codon of each domain is in frame with the carboxy-terminal end of 
the Green Fluorescent Protein, and entirely sequenced. 
Transient and stable transfections of plasmid constructs were performed as described (2).  
 
 
 
XCELLigence proliferation assay 
For measurement of cell proliferation by XCELLigence technology, D3H2LN cell clones 
(WT, GFP, Cl3 and Cl6) were seeded in quadruplicate (15,000 cells per well) in 100 ȝl 
complete medium on the top of gold electrodes in 96-well E-plates (Roche Diagnostics, 
France). Electrical impedance was monitored every 15 min during 80 hrs by the RTCA 
software (Real-time Cell Analyzer) as described (3, 4).  
 
Histological analysis 
Sections (5 µm) of metastatic organs were cut from formalin-fixed, paraffin-embedded tissue 
blocks, counterstained with hematoxylin-eosin and examined under an inverted microscope. 
 
Time-lapse videomicroscopy of wound healing 
D3H2LN cells were transfected for 14 hrs with appropriate constructs prior to seeding 
(100,000 cells/well) for 7 hrs in each compartment of IBIDI culture insert (Biovalley, France). 
Time-lapse acquisitions were each 5 min (bright field acquisition) and each 30 min (GFP 
acquisition) for at least 13h in a Zeiss Axiovert 200M microscope and 10X objective lens. 
Cell tracking was done using the manual tracking plugin of ImageJ. Cell velocity was 
calculated by a regression analysis of the distance versus time plot. Migratory properties were 
evaluated by measuring the euclidean distance for each cell at time 8h. Cell directionality was 
measured by ImageJ chemotaxis and migration tool plugin (Euclidean distance/Accumulated 
distance). A value of 1 means straight motion and a value of 0 means non-straight motion. 
 
Microtubule stability and regrowth 
For analysis of MT stability, HeLa cells transfected with control or ATIP3-specific siRNAs, 
or stable MCF7 cell clones (2) were treated for 1 hr at 37°C with different doses of 
nocodazole and free tubulin was extracted with PEM (PIPES 80 mM, EGTA 2mM, MgCl2 1 
mM) Triton X100 0.1% buffer solution. Cells were fixed with cold methanol prior to staining 
for 1 hr at room temperature with anti-α-tubulin (clone F2C, a kind gift of Dr Franck Perez, 
Institut Curie, Paris), and anti-acetylated-tubulin (clone 6-11B-1; Sigma) antibodies. Cy2, 
Cy3 and Cy5 conjugated secondary antibodies were from Jackson Laboratories. Fluorescence 
images were captured in a Zeiss Axiovert 200M inverted fluorescence microscope equipped 
with a CCD camera (CoolSNAP HQ, Photometrics) and 100X objective lens. Multi-
dimensional acquisitions were performed using Metamorph 7.1.7 software. 
For analysis of MT regrowth after nocodazole washout, transiently transfected RPE-1 cells 
were treated for 1 hr at 4°C with 10µM of nocodazole, then washed with cold PBS and 
warmed in complete medium to allow MT regrowth for 2, 5 and 15 min prior to fixation in 
cold methanol and staining as described above. Alpha-tubulin fluorescence intensity was 
measured in concentric circles of different diameters (2, 4, 6, 8 µm) around the centrosome 
(stained by anti-γ-tubulin). Values for 2 µm were subtracted from 4, 6 and 8 µm to eliminate 
fluorescence due to MT nucleation.  
 
Live cell imaging and microtubule dynamics 
HeLa cells co-transfected for 48 hrs with (50 nM) siRNA (control or ATIP3-specific) and (2 
µg) EB1-GFP were seeded in 35 mm glass bottom dishes (IBIDI) and analyzed with inverted 
fluorescence microscope using the TIRF module and 60X objective lens. Only cells with low 
levels of EB1-GFP were chosen. Time-lapse series of 1000 images were acquired with a 157 
ms interval using Live Acquisition (TILL Photonics) software. Time-lapse recordings were 
then reduced to 1 frame each 1.57s and ImageJ manual tracking plugin was used for 
measurement. At least 10 MTs per cell in 10 separate cells were tracked for each condition. 
The changes in length of 0.5 µm were considered as a growth phase, and movements of <0.5 
µm were considered as pause events. MT growth rate was calculated by linear regression 
analysis of the lifetime history plots and catastrophe frequency based on time and distance 
were calculated according to the following formula : C 
time-1
: SCatastrophes/Sgrowth + pause duration until 
catastrophe and C 
length-1
: SCatastrophes/Sgrowth length until catastrophe  as described (5).  
 
Microtubule cosedimentation assay 
Microtubule cosedimentation assay was performed as described (2). Briefly, cells were 
incubated for 20 min at 4°C in PEM buffer (100 mM PIPES, pH 6.9, 1 mM MgSO4, 1 mM 
EGTA), scraped and sonicated prior to centrifugation at 15000 rpm for 10 min, 4°C. Clarified 
samples were incubated with Taxol (20 µM) in the presence of GTP (1 mM) and DTT (1 
mM) for 45 min at 37°C and were spun at 70 000 g for 30 min at 30°C through a cushion 
buffer containing 40% glycerol, 20 µM taxol and 1 mM GTP. The supernatant (S) and pellet 
(P) fractions were collected separately and subsequently immunoblotted with anti-GFP 
antibody. Blots were reprobed using anti-alpha-tubulin antibody. 
 
 
 
Legends to Supporting Information Movies 
 
Supporting Information Movie 1. Time-lapse videomicroscopy of wound healing assay 
using GFP-transfected D3H2LN clone 
Stably transfected GFP cells were seeded in IBIDI chambers and wound closure was analyzed 
for 12 hrs by time-lapse videomicroscopy using a wide field Zeiss microscope (10X lens). 
Shown is 1 image every 20 min. 
 
Supporting Information Movie 2. Time-lapse videomicroscopy of wound healing assay 
using GFP-ATIP3-transfected D3H2LN clone (Cl3) 
GFP-ATIP3-expressing stable clone was analyzed as described for movie 1. 
 
Supporting Information Movie 3. Time-lapse videomicroscopy of wound healing assay 
using GFP-transiently transfected D3H2LN cells 
Transiently transfected GFP cells were seeded in IBIDI chambers and wound closure was 
analyzed for 12 hrs by time-lapse videomicroscopy using a Zeiss microscope (10X lens). 
Images were acquired every 5 min (bright field) and every 30 min (GFP filter). Shown is 1 
image every hour. 
 
Supporting Information Movie 4. Time-lapse videomicroscopy of wound healing assay 
using GFP-ATIP3-transiently transfected D3H2LN cells  
GFP-ATIP3 transient transfectants were analyzed as described for movie 3. 
 
 
 
Supporting Information Movie 5. Time-lapse videomicroscopy of EB1-GFP comets in 
siRNA-silenced HeLa cells 
Cells were co-transfected with EB1-GFP and siRNA (control or ATIP3-specific si#1) for 48 
hrs. EB1 comets were analyzed by time-lapse TIRF microscopy (60X lens). Time-lapse series 
of 1000 images were acquired with a 157 ms interval and shown at 8 frames per second. 
 
Supporting Information Movie 6. Time-lapse videomicroscopy of EB3-GFP comets in 
wild type and mCherry-ATIP3 transfected MRC5 cells 
Cells were transfected for 24 hrs with EB3-GFP-construct without (upper panel) or with 
(lower panel) mCherry-ATIP3 cDNA. EB3-GFP comets were analyzed by time-lapse 
videomicroscopy using a spinning disk microscope (CSU-X1-A1; Yokogawa). On the lower 
panel, movies taken with GFP and mCherry filters are shown on the left and right panels, 
respectively. Time-lapse series of 500 images were acquired with a 100 ms interval and 
shown at 8 frames per second. 
 
Supporting Information Movie 7. Time-lapse videomicroscopy of wound healing assay 
in GFP-D2-transiently transfected D3H2LN cells 
GFP-D2 transient transfectants were analyzed as described for movie 3. 
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Supporting Information Figure S1. Low levels of ATIP3 associate with decreased overall and
relapse-free survival of the patients
(A) Overall survival (OS) curves from patients (n=150) with tumors expressing normal (>0.5, gray
line) or low (<0.3, black line) ATIP3 levels, relative to the median value of Affymetrix MTUS1
probeset intensities in non tumoral tissues. Results shown are from Affymetrix MTUS1 probesets
212093_s_at and 239576_at on the Institut Curie cohort (B) Relapse-free survival (RFS) curves from
patients (n=150) with tumors expressing normal or low ATIP3 levels as in (A) Results shown are from.
Affymetrix MTUS1 probesets 212096_s_at, 212093_s_at and 239576_at. (C) Overall survival (OS, n=
791) curves from patients with tumors expressing normal to high (grey line) or low (black line)
MTUS1 level using Kaplan-Meier plotter (http://www.kmplot.com). All percentiles between the lower
and the upper quartiles were automatically computed, and the best performing threshold was used as a
cut off. Results shown are from Affymetrix MTUS1 probesets 212093_s_at and 212095_s_at. (D)
Relapse-free survival (RFS, n=2898) curves from patients with tumors expressing normal to high
(grey line) or low (black line) MTUS1 level using Kaplan Meier plotter as in (C) Results shown are- .
from Affymetrix MTUS1 probesets 212096_s_at, 212093_s_at and 212095_s_at. (E) Percentage of
patients remaining alive after 5 years with non metastatic (-) and metastastic (+) tumors expressing
normal (white bar) or low (black bar) levels of ATIP3, based on Affymetrix MTUS1 probesets
212093_s_at and 239756_at as in (A). Number of tumors is indicated below under brackets
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Supporting Information Figure S2. Anti-metastatic effects of ATIP3 in vivo
(A) Total number of photons/sec per mouse at day 24. *p<0.05 as compared to WT, #p<0.05 as
compared to GFP. (B) Histological analysis of metastatic foci at day 24 after H&E coloration.
Magnification x100 (lung) and x400 (brain).
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Supporting Information Figure S3. ATIP3 inhibits breast cancer cell proliferation and migration
(A) Real-time measurement of impedance-based cell proliferation of ATIP3-negative (WT, GFP) and
ATIP3-positive (Cl3, Cl6) D3H2LN cells as measured by the XCELLigence methodology. Shown is
one representative experiment out of 3 performed in quadruplicate. (B) Boyden chamber migration
assay of ATIP3-negative (GFP-transfected) and GFP-ATIP3-positive MDA-MB-231 cell clones. Cell
migration was quantified by densitometry. Results (mean±SD) are expressed as percent of GFP-
transfected cells (n 3) (C) Q antification of o nd clos re (in percent) at time T18 in GFP ATIP3= . u w u u - -
expressing MCF-7 clones (HC1, HC6, HC7, described in Rodrigues-Ferreira et al., PLoS One
2009;4:e7239) as compared to ATIP3-negative MCF-7 transfected GFP clone (n=2). (D) Diagrams
representing the migration trajectories covered within 12 hrs by transiently transfected GFP (n=19)
and GFP-ATIP3 (n=19) cells. Directionality coefficient (Dir) is indicated inside the graph. (E)
Scattered dot plot of GFP- (black square) and GFP-ATIP3-expressing (black triangle) cell velocity
(n=19 cells for each condition). (F) Representative pictures of wound closure (times T0 and T12 after
l f th i t) f D3H2LN t i tl t f t d ith GFP d GFP ATIP3 t t Shremova o e nser o rans en y rans ec e w an - cons ruc s. own
are merge pictures taken in bright field and GFP fluorescence filters. Lower panel : cell tracking of
fluorescent positive cells at time T12. Dashed lines indicate wound border. *p<0.05, **p<0.001.
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Supporting Information Figure S4. ATIP3 regulates MT dynamics
(A) Western blot analysis of RPE-1 cells either non-transfected (NT) or transfected with mCherry-
ATIP3 (Ch-ATIP3) using anti-EB1 antibody. Blots were probed using anti-cherry and anti-ezrin
antibodies for control of transfection and loading respectively. (B) Kymographs of two microtubules
extracted from supplemental movie 6. EB3-GFP labels MT plus end and allows the quantification of
dynamic parameters on control (WT, left) and mCherry-ATIP3 expressing cells (Ch-ATIP3, right).
Calculated velocity of EB3-GFP comets was 0.5µm/sec for control cells (WT) and 0.2µm/sec for cells
co-transfected with Ch-ATIP3.
Molina et al, Supporting Information Fig S4
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Supporting Information Figure S5. Characterization of ATIP3 domains
(A) Microtubule co-sedimentation assay performed on MCF-7 transfected with GFP, GFP-ATIP3
(ATIP3) or GFP-D2 (D2). Immunoblots were revealed using anti-GFP and reprobed with anti-tubulin
antibodies. Molecular weights are indicated on the left. L: total cell lysate; S: supernatant; P: pellet.
(B) Representative pictures of wound closure of GFP and GFP-D2 transfected D3H2LN cells at times
T0 and T12 after removal of the insert. Shown are merge pictures taken in bright field and GFP
Molina et al, Supporting Information Fig S5
fluorescence filters. Lower panel: cell tracking of fluorescent positive cells at time T12. Dashed lines
indicate wound border.
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ARTICLE 2: 
ATIP3 interacts with End Binding protein EB1 to limit its 
accumulation at the microtubule plus ends 
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Results from the Cancer Research paper demonstrate that ATIP3 was able to regulate 
microtubule (MT) dynamics to, in turn, control cell polarity and cell migration. Thus, the 
aim of this second submitted article was to investigate how ATIP3 decreases MT dynamic 
instability parameters. 
Analysis of ATIP3 amino acid sequence revealed one SxIP (SAIP) motif in the D3 region and 
two SxIP-like (KNIP and RPLP) motifs in the D2 region, all surrounded by serine and basic 
rich residues. To date SxIP motifs are recognized as one of the EB1 interaction motifs and 
as a Microtubule Tip Localization Signals (MtSL) that confers tip tracking properties. The 
presence of these three motifs suggest that ATIP3 is a novel EB1 interacting partner. 
Cell lysates from MCF7 breast cancer cells transiently transfected with GFP-ATIP3 were 
incubated with GST-EB1 as an affinity matrix for GST-pull-down experiments. Interestingly, 
results indicated that GFP-ATIP3 was able to interact with EB1. Experiments using ATIP3-
expressing HeLa cells confirmed the first result, showing that endogenous ATIP3 was also 
interacting with GST-EB1. Finally, co-immunoprecipitation experiments in MCF7 cells co-
transfected with mCherry-ATIP3, EB1-GFP, EB3-GFP and GFP-EB3 confirmed the 
interaction of ATIP3 with EB1 and revealed that ATIP3 was able to interact with EB3 as 
well. 
To further characterize the interaction, GFP-ATIP3 cell lysates were incubated with GST-
EB1 comprising the C-terminal or the N-terminal region. As for most of the SxIP-containing 
EB1 partners, ATIP3 interacts with the C-terminal domain of EB1. The interacting domain 
of ATIP3 was then investigated by transfecting the D1, D2 and D3 GFP-constructs in MCF7 
cells. Cell lysates were then incubated with GST-EB1 and pull-down experiments were 
performed. Western blot analysis indicate that only the D2 domain was interacting with 
EB1 and more precisely with the C-terminal domain of EB1, eliminating the SAIP domain 
present in D3 region of ATIP3 as involved in the interaction with EB1. 
To investigate which of the two SxIP-like (KNIP and RPLP) motifs of D2 was interacting with 
EB1, D2 deletion mutants (D2C terminal and D2N terminal) were constructed and tagged 
with GFP. Transfection of these constructs on MCF7 cells followed by the incubation of the 
lysates with GST-EB1 was performed. Results showed that only the D2C domain was able 
to interact with EB1. Refining of this D2C domain using shorter deletion mutants allowed 
the identification of a domain, termed CN, capable to interact with EB1. Deletion of the 
CN domain from the full-length protein and the D2 domain (ATIP3delCN and D2delCN) led 
to a marked decrease in EB1 interaction. Additionally, deletion of the RPLP motif from the 
CN domain (CN67delP) also reduces the interaction with EB1.  
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Fluorescent peptides corresponding to a smaller sequence of the CN, termed CN45 
comprising the RPLP motif, and the CC motif that do not interact with EB1, were incubated 
together with GST-EB1. Results revealed that CN interacts directly with EB1. Altogether 
these results indicate that ATIP3 directly interacts with EB1 via an SxIP-like domain, RPLP, 
located in the CN domain. 
To investigate if EB1-interaction may contribute to MT-association, examination of cellular 
localization of D2 deletion mutants was then performed in RPE1 cells stained with anti-
GFP and anti-tubulin antibodies after transient transfection of the different constructs. 
Similar to ATIP3 and D2, D2N, D2C and CN associate with MTs. The CN domain weakly 
interacts with MTs and remains mostly cytosolic. EB1-interacting domain termed CN67 
(which is smaller than the CN but 22 residues longer than CN45) remains completely 
diffuse at the cytosol. Of note, the D2delCN deletion mutant still decorates MT lattice, 
even if the EB1-interacting domain was removed. These results indicate that EB1 
interaction and MT interaction involve two different regions located in the central 
functional domain of ATIP3. 
As mentioned above, the presence of SxIP motif often confers tip tracking properties. 
Transiently transfection of low levels of GFP-ATIP3 in RPE1 cells followed by EB1 staining 
was performed. Immunofluorescence images showed that ATIP3 decorates the MT lattice 
but does not co-localize with EB1 at the MT plus-end. Time-lapse images of MRC5 cells co-
transfected with mCherry-ATIP3 and EB3-GFP were then taken. Analysis of the videos 
confirmed the previous result, in which ATIP3 does not accumulate at the MT growing-
ends, and consequently is not a MT plus-end tracking protein (+TIP). Interestingly, time-
lapse videomicroscopy of MCF7 stably expressing GFP-ATIP3 showed that rather than an 
accumulation at the end of growing MTs, ATIP3 accumulate at the end of shrinking MTs. 
As ATIP3 does not interact with EB1 at the MT growing-end, Proximity Ligation Assay (PLA) 
experiments were design to identify the cellular compartment where the interaction 
occurs. Two conditions were tested. First, transient transfection of full-length and ATIP3 
deletion mutants in RPE1 cells and amplification using anti-GFP and anti-EB1 antibodies, 
and the second condition using ATIP3-expressing HeLa cells, that were amplified using 
anti-MTUS1 and anti-EB1 antibodies to reveal the interaction of endogenous proteins. PLA 
amplification signals (or RCP for rolling circle product) was observed in cells transfected 
with ATIP3, D2, D2C and CN, as well as in the endogenous condition. Transfection of the 
full-length and D2 depleted for the CN domain (ATIP3delCN and D2delCN) showed a 
significant reduction in the PLA amplification signals. 
Detailed analysis of PLA immunofluorescence images showed that the interaction happens 
mostly in the cytosol, which is coherent with the interaction of CN67 domain which is 
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completely cytosolic and interacts with EB1. Interestingly, some PLA signals were also 
detected along MT lattice in ATIP3 and D2 transfection and endogenous ATIP3. Altogether 
these results indicate that ATIP3 interacts with EB1 in intact cells through the CN domain 
mainly in the cytosol and along the MT lattice. 
Cancer Research published results showed that ATIP3 silencing increases MT dynamic 
instability, and that ATIP3 and D2 re-expression limits EB1 accumulation at the MT 
growing end. To investigate the consequence of ATIP3-EB1 interaction on EB1 localization 
at the MT plus-end, D2 deletion mutants were transfected in RPE1 cells and staining of 
GFP, tubulin and EB1 was performed. Observation of the immunofluorescence images 
revealed all the EB1-interacting domains (D2C, CN and CN67) impaired EB1 accumulation 
at the plus-end, whereas domains that do not bind EB1 (CC, D2delCN and CN67delP) had 
no effect on EB1 comet number and length. Delocalization of EB1 in the cells transfected 
with D2, D2C and CN from the MT tip to the lattice and cytosol, were in line with PLA 
results. These data suggest a functional involvement of the EB1-interacting domain of 
ATIP3 in reducing EB1 accumulation at the MT plus-ends. 
Rescue experiments were then design in ATIP3-silenced HeLa cells in which GFP-ATIP3 and 
deletion mutants were re-introduced at endogenous levels and EB1 immunostaining was 
performed. Results showed that GFP-ATIP3 restore ATIP3 knock-down phenotype 
decreasing EB1 comet-like structures. In addition, GFP-D2 and GFP-CN, similar to GFP- 
ATIP3, restore the impaired accumulation of EB1, whereas GFP-D2delCN does not.  
Altogether these results demonstrate that functional ATIP3-EB1 complexes are formed in 
the cytosol and near to the MT lattice. This interaction may contribute to restrain the 
accumulation of EB1 at the MT growing end. Given that EB1 play a key role in regulating 
MT dynamics from the plus-ends, these data may account for decreased MT dynamics in 
the presence of ATIP3. 
The findings reported suggest that altered expression of either ATIP3 or EB1 may modify 
the number of ATIP3-EB1 molecular complexes and subsequent accumulation of EB1 at 
the MT plus ends. In order to investigate the functional relevance of these data in human 
pathology, examination of the prognostic value in respect to ATIP3 and EB1 expression 
levels in breast cancer was evaluated. Using a panel of 150 breast cancer patients with 
known clinico-pathological characteristics, DNA microarray probeset values for MTUS1 
(ATIP3) and MAPRE1 (EB1) genes were compared with overall survival of the patients. 
Hierarchical clustering of these tumors allowed the classification in four groups according 
to the expression levels of both genes: group 1, low expression of both genes; group 2, 
high expression levels of MTUS1 and low of MAPRE1; group 3, low levels of MTUS1 and 
high of MAPRE1; and group 4, very high levels of MTUS1 and low levels of MAPRE1. 
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Overall survival curves indicate that tumors from cluster 3 (low ATIP3-high EB1) are 
associated with significantly reduced overall survival of the patients as compared to all 
other breast tumors analyzed. In addition, the percent of patients surviving after 5 years 
was also markedly decreased in tumors from group 3. These analyses indicate that 
combined information on ATIP3 and EB1 could be considered as a prognostic marker of 
breast cancer progression and clinical outcome. 
To conclude, this work showed that ATIP3 interacts with EB1 and that this interaction may 
regulate MT dynamics and functions at the growing ends. Of relevance, combined 
ATIP3/EB1 may represent a novel prognostic marker that should be taken into account for 
better medical follow up. 
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Abstract  
 
Microtubule-associated protein ATIP3 is the major product of candidate tumor 
suppressor MTUS1 gene down-regulated in breast cancer. We have previously 
reported that ATIP3 is a potent microtubule stabilizer whose depletion increases 
microtubule dynamics, cell proliferation and migration. We show here that ATIP3 
directly interacts with End Binding protein 1 (EB1) via an SxIP-like motif but has no 
tip-tracking properties. Proximity ligation assays reveal that molecular interaction 
between ATIP3 and EB1 takes place in the cytosol and along the microtubule 
lattice in living cells. ATIP3-EB1 interaction is functionally involved in regulating 
EB1 accumulation at the MT plus ends. We propose a novel mechanism by which 
ATIP3-EB1 molecular complexes may locally reduce the effective concentration of 
EB1, thereby limiting EB1 diffusion and access to the MT plus ends. This in turn 
may limit the recruitment of regulatory +TIPs and subsequently decrease MT 
dynamics. Finally, we provide evidence for reduced clinical outcome in breast 
cancer patients with low ATIP3 and high EB1 expression levels, illustrating 
functional relevance of our findings in human pathology.  
  
 ͵
Introduction 
 
Microtubules (MTs) are highly polarized structures that continuously switch 
between periods of polymerization (growth) and depolymerization (shrinkage) at 
their growing (plus) ends (Mitchison and Kirschner, 1984; Desai and Mitchison, 
1997; Howard and Hyman, 2003). This process, termed MT dynamic instability, 
allows rapid reorganization of the MT cytoskeleton during essential cell functions 
such as cell polarity and migration, mitosis and intracellular transport of proteins 
and organelles. Alterations in MT dynamic instability parameters lead to defects in 
mitotic spindle formation and chromosome segregation and are a major cause of 
cancer initiation and progression. 
MT dynamic instability is tightly regulated by microtubule-associated proteins 
(MAPs) and MT plus end tracking proteins (+TIPs) that accumulate at the MT 
growing ends (Akhmanova and Steinmetz, 2008). End Binding proteins (EB1, 
EB2, EB3) are +TIPs that play a pivotal role in the regulation of MT dynamics. EB1 
and EB3 can autonomously recognize growing MT ends through binding to GTP-
cap structures (Maurer et al., 2011, 2012) and have been shown to control 
persistent MT growth (Komarova et al., 2009). EBs interaction with the plus ends 
is highly dynamic, and rapid exchange of EBs at the MT plus ends requires free 
diffusion and mobility of the cytosolic pool of EB proteins (Dragestein et al., 2008). 
A major function attributed to EBs is their ability to recruit a variety of regulatory 
+TIPs at the growing ends to orchestrate MT dynamics in a coordinated fashion. 
Numerous +TIPs bind to EB1 through a core SxIP motif (Serine - any amino acid – 
Isoleucine - Proline) embedded in an intrinsically unstructured polypeptide region 
rich in basic, proline and serine amino acids (Honnappa et al., 2009; Galjart, 2010, 
Slep 2010; Kumar and Wittmann, 2012; Jiang et al., 2012). Efficient SxIP-EB1 
interaction requires that at least one basic residue, and no acidic residue, is 
present within the 9 amino acids surrounding the SxIP motif (Buey et al., 2012, 
Jiang et al., 2012). Consensus SxIP motifs have been shown to confer both EB1 
binding and tip-tracking properties (Honnappa et al., 2009, Buey et al., 2012). 
Recent high throughput and in silico analyses have identified a broad and 
heterogeneous group of SxIP-containing EB1 partners (Jiang et al., 2012). Most of 
them are localized at the MT plus ends and regulate MT dynamics while others 
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may connect MT plus ends with cellular compartments, indicating a diversity of 
functions associated with EB1 interaction (Jiang et al., 2012).  
The ATIP3 protein is a novel MAP whose expression is markedly decreased in 
highly proliferative and metastatic breast tumors (Rodrigues-Ferreira et al., 2009; 
Rodrigues-Ferreira and Nahmias, 2010; Molina et al., 2013). Restoring ATIP3 
expression at normal levels in breast cancer cells significantly reduces cell 
proliferation and migration, as well as tumor growth and metastasis formation in 
experimental animal models (Rodrigues-Ferreira et al., 2009; Molina et al., 2013). 
Our group has recently shown that ATIP3 is a potent MT-stabilizing protein and 
that its depletion increases MT dynamics. Accordingly, expression of ATIP3 in 
breast cancer cells reduces cell migration by decreasing cell polarity and 
directionality, and impairs the ability of MTs to reach the cell cortex as a 
consequence of reduced MT dynamics at the plus ends (Molina et al., 2013). 
However, the molecular mechanisms by which ATIP3 regulates MT dynamic 
instability remain unknown.  
ATIP3 is the major product of MTUS1 gene, a paralog of MTUS2 gene encoding 
TIP150 (Du Puy et al., 2009; Jiang et al., 2009) and the ortholog of Xenopus ICIS 
(Ohi et al., 2003). Of interest, both TIP150 and ICIS localize at MT growing ends 
where they interact with other +TIPs (Jiang et al., 2009, Ohi et al., 2003). 
Structural homology between ATIP3, ICIS and TIP150 (Di Benedetto et al., 2006; 
Rodrigues-Ferreira and Nahmias, 2010) prompted us to investigate whether ATIP3 
may regulate MT dynamics through functional interaction with +TIPs. 
In the present study, we show that ATIP3 directly interacts with EB1 via an SxIP-
like sequence but does not accumulate at the MT plus ends. We provide evidence 
that ATIP3-EB1 molecular complexes are present in the cytosol and along the MT 
lattice in intact cells. Our results support the notion that ATIP3-EB1 interaction 
limits EB1 accumulation at the MT growing ends, which in turn may contribute to 
the regulation of MT dynamics and function. 
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Results 
 
ATIP3 interacts with EB1 
Close examination of the ATIP3 amino acid sequence revealed three SxIP or 
SxIP-like motifs, each surrounded by intrinsically unstructured stretches of basic 
and proline/serine residues (Fig.1A). These features are recognized as hallmarks 
of EB1 binding and MT tip-tracking (Akhmanova and Steinmetz 2008; Honnappa 
et al., 2009; Galjart 2010; Jiang et al., 2012), suggesting that ATIP3 may be a 
novel cellular partner of EB1. 
To investigate whether ATIP3 interacts with EB1, we performed pull-down assays 
using Gluthation-S-transferase (GST)-EB1 as an affinity matrix to precipitate GFP-
ATIP3 proteins expressed in cell lysates. Results indicate that GST-EB1 
precipitates GFP-ATIP3 fusion proteins (Fig.1B, 1C) as well as endogenous ATIP3 
expressed in HeLa cells (Fig.1C). ATIP3-EB1 complexes were also detected by 
co-immunoprecipitation using either anti-Cherry or anti-GFP antibodies following 
co-transfection of Cherry-ATIP3 with EB1-GFP (Fig.1D). Cherry-ATIP3 also co-
immunoprecipitated with GFP-EB3 as well as EB3-GFP (Expanded view Fig.E1A) 
indicating that ATIP3 interacts with End Binding proteins (EBs) in intact cells. 
Since EB1 is the leader member of the EB family studied in most cell types, we 
focused here on ATIP3 interaction with EB1. 
To map the domain of EB1 that interacts with ATIP3, we used GST-EB1 deletion 
mutants comprising either the N-terminal (EB1-N) or C-terminal (EB1-C) portion of 
the molecule (Fig.1E). Similar to what observed for other SxIP-containing +TIPs 
(Askham et al., 2002; Komarova et al., 2005; Mimori-Kiyosue et al., 2005, Jiang et 
al., 2009), ATIP3 interacts with the C-terminal portion of EB1 (Fig.1F). ATIP3 also 
binds to EB1 in the presence of microtubule depolymerizing agent nocodazole 
(Fig.1G) indicating that EB1-ATIP3 interaction does not require an intact 
microtubule network.  
To get further insight into the ATIP3-EB1 interaction, ATIP3 was cleaved into three 
distinct domains designated D1, D2 and D3 (see Fig.1A) that were fused to GFP 
and used in GST-EB1 pull-down experiments. As shown in Fig.1H, the central D2 
domain clearly interacts with EB1, whereas the N-terminal (D1) and C-terminal 
(D3) domains of ATIP3 are not retained on GST-EB1 beads. These results 
indicate that the consensus C-terminal SxIP motif (SAIP, position 1249) present in 
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the D3 domain of ATIP3 (Fig.1A) is not mainly involved in EB1 interaction. 
Accordingly, an ATIP3 deletion mutant lacking the last 30 amino acids of the 
protein (ATIP3delCTer) was still able to bind EB1 (Expanded View Fig.E1B). 
Furthermore, site-directed mutagenesis of either Ile or Pro residues of the SAIP 
sequence (positions 1251 and 1252) into Asn or Ala, respectively, did not affect 
the EB1-binding properties of ATIP3 (Expanded View Fig.E1B). Altogether these 
results indicate that the central D2 domain is the major EB1-binding domain of 
ATIP3. As for the whole ATIP3 protein, the D2 domain interacts with the C-
terminal part of EB1 and this interaction is not affected by nocodazole treatment 
(Fig.1I).  
As illustrated in Fig.1A, the D2 domain contains two SxIP-related motifs (KNIP and 
RPLP at positions 462 and 780, respectively), in which a basic amino acid is 
present instead of the canonical serine residue. To investigate whether one or 
both of these non-classical motifs may be involved in EB1 binding, we generated 
D2 deletion mutants tagged with GFP (Fig.2A) and analyzed their ability to interact 
with EB1 in GST pull-down assays. As shown in Fig.2B, the C-terminal (D2C) 
fragment containing the RPLP sequence was precipitated by GST-EB1 whereas 
the N-terminal (D2N) fragment containing the KNIP motif remained unbound. Site-
directed mutagenesis of Ile and/or Pro residues (positions 464 and 465) into Asn 
and/or Ala, respectively, in the KNIP sequence of either ATIP3 or D2 fragment did 
not abrogate EB1 binding (Expanded View Fig.E1B), confirming minor involvement 
of the KNIP sequence in EB1 interaction. The presence of an asparagine at 
position +2 and a negatively charged aspartic acid at position +5 of the KNIP 
sequence (see Fig.1A) may account for weak interaction of this motif with EB1. In 
contrast, the sequence surrounding the RPLP motif (see Fig.1A) follows the SxIP-
9AA rule (Jiang et al., 2012), showing three basic and no acidic amino acid within 
the nine residues proximal to the SxIP sequence.  
By refining the analysis of D2C fragments using shorter deletion mutants, we 
identified an EB1-interacting sequence of 112 residues (CN) (Fig.2B) that could be 
further reduced to 67 and 45 amino acids (CN67 and CN45 domains, respectively) 
(Fig.2C, Table I, Expanded view Fig.E1C). The minimal EB1-interacting fragment 
CN45 includes the consensus RPLP motif, has a net positive charge and displays 
significant homology to the EB1-interacting region of TIP150 (Jiang et al., 2009) 
(Expanded View Fig.E1D) as well as high evolutionary conservation (Expanded 
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View Fig.E1E). Importantly, deletion of the CN sequence in ATIP3 and D2 
polypeptides (ATIP3delCN and D2delCN) led to a marked decrease in EB1 
interaction (Fig.2D). Deletion of the RPLP sequence (CN67delP mutant) also 
significantly reduced the ability of CN67 to interact with EB1 (Fig.2D), further 
indicating major involvement of this SxIP-like motif in EB1-binding.  
To investigate whether the ATIP3-EB1 interaction is direct, or whether it requires 
the presence of intermediate proteins present in the cell lysate, fluorescent 
peptides corresponding to the sequence of CN45 were synthesized and analyzed 
in GST-EB1 pull-down assays in vitro. The short CC domain that does not bind 
EB1 (Fig. 2A, 2B) was used as a negative control. As shown in Fig.2E, FITC-CN45 
(but not FITC-CC) was specifically retained on GST-EB1 beads, indicating direct 
interaction between CN45 and EB1.  
Altogether, these results demonstrate that ATIP3 directly interacts with EB1 via a 
non-canonical (RPLP) motif present in the C-terminal portion of the D2 domain. 
 
EB1-binding domain is distinct from MT-localization domain 
Our studies have shown that D2 is a positively charged domain whose expression 
is sufficient to recapitulate all functional features of ATIP3, including the ability to 
associate with MTs (Molina et al., 2013). To investigate whether EB1-interaction 
may require or contribute to MT-association, we examined the cellular localization 
of GFP-fused D2 deletion mutants in RPE1 cells, that are well-spread and suited 
for analyzing microtubule arrays and protein localization. Immunofluorescence 
studies (Fig.3) revealed that both N-terminal (D2N) and C-terminal (D2C) portions 
of the D2 domain are co-localized with tubulin at the MT lattice. Shorter deletion 
mutants of D2C (CN and CC fragments) remained mostly cytosolic, suggesting 
that MT localization involves a conformational recognition motif that requires both 
parts of the sequence. Of note, the CN fragment retained weak MT-binding (Fig.3, 
insets). Importantly, the minimal EB1-interacting domain CN67 was diffuse in the 
cytosol whereas the D2delCN deletion mutant, that has lost EB1 binding, still 
decorated the MT lattice (Fig.3, Table I). Thus, EB1 interaction and MT localization 
involve two distinct, although adjacent, regions of ATIP3.  
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ATIP3 is not a tip-tracking protein 
The presence of SxIP motifs, also designated MtLS (microtubule tip localisation 
signal), often confers tip-tracking properties to EB1 partners (Honnappa et al., 
2009, Slep, 2010; Buey et al., 2012, Jiang et al., 2012; Kumar and Wittmann, 
2012), leading us to examine whether ATIP3 may accumulate with EB1 at the MT 
plus ends. 
RPE-1 cells were transfected with low levels of GFP-ATIP3 in order to avoid 
extensive MT stabilization and subsequent loss of EB1 comets due to ATIP3 
expression (Molina et al., 2013). As shown in Fig.4A, EB1 comet-like structures 
were still detectable in low GFP-ATIP3-expressing RPE-1 cells. Under these 
conditions, GFP-ATIP3 localized along the MT lattice but did not accumulate at the 
MT plus tips together with endogenous EB1. Time-lapse microscopy analysis of 
co-transfected MRC5 cells (movies 1 to 4; Expanded View Fig.E2) also clearly 
showed distinct patterns of Cherry-ATIP3 and EB3-GFP localization in living cells 
and confirmed that ATIP3 does not accumulate at the MT growing ends close to 
the cell cortex. Thus, ATIP3 is not a +TIP.  
Time-lapse images of MCF-7 cells stably expressing moderate levels of GFP-
ATIP3 (Fig.4B, movies 5 and 6) further confirmed that ATIP3 localizes along the 
MT lattice and is not a tip-tracking protein. They also revealed for the first time that 
ATIP3 accumulates on the plus end of shrinking microtubules in living cells, 
therefore highlighting its back-tracking properties. 
 
ATIP3-EB1 complexes are present in the cytosol  
To identify the cellular compartment in which ATIP3 and EB1 co-localize in vivo, 
we used Proximity Ligation Assay (PLA) technology that allows in situ detection of 
molecular complexes in single cells, at the location where the proteins of interest 
interact (Soderberg et al., 2006; Jarvius et al., 2007). RPE-1 cells were transfected 
with GFP-ATIP3 and molecular proximity between GFP-ATIP3 and endogenous 
EB1 was assessed by PLA using anti-GFP and anti-EB1 primary antibodies 
followed by in situ detection of fluorescent Rolling Circle Products (RCP). As 
shown in Fig.5A, PLA amplification signals were detected in cells transfected with 
GFP-ATIP3 and GFP-D2, but not GFP-D1, indicating that ATIP3 and D2 
specifically interact with EB1 in intact cells. No signal was detected in negative 
control conditions, either following incubation with only one of the two primary 
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antibodies (Expanded View Fig.E3A) or in the presence of both antibodies in EB1-
silenced cells (Expanded View Fig.E3B) or in cells transfected with GFP empty 
vector (Expanded View Fig.E3C). Specific PLA signals were also detected in 
Cherry-ATIP3-transfected RPE-1 cells stably expressing EB1-GFP, following 
incubation with both anti-Cherry and anti-GFP antibodies but not with anti-Cherry 
alone (Expanded View Fig.E3D).  
As shown in Fig.5A and 5B, the number of in situ PLA amplification signals was 
markedly reduced in cells transfected with ATIP3delCN and D2delCN deletion 
mutants as compared to full-length ATIP3 and D2 domains. These results 
corroborate our GST-EB1 pull-down assays (see Fig.2D, Table I) and further 
demonstrate the involvement of the CN domain in the formation of EB1-ATIP3 
molecular complexes in intact cells. In line with these results, PLA analyses of D2 
deletion domains revealed in situ molecular complexes of endogenous EB1 with 
GFP-D2C and GFP-CN, but not GFP-D2N and GFP-CC domains (Expanded View 
Fig.E3E).  
In all positive cells, individual bright fluorescent signals specifying protein complex 
formation were distributed throughout the cytosol, indicating cytosolic localization 
of ATIP3-EB1 complexes (Fig.5A). These results are consistent with GST pull-
down experiments performed in the presence of nocodazole (Fig.1G, 1I) indicating 
that interaction of ATIP3 and D2 with EB1 does not require intact MTs. They are 
also consistent with the observation that the minimal EB1-interacting domain 
CN67 has a diffuse localization in the cytosol (Fig.3). Of note, bright PLA signals 
were also detected along MTs in GFP-ATIP3 and GFP-D2-expressing cells 
(insets, Fig.5C), indicating that some ATIP3/EB1 molecular complexes may also 
associate with the MT lattice in vivo.  
We then sought to investigate the presence of endogenous ATIP3/EB1 complexes 
in intact cells. PLA experiments were conducted using rabbit anti-MTUS1 and 
mouse anti-EB1 primary antibodies in HeLa cells that express detectable levels of 
endogenous ATIP3 (Expanded view Fig.E4A). As shown in Fig.5D, RCP signals 
specifying interaction between endogenous ATIP3 and EB1 proteins were 
detected in control conditions, but not following transfection with ATIP3- or EB1-
siRNA. No RCP signal was detected in negative control conditions using only anti-
MTUS1 primary antibodies (Expanded view Fig.E4B). Endogenous ATIP3/EB1 
complexes were located in the cytosol and along the MT lattice (Fig.5D, inset), 
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comforting previous results obtained in RPE-1 cells transfected with GFP-ATIP3. 
PLA analysis of several breast cancer cell lines expressing or not ATIP3 
(Expanded View E4C) further indicated endogenous interaction between ATIP3 
and EB1 in ATIP3-positive (MDA-MB-468 and HCC1143) but not ATIP3-negative 
(MDA-MB-231, CAL-120) breast cancer cells (Expanded View Fig.E4D). 
Altogether, these results provide evidence that ATIP3 interacts with EB1 through 
its CN domain and that endogenous ATIP3/EB1 molecular complexes are present 
in the cytosol and along the MT lattice of ATIP3-expressing cells. 
 
ATIP3-EB1 interaction limits EB1 accumulation at the MT plus ends 
Our previous studies have shown that ATIP3 silencing increases MT dynamics 
whereas ATIP3 (and D2 domain) expression limits the accumulation of EB1 
comet-like structures at the MT plus ends (Molina et al., 2013). To investigate the 
consequence of ATIP3-EB1 interaction on EB1 localization at the MT growing 
ends, we analyzed the effects of D2 deletion mutants on the number and size of 
EB1 comet-like structures. As shown in Fig.6A, expression of EB1-interacting 
domains D2C and CN reduced EB1 comet formation to the same extent as D2, 
whereas CC - that does not bind EB1 - had no significant effect on the number or 
length of EB1 comets. In cells expressing D2, D2C and CN, EB1 staining was 
visualized in the cytosol and along MT segments (Fig.6A), in line with previous 
observations that ATIP3/EB1 complexes are present at the vicinity of the MT 
lattice. Of importance, deletion mutants (D2delCN and CN67delP) having lost the 
ability to interact with EB1 were no longer able to reduce EB1 comet number and 
size (Fig.6B, Table I), highlighting the functional involvement of the EB1-interacting 
domain of ATIP3 in reducing EB1 accumulation at the MT growing ends.  
Rescue experiments were performed on ATIP3-silenced HeLa cells in which GFP-
ATIP3 was re-introduced at levels close to endogenous (Expanded view Fig.E5A). 
As shown in Expanded view Fig.E5B, moderate levels of GFP-ATIP3 were 
sufficient to fully restore the ATIP3 knock-down phenotype, and abolish EB1 
comets number and length. We then investigated whether GFP-D2 and deletion 
mutants were also able to rescue the phenotype. Expression levels of GFP-D2, 
GFP-D2delCN and GFP-CN domains were monitored by immunofluorescence 
(Expanded view Fig.E5C) and shown to be comparable to GFP-ATIP3 levels 
previously determined to be close to endogenous. As shown in Expanded Views 
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Fig.E5D and Fig.E5E, moderate expression of GFP-D2 and GFP-CN, but not 
GFP-D2delCN constructs in ATIP3-silenced HeLa cells was sufficient to restore 
EB1 comets number and length at levels close to those of wild type cells.  
Altogether, our data indicate that functional ATIP3-EB1 complexes are formed in 
the cytosol and close to the MT lattice in vivo and contribute to restraining the 
accumulation of EB1 at the MT plus ends. Given the pivotal role of EB1 in 
regulating MT plus ends dynamics, our results may account for decreased MT 
dynamics in the presence of ATIP3. 
 
Prognostic value of relative ATIP3 and EB1 levels in breast tumors 
Our results suggest that altered expression of either ATIP3 or EB1 may modify the 
number of ATIP3-EB1 molecular complexes and subsequent accumulation of EB1 
at the MT plus ends, and be deleterious to essential cell functions. To investigate 
the functional relevance of these findings in human pathology, we examined the 
prognostic value of respective ATIP3 and EB1 expression levels in breast cancer, 
a disease in which loss of ATIP3 correlates with tumor aggressiveness 
(Rodrigues-Ferreira et al., 2009) and represents a prognostic biomarker of patient 
survival (Molina et al., 2013). We reasoned that increased levels of EB1 in low 
ATIP3-expressing tumors may result in poor prognosis as compared to low EB1-
expressing tumors. 
In a panel of 150 breast cancer patients with known clinico-pathological 
characteristics, Affymetrix DNA array probeset values for MTUS1 (ATIP3) and 
MAPRE1 (EB1) genes were compared with overall survival of the patients 
(Expanded View Table E1). Unsupervised classification of the tumors was 
performed using intensity values for three MTUS1 (212096_s_at; 212093_s_at; 
239576_at) and two MAPRE1 (200712_s_at ; 200713_s_at) probesets. Results of 
hierarchical clustering (Fig.7A) allowed us to distinguish four groups of tumors 
expressing various levels of ATIP3 and EB1.  
Tumors from clusters 1 and 3 expressed low levels of ATIP3 (median values 473 
and 425, respectively, for probeset 212093_s_at) as compared to those in clusters 
2 and 4 (median values of 692 and 1056, respectively) (Fig.7B). In tumors from 
cluster 3, EB1 levels were significantly increased (median value 1399 for probeset 
200713_s_at) as compared to those in clusters 1, 2 and 4 (median values 812, 
809 and 910, respectively) (Fig.7C) (Table II). 
 ͳʹ
Kaplan-Meier survival curves (Fig.7D) indicated that tumors from cluster 3 (low 
ATIP3-high EB1) are associated with significantly reduced overall survival of the 
patients as compared to all other breast tumors analyzed. As shown in Fig.7E and 
Table II, the median value for survival times of patients with tumors from cluster 3 
was decreased by a factor of two compared to those from clusters 1, 2 and 4. The 
percent of patients surviving after 5 years was also markedly decreased (36.3%) in 
group 3 tumors as compared to tumors from other groups (60.8%, 71.4% and 
76.2% survival for patients from clusters 1, 2 and 4, respectively) (Fig.7F, Table II).  
Of note, among tumors expressing low ATIP3 levels (clusters 1 and 3), those 
showing high EB1 levels (cluster 3) are of poorer outcome, indicating that 
combined information on ATIP3 and EB1 levels provides a more powerful 
prognostic marker than considering low ATIP3 levels alone. Furthermore, among 
tumors expressing similar levels of EB1 (clusters 1, 2 and 4), those showing high 
ATIP3 levels (clusters 2 and 4) were of better prognosis. 
Altogether, these results illustrate the importance of coordinated ATIP3 and EB1 
expression levels in breast cancer progression and clinical outcome.  
 ͳ͵
Discussion 
 
Results presented here demonstrate that MT-associated protein ATIP3 directly 
interacts with EB1 and that functional ATIP3-EB1 complexes present in the cytosol 
and at the MT lattice in living cells may regulate the accumulation, and hence the 
function, of EB1 at the MT plus ends. 
ATIP3 interacts with EB1 through an RPLP motif surrounded by a positively 
charged sequence rich in proline and serine/threonine residues. This motif is very 
similar to the previously described consensus SxIP motif conferring EB1 
interaction and tip-tracking properties (Honnappa et al., 2009; Buey et al., 2012, 
Kumar and Wittmann 2012; Jiang et al., 2012). Other EB1 partners such as 
SLAIN2 also present a positively charged arginine residue in place of the 
canonical serine at position +1 of the SxIP-like motif (Van der Vaart et al., 2011), 
suggesting that additional EB1 partners with divergent [S/R-x-I/L-P]-like motifs 
may be identified in the future. ATIP3 also contains a bona-fide SAIP motif in its C-
terminal portion and a SxIP-like (KNIP) motif in its central region. Mutations and 
deletions of corresponding sequences indicate that these motifs are not necessary 
for EB1 binding, however they may contribute to stabilizing the interaction, as 
reported for other EB1-interacting proteins (Jiang et al., 2009; Van der Vaart et al., 
2011).  
The amino acid sequence surrounding the RPLP motif of ATIP3 is conserved in 
different species and is homologous to the EB1-interacting sequence of TIP150 
(Jiang et al., 2009). TIP150, the major product of MTUS2 gene (Jiang et al., 2009; 
Du Puy et al., 2009) and ICIS, the Xenopus ortholog of MTUS1 (Ohi et al., 2003) 
belong to the same superfamily as ATIP3 (Di Benedetto et al., 2006; Rodrigues-
Ferreira and Nahmias, 2010). Both proteins have been shown to interact with 
+TIPs and they localize at the MT plus ends, either at the cell cortex (TIP150) or at 
the kinetochore (ICIS). Our results clearly show that although binding to EB1, 
ATIP3 does not accumulate at the MT plus ends and shows no tip-tracking activity. 
Time-lapse images of GFP-ATIP3 rather indicate that ATIP3 is mainly associated 
along the MT lattice in living cells and displays back-tracking properties.  
The observation that ATIP3 and EB1 do not accumulate together at the MT plus 
ends raises the question of the intracellular location at which ATIP3 and EB1 
interact in intact cells. Results from Proximity Ligation Assays, that highlight 
 ͳͶ
molecular proximity between two proteins in situ, revealed that endogenous 
ATIP3-EB1 molecular complexes are formed in living cells and are distributed 
throughout the cytosol. Interestingly, in cells expressing ATIP3 or the D2 domain, 
molecular complexes were also detected along the MT lattice, in line with 
immunofluorescence studies showing increased endogenous EB1 staining at the 
MT lattice in cells transfected with MT-associated proteins ATIP3, D2 and D2C but 
not ATIP3delCN and D2delCN that associate with MTs but do not bind EB1.  
As previously reported (Molina et al., 2013), the number and length of EB1 comet-
like structures, that are characteristic of EB1 accumulation at the MT growing 
ends, are strongly reduced in cells expressing ATIP3 and D2. We report here that 
loss of EB1 comets correlates with the presence of EB1-interacting domain but is 
not related with MT-association. Of importance, the effect of ATIP3 and D2 
domains on EB1 comet formation is lost in cells expressing D2delCN and 
CN67delP deletion mutants that are unable to bind EB1, therefore indicating that 
the ATIP3-EB1 interaction is functionally involved in reducing EB1 accumulation at 
the MT plus ends.  
Based on our data, we propose the model shown in Fig.8. In control cells 
expressing ATIP3, ATIP3/EB1 complexes are formed in the cytosol and retained 
at close vicinity of the MT lattice, therefore locally reducing the ‘efficient 
concentration’ of cytosolic EB1 available to exchange at MT plus-ends. In ATIP3-
deficient cells, more cytosolic EB1 is totally free to exchange and accumulate at 
MT plus-ends, leading to increased MT persistent growth and recruitment of 
regulatory +TIPs, thereby increasing MT dynamic instability. This in turn might 
account for the increase in proliferation and migration reported in ATIP3-depleted 
cells (Rodrigues-Ferreira et al., 2009; Molina et al., 2013). 
According to this model, EB1 localization and function at the MT plus ends should 
be tightly regulated by the relative expression levels of ATIP3 and EB1. We 
challenged our hypothesis in the context of human breast cancer, as we have 
previously reported that loss of ATIP3 in breast tumors is associated with poor 
prognosis (Molina et al., 2013). Using a panel of 150 breast cancer patients, we 
provide evidence that relative levels of ATIP3 and EB1 in tumors are related with 
clinical outcome. Among breast tumors with low levels of ATIP3, those showing 
elevated EB1 levels are associated with significantly reduced overall survival of 
the patients, probably reflecting higher proportion of free EB1 molecules that do 
 ͳͷ
not interact with ATIP3. This in turn may increase EB1 accumulation at the MT 
plus ends and subsequent increase in MT dynamics, and may account for 
increased tumor growth and metastasis in ATIP3-deficient breast tumors. 
Conversely, among tumors expressing similar levels of EB1, those showing high 
levels of ATIP3 were associated with better clinical outcome, possibly due to 
increased formation of ATIP3/EB1 molecular complexes and cytosolic 
sequestration of EB1. Of note, other groups have reported the poor prognostic 
value of elevated EB1 expression in hepatocellular carcinoma (Orimo et al., 2008), 
breast cancer (Dong et al., 2010) and colorectal cancer (Sugihara et al., 2012), 
raising the interest to investigate combined EB1/ATIP3 expression levels in these 
tumor samples. 
Altogether, these results extend our knowledge of EB1 interaction with cellular 
partners, and depict a novel way to indirectly regulate MT functions at the growing 
ends through cytosolic interaction of EBs with the ATIP3 protein. A similar 
mechanism of EB1 sequestration in the cytosol by the MAP1B protein has recently 
been described in developing neurons (Tortosa et al., 2013), suggesting that these 
findings may be extended to other EB1-interacting MAPs acting in diverse 
physiopathological situations. Our studies also bring a major milestone in the field 
of breast cancer, being the first to provide a link between combined ATIP3/EB1 
expression levels in tumors and clinical outcome of the patients. We propose that 
coordinated expression of these two proteins in breast tumors represents a novel 
prognostic marker that should be taken into account for better handling of the 
patients and choice of future therapeutic options. 
 
 ͳ͸
Materials and Methods 
 
Cell lines 
Human breast cancer cell line MCF-7 and stable MCF-7 cell line (clone HC7) 
expressing endogenous levels of GFP-ATIP3, SV-MRC5 lung fibroblasts, as well 
as HeLa and RPE-1 (h-TERT-immortalized, retinal pigment epithelial) cells were 
described previously (Rodrigues-Ferreira et al., 2009; Molina et al., 2013). RPE-1 
cells stably expressing EB1-GFP were a kind gift of Dr Matthieu Piel (Institut Curie, 
Paris, France). All cells were used at passages 2 to 20 after thawing and grown as 
described (Molina et al., 2013). Cells were routinely authenticated by morphologic 
observation and tested for absence of mycoplasma contamination using MycoAlert 
Assay detection kit (Lonza, France). 
 
Plasmids constructs and transfections 
Plasmids encoding GFP-ATIP3, Cherry-ATIP3 and domains GFP-D1, GFP-D2, 
GFP-D3 were described elsewhere (Molina et al., 2013). GFP-fused D2 
subdomains (D2N, D2C, CN, CC, CN67 and CN45) were obtained by PCR-
amplification of full-length ATIP3 sequence as described (Molina et al., 2013) 
using specific oligonucleotides shown in Expanded View Table E2A. Deletion 
mutants (GFP-ATIP3delCN, GFP-D2delCN, and GFP-CN67delP) were obtained 
by Site-Directed Mutagenesis according to the Quick Change kit (Stratagene) 
using oligonucleotides shown in Expanded View Table E2B. Procaryotic 
expression vectors encoding GST-EB1, GST-EB1-C, and GST-EB1-N were kind 
gifts of Dr Anna Akhmanova (Utrecht University, The Netherlands). EB1-GFP 
construct was kindly provided by Dr Franck Perez (Institut Curie, Paris, France). 
EB3-GFP and GFP-EB3 expression constructs were described by Stepanova et 
al. (2003).  
Plasmids were transiently transfected into MCF-7, RPE-1 or HeLa cells for 24h 
using Turbofect (Fermentas GMBH, St Leon Rot, Germany), X-tremeGENE DNA 
(Roche, Mannheim, Germany) or Dreamfect (Oz-Bioscience, Marseille, France) 
transfection reagents as described by the manufacturer. ATIP3-specific siRNAs 
were described previously (Rodrigues-Ferreira et al., 2009). EB1-specific siRNA 
(on-target plus smart pool, NM_012325) and scrambled siRNA used as a control, 
were purchased from Dharmacon (ThermoFisher Scientific) and Qiagen SAS, 
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respectively. All siRNAs (50 nM) were transfected using lipofectamine 2000 
(Invitrogen) and silencing efficiency was evaluated by immunoblotting using rabbit 
anti-MTUS1 polyclonal antibodies (ARP44419; Aviva Systems Biology, San Diego, 
CA, USA) and rat anti-EB1 (clone KT51; Santa Cruz). For rescue experiments, 
HeLa cells were transfected with specific ATIP3-siRNA (sens strand UGG CAG 
AGG UUU AAG GUU A) that targets the 5’ untranslated sequence of ATIP3 and 
allows expression of wild type ATIP3 coding sequence. 
 
GST pull-down assays and immunoprecipitations 
Production and purification of GST fusion proteins (GST-EB1, GST-EB1-C, and 
GST-EB1-N) on gluthatione-agarose beads were performed as described 
(Komarova et al., 2005). Transfected MCF-7 cell lysates or endogenous proteins 
from HeLa cells were retained on the beads for 1h at room temperature as 
described (Grigoriev et al., 2008). GST pull-down were analyzed by Western 
blotting using polyclonal anti-MTUS1 antibodies diluted 1:1000 or monoclonal anti-
GFP antibodies (clone 7.1/13.1, Roche (Mannheim, Germany), diluted 1:3000) as 
indicated. 
For in vitro interaction, chemically synthesized peptides (CN45 and CC) coupled to 
FITC were purchased from GL Biochem (Shanghai, China). Sequences of FITC-
CN45 and FITC-CC correspond to amino acids 755-799 and 816-874 of ATIP3 
(accession number NP_001001924), respectively. Purified peptides (10 or 15µg) 
were incubated for 1 hr at room temperature with GST- or GST-EB1 fusion 
proteins in 50mM HEPES containing 150mM NaCl, 0.01% Triton X100 (pH 7.4) 
then washed in the same buffer. Interaction was assessed by FITC fluorescence 
measurement using Fusion Universal Microplate Analyzer (Packard BioScience 
Company, Excitation 485nm Fluorescein and Emission 525-530 nm) and with 
Typhoon™ system (Amersham Biosciences) following 15% SDS-PAGE.  
For immunoprecipitation, MCF-7 cells were transfected with appropriate plasmid 
constructs and cell lysates were incubated for 2 hrs at 4°C with 4µg of mouse 
monoclonal anti-GFP (Roche), or mouse monoclonal anti-Cherry (Clonetech) 
antibodies prior to incubation with G protein-sepharose beads. Bound proteins 
were detected by Western blotting using rabbit anti-MTUS1 antibodies (Aviva 
Systems Biology) or rabbit anti-GFP (Roche) as described before. 
 
 ͳͺ
Immunofluorescence  
RPE-1 cells were plated on glass coverslips, transfected for 24 hrs with 
appropriate plasmids, then fixed with ice-cold methanol and incubated as 
described (Molina et al., 2013) with human anti-alpha-tubulin clone F2C (Nizak et 
al., 2003), rat anti-EB1 (clone KT51; Santa Cruz) or mouse anti-GFP (Roche).  
Linescan analyses of alpha-tubulin and EB1 fluorescence intensity were 
performed on a 5 µm line along the length of MT plus end as described (Molina et 
al., 2013). For quantification of comet number, 5 different areas of at least 5 single 
cells were analyzed. 
 
Live cell imaging 
SV-MRC5 co-transfected for 24h with mcherry-ATIP3 and EB3-GFP were imaged 
by spinning disc confocal microscopy on a Nikon Ti-E (Nikon) with perfect focus 
system (PFS, Nikon) equipped with a Plan APO VC 60x 1.40 N.A. oil objective, a 
Yokogawa motorized CSU-X1-A1 confocal head, a Photometrics Evolve 512 
EMCCD camera (Roper Scientific) and controlled with MetaMorph 7.5 software 
(Molecular Devices). For simultaneous excitation of GFP and mCherry we used 
491nm 50mW Calypso (Cobolt) and 561nm 50mW Jive (Cobolt) lasers together 
with a DV2 beam splitter (MAG Biosystems, Roper) equipped with a dichroic filter 
565dcxr (Chroma) and a HQ630/50m emission filter (Chroma). To keep cells at 
37°C we used a stage top incubator (model INUG2E-ZILCS, Tokai Hit). Images 
were acquired in a stream mode at 500 ms exposure. Movies are played at 15 
frames per second.   
For backtracking experiments, GFP-ATIP3 stable MCF-7 clones were imaged on a 
Nikon Eclipse Ti-E with the PFS, equipped with a Nikon CFI Apo TIRF 100X 1.49 
N.A. oil objective (Nikon), a TIRF-E motorized TIRF illuminator modified by Roper 
Scientific France/PICT-IBiSA, Institut Curie, a stage top incubator (model INUG2E-
ZILCS, Tokai Hit) set at 37°C, a Photometrics Evolve 512 EMCCD camera and 
controlled with MetaMorph 7.7 software. For excitation of GFP we used a Cobolt 
Calypso 491 nm (100 mW) laser and green fluorescent light was collected via a 
ET-GFP filter set (Chroma). Images were acquired in a stream mode at 100 ms 
exposure. Movies are played at 30 frames per second.  
 ͳͻ
Timelapse inset images were denoised using the ImageJ Safir Filter plugin 
(Kervrann and Boulanger, 2006). Four iterations and a patch size of 1 were used 
as parameters of the denoising process.   
 
Proximity Ligation Assay 
In situ PLA detection was carried out using DUOLINK II In Situ Far Red kit (Sigma-
Aldrich, St Louis, USA). RPE-1 cells were plated on glass coverslips at 100,000 
cells per well, transfected for 24 hrs with indicated plasmids, then fixed with ice-
cold methanol and incubated for 1h at room temperature with rabbit anti-GFP 
(Roche, 1:10000) and mouse anti-EB1 (clone 5, BD Bioscience, 1:1000) 
antibodies diluted in PBS-0.2% BSA as a blocking solution. For detection of 
endogenous ATIP3/EB1 interaction, HeLa cells were either left untreated or 
transfected with 50 nM appropriate siRNA as indicated, then fixed in ice-cold 
methanol and incubated for 1hr at room temperature with rabbit anti-MTUS1 
(Aviva, 1:300) and mouse anti-EB1 (clone 5, BD Bioscience, 1:1000) antibodies in 
PBS-0.2% BSA. Following one wash in PBS with gentle shaking, cells were 
incubated with Duolink PLA Probes anti-mouse PLUS and anti-rabbit MINUS (1:5 
dilution in PBS-BSA 0.2%) for 1h at 37°C in a humidified chamber, and then 
processed for ligation and rolling circle amplification (RCA) in the presence of cy5-
labeled oligonucleotide probe according to manufacturer’s protocol. Specificity of 
DUOLINK signals was assessed using only one of each primary antibody in the 
presence of both Duolink PLA probes and labeled oligonucleotide. For imaging, 
coverslips were stained with DAPI (1µg/mL) and analyzed by fluorescence 
microscopy (objective 100X, Zeiss Axiovert 200M inverted fluorescence 
microscope equipped with a CCD camera (CoolSNAP HQ, Photometrics)). Multi-
dimensional acquisitions were performed using Metamorph 7.1.7 software. For 
quantification of RCP number, 5 different areas of at least 6 single cells were 
analyzed.  
 
Breast tumor samples and gene arrays 
Affymetrix microarray data for a series of 150 infiltrating breast carcinomas from 
the Institut Curie (Paris, France) and clinical data for the patients were described 
elsewhere (Rodrigues-Ferreira et al., 2009, Molina et al., 2013).  
 ʹͲ
Heat map and hierarchical clustering were performed on MTUS1 (212093_s_at; 
212096_s_at; 239576_at) and MAPRE1 (200712_s_at; 200713_s_at) probesets, 
using JMP7 software. Four main clusters were isolated and the relative expression 
of MTUS1 and MAPRE1 genes in each cluster was evaluated using JMP7 and 
GraphPad Prism6 softwares. One tumor sample did not fit into any of the 4 
clusters identified and was therefore eliminated from our study, that was further 
conducted on 149 tumors.  
 
Statistical analysis 
Statistical analyses were done using GraphPad Prism softwares. Overall survival 
(OS) curves were plotted according to the method of Kaplan–Meier and compared 
by the log-rank test. Data in bar graphs (mean +/- SD) and dot plots were analyzed 
using two-tail unpaired t-test. p<0.05 was considered statistically significant.  
 
 ʹͳ
Acknowledgements 
We wish to thank Dr. Anna Akhmanova (Utrecht University, The Netherlands) for 
kindly providing plasmids encoding GST-EB1, GST-EB1-C and GST-EB1-N fusion 
proteins and for helpful advice and critical reading of the manuscript. We thank Dr. 
Matthieu Piel (I. Curie, Paris, France) for the kind gift of RPE-1 cells stably 
expressing EB1-GFP. We are grateful to Anne Nehlig for excellent technical 
assistance and to Dr. Celine Lefebvre (Inserm U981, Institut Gustave Roussy, 
Villejuif, France) for help with bio-informatics analysis. We thank the Institut Cochin 
imaging facility. This work was supported by the Inserm, the CNRS, the University 
Paris Descartes, Roche SAS, the association Odyssea, Le cancer du sein, 
Parlons-en! and Prolific. 
 
 
Authors contribution 
Designed the experiments: LV, AM, SRF, CN 
Performed the experiments: LV, AM, SRF, BPB, MM 
Discussed and interpretated the data : LV, AM, SRF, BPB, DB, AS, SH, CN 
Wrote the paper : LV, AM, SRF, CN 
Contributed to essential data : FA, DB, SH, VB, AVS 
 
 
Conflict of interest 
The authors declare that they have no conflict of interest 
 
 
Expanded View information is available at The EMBO Journal Online. 
 ʹʹ
References 
 
Akhmanova A, Steinmetz MO (2008) Tracking the ends: a dynamic protein 
network controls the fate of microtubule tips. Nat Rev Mol Cell Biol 9: 309–322 
Askham JM, Vaughan KT, Goodson HV, Morrison EE (2002) Evidence that an 
interaction between EB1 and p150(Glued) is required for the formation and 
maintenance of a radial microtubule array anchored at the centrosome. Mol Biol 
Cell 13:3627-3645 
Buey RM, Sen I, Kortt O, Mohan R, Gfeller D, Veprintsev D, Kretzschmar I, 
Scheuermann J, Neri D, Zoete V, Michielin O, de Pereda JM, Akhmanova A, 
Volkmer R, Steinmetz MO (2012) Sequence determinants of a microtubule tip 
localization signal (MtLS). J Biol Chem 287:28227-28242 
Desai A, Mitchison TJ (1997) Microtubule polymerization dynamics. Annu Rev Cell 
Dev Biol 13:83-117 
Di Benedetto M, Bièche I, Deshayes F, Vacher S, Nouet S, Collura V, Seitz I, 
Louis S, Pineau P, Amsellem-Ouazana D, Couraud PO, Strosberg AD, Stoppa-
Lyonnet D, Lidereau R, Nahmias C (2006) Structural organization and 
expression of human MTUS1, a candidate 8p22 tumor suppressor gene 
encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. 
Gene 380:127-136  
Dragestein KA, van Cappellen WA, van Haren J, Tsibidis GD, Akhmanova A, 
Knoch TA, Grosveld F, Galjart N (2008) Dynamic behavior of GFP-CLIP-170 
reveals fast protein turnover on microtubule plus ends. J Cell Biol 180: 729–737 
Du Puy L, Beqqali A, Monshouwer-Kloots J, Haagsman HP, Roelen BA, Passier R 
(2009) CAZIP, a novel protein expressed in the developing heart and nervous 
system. Dev Dyn 238:2903-2911 
Dong X, Liu F, Sun L, Liu M, Li D, Su D, Zhu Z, Dong JT, Fu L, Zhou J (2010) 
Oncogenic function of microtubule end-binding protein 1 in breast cancer. J 
Pathol 220:361-369  
 ʹ͵
Galjart N (2010) Plus-end-tracking proteins and their interactions at microtubule 
ends. Curr Biol 20:R528-537  
Grigoriev I, Gouveia SM, van der Vaart B, Demmers J, Smyth JT, Honnappa S, 
Splinter D, Steinmetz MO, Putney JW Jr, Hoogenraad CC, Akhmanova A 
(2008) STIM1 is a MT-plus-end-tracking protein involved in remodeling of the 
ER. Curr Biol 18:177-182  
Honnappa S, Gouveia SM, Weisbrich A, Damberger FF, Bhavesh NS, Jawhari H, 
Grigoriev I, van Rijssel FJ, Buey RM, Lawera A, Jelesarov I, Winkler FK, 
Wüthrich K, Akhmanova A, Steinmetz MO (2009) An EB1-binding motif acts as 
a microtubule tip localization signal. Cell 138:366-376 
Howard J, Hyman AA (2003) Dynamics and mechanics of the microtubule plus 
end. Nature 422:753-758  
Jarvius M, Paulsson J, Weibrecht I, Leuchowius KJ, Andersson AC, Wählby C, 
Gullberg M, Botling J, Sjöblom T, Markova B, Ostman A, Landegren U, 
Söderberg O (2007) In situ detection of phosphorylated platelet-derived growth 
factor receptor beta using a generalized proximity ligation method. Mol Cell 
Proteomics 6:1500-1509  
Jiang K, Wang J, Liu J, Ward T, Wordeman L, Davidson A, Wang F, Yao X (2009) 
TIP150 interacts with and targets MCAK at the microtubule plus ends. EMBO 
Rep 10:857-865  
Jiang K, Toedt G, Montenegro Gouveia S, Davey NE, Hua S, van der Vaart B, 
Grigoriev I, Larsen J, Pedersen LB, Bezstarosti K, Lince-Faria M, Demmers J, 
Steinmetz MO, Gibson TJ, Akhmanova A (2012) A Proteome-wide screen for 
mammalian SxIP motif-containing microtubule plus-end tracking proteins. Curr 
Biol 22:1800-1807  
Kervrann C, Boulanger J (2006) Optimal spatial adaptation for patch-based image 
denoising. IEEE Trans. Image Processing 15:2866-2878 
 
 ʹͶ
Komarova Y, Lansbergen G, Galjart N, Grosveld F, Borisy GG, Akhmanova A 
(2005) EB1 and EB3 control CLIP dissociation from the ends of growing 
microtubules. Mol Biol Cell 16: 5334–5345 
Komarova Y, De Groot CO, Grigoriev I, Gouveia SM, Munteanu EL, Schober JM, 
Honnappa S, Buey RM, Hoogenraad CC, Dogterom M, Borisy GG, Steinmetz 
MO, Akhmanova A (2009) Mammalian end binding proteins control persistent 
microtubule growth. J Cell Biol 184: 691–706 
Kumar P, Wittmann T (2012) +TIPs: SxIPping along microtubule ends. Trends Cell 
Biol 22:418-428  
Maurer SP, Bieling P, Cope J, Hoenger A, Surrey T (2011) GTPgammaS 
microtubules mimic the growing microtubule end structure recognized by end-
binding proteins (EBs). Proc Natl Acad Sci U S A 108:3988-3993  
Maurer SP, Fourniol FJ, Bohner G, Moores CA, Surrey T (2012) EBs recognize a 
nucleotide-dependent structural cap at growing microtubule ends. Cell 149:371-
382  
Mimori-Kiyosue Y, Grigoriev I, Lansbergen G, Sasaki H, Matsui C, Severin F, 
Galjart N, Grosveld F, Vorobjev I, Tsukita S, Akhmanova A (2005) CLASP1 and 
CLASP2 bind to EB1 and regulate microtubule plus-end dynamics at the cell 
cortex. J Cell Biol 168:141-153 
Mitchison T, Kirschner M (1984) Dynamic instability of microtubule growth. Nature 
312:237-242 
Molina A, Rodrigues-Ferreira S, Di Tommaso A, Nahmias C (2011) ATIP, a novel 
superfamily of microtubule-associated proteins. Med Sci (Paris) 27:244-246  
Molina A, Velot L, Ghouinem L, Abdelkarim M, Bouchet BP, Luissint AC, Bouhlel I, 
Morel M, Sapharikas E, Di Tommaso A, Honoré S, Braguer D, Gruel N, Vincent-
Salomon A, Delattre O, Sigal-Zafrani B, André F, Terris B, Akhmanova A, Di 
Benedetto M, Nahmias C, Rodrigues-Ferreira S (2013) ATIP3, a novel 
prognostic marker of breast cancer patient survival, limits cancer cell migration 
 ʹͷ
and slows metastatic progression by regulating microtubule dynamics. Cancer 
Res 73:2905-2915 
Nizak C, Martin-Lluesma S, Moutel S, Roux A, Kreis TE, Goud B, Perez F (2003) 
Recombinant antibodies against subcellular fractions used to track endogenous 
Golgi protein dynamics in vivo. Traffic 4:739-753 
Ohi R, Coughlin ML, Lane WS, Mitchison TJ (2003) An inner centromere protein 
that stimulates the microtubule depolymerizing activity of a KinI kinesin. Dev 
Cell 5:309-321 
Orimo T, Ojima H, Hiraoka N, Saito S, Kosuge T, Kakisaka T, Yokoo H, Nakanishi 
K, Kamiyama T, Todo S, Hirohashi S, Kondo T (2008) Proteomic profiling 
reveals the prognostic value of adenomatous polyposis coli-end-binding protein 
1 in hepatocellular carcinoma. Hepatology 48:1851-1863 
Rodrigues-Ferreira S, Di Tommaso A, Dimitrov A, Cazaubon S, Gruel N, Colasson 
H, Nicolas A, Chaverot N, Molinié V, Reyal F, Sigal-Zafrani B, Terris B, Delattre 
O, Radvanyi F, Perez F, Vincent-Salomon A, Nahmias C (2009) 8p22 MTUS1 
gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive 
breast carcinoma of poor prognosis. PLoS One 4(10):e7239 
Rodrigues-Ferreira S, Nahmias C (2010) An ATIPical family of Angiotensin II AT2 
receptor interacting proteins. Trends Endocrinol Metab 21:684-690  
Slep KC (2010) Structural and mechanistic insights into microtubule end-binding 
proteins. Curr Opin Cell Biol 22: 88–95 
Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius KJ, Jarvius J, 
Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U (2006) Direct 
observation of individual endogenous protein complexes in situ by proximity 
ligation. Nat Methods 3:995-1000  
Stepanova T, Slemmer J, Hoogenraad CC, Lansbergen G, Dortland B, De Zeeuw 
CI, Grosveld F, van Cappellen G, Akhmanova A, Galjart N (2003) Visualization 
 ʹ͸
of microtubule growth in cultured neurons via the use of EB3-GFP (end-binding 
protein 3-green fluorescent protein). J Neurosci 23:2655-2664 
Sugihara Y, Taniguchi H, Kushima R, Tsuda H, Kubota D, Ichikawa H, Sakamoto 
K, Nakamura Y, Tomonaga T, Fujita S, Kondo T (2012) Proteomic-based 
identification of the APC-binding protein EB1 as a candidate of novel tissue 
biomarker and therapeutic target for colorectal cancer. J Proteomics 75:5342-
5355.  
Tortosa E, Galjart N, Avila J, Sayas CL (2013) MAP1B regulates microtubule 
dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells. 
EMBO J. 32:1293-1306  
Van der Vaart B, Franker MA, Kuijpers M, Hua S, Bouchet BP, Jiang K, Grigoriev 
I, Hoogenraad CC, Akhmanova A (2011) Microtubule plus-end tracking proteins 
SLAIN1/2 and ch-TOG promote axonal development. J Neurosci 32:14722-
14728  
 
 
 
  
 ʹ͹
Figure legends 
 
Figure 1. ATIP3 interacts with EB1 
(A). Schematic representation of ATIP3 protein and domains (D1, D2, D3) 
showing microtubule (MT)-binding domain (in grey) and coiled-coil (CC) motifs (in 
blue). Positions of KNIP, RPLP and SAIP motifs (residues 462, 780 and 1249, 
respectively) are shown in red. Amino acid numbering is from Accession number 
NP_001001924. Lower panel: ATIP3 amino acid sequence surrounding each 
motif. Basic residues are indicated in red. Acidic residues (blue) are bold and 
underlined. SxIP and SxIP-like motifs are boxed.  
 
(B). GST pull-down analysis showing specific interaction between GFP-ATIP3 
expressed in MCF-7 cell lysates and purified GST–EB1 agarose beads. Blots were 
probed with anti-GFP antibodies. Polypeptides corresponding to GFP-ATIP3 and 
GFP are indicated on the right. A star indicates cleavage product of GFP-ATIP3.  
 
(C). Purified GST-EB1 beads were used to precipitate GFP-ATIP3 (210 KDa) and 
endogenous ATIP3 (180 KDa) expressed in HeLa cells. Blots were probed with 
anti-ATIP (MTUS1) antibodies.  
 
(D). Co-immunoprecipitation of Cherry-ATIP3 (Ch-ATIP3) and/or EB1-GFP 
transfected in MCF-7 cells, using anti-GFP or anti-Cherry (Ch) antibodies as 
indicated below. Western blots were probed with anti-GFP and anti-ATIP 
antibodies to reveal EB1-GFP (55 KDa) and Ch-ATIP3 (210 KDa), as indicated on 
the right. IgH: Immunoglobulin heavy chain.  
 
(E). Schematic drawing of EB1 deletion mutants. Amino acid positions at domain 
boundaries are indicated.  
 
(F). Pull-down analysis of MCF-7 cell lysates expressing GFP-ATIP3 using 
indicated purified GST-fusion proteins. Blots were probed using anti-GFP 
antibodies.  
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(G). MCF-7 cell lysates expressing GFP-ATIP3 were treated or not (Ctrl) with 10 
µm nocodazole (Nz) for 1 hr at 4°C, then incubated with GST-EB1 beads as in B.  
 
(H). GST-EB1 pull-down assays on MCF-7 cell lysates expressing GFP-D1, GFP-
D2 or GFP-D3, performed as in B.  
 
(I). GST pull-down assays on MCF-7 cell lysates expressing GFP-D2, performed 
as in F and G. 
 
 
Figure 2. Minimal interacting domain of ATIP3 
(A). Schematic drawing of deletion mutants and their ability to bind EB1 (+) or not 
(-).  
(B). Pull-down analysis of GFP-D2 domain and GFP-fused deletion mutants (D2N, 
D2C, CN, CC) using GST or GST-EB1 agarose beads, as indicated in Fig.1B. 
Blots were probed with anti-GFP antibodies. Molecular weights are indicated in 
KDa on the left.  
(C) Pull-down analysis of GFP-fused deletion mutants (D2C, CN67, CN45) as 
indicated in B.  
(D) Pull-down analysis of deletion mutants lacking the CN domain (D2delCN) or 
RPLP motif (CN67delP), as indicated in B.  
(E). In vitro pull-down assay using purified GST (white bars) or GST-EB1 (black 
bars) and 10 or 15µg of synthetic fluorescent peptides (CN45 and CC coupled to 
FITC) as indicated below. Upper panel: fluorescence intensity (arbitrary units) in 
the precipitates was measured using Fusion fluorimeter. Lower panel: samples 
before (input) and after GST pull-down were resolved on 15% SDS-PAGE and 
fluorescent peptides were detected using Typhoon scanner. 
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Figure 3. Cellular localization of D2 deletion mutants. 
Immunofluorescence imaging of RPE-1 cells expressing GFP-D2 domain and 
GFP-tagged deletion mutants as indicated. Cells were fixed and stained with anti-
GFP (green), anti-alpha-tubulin (red) antibodies and DAPI (blue). Enlarged 
portions of the selected areas are shown in the insets. Red arrowheads show MT-
localization of GFP-fusion proteins. Scale bar, 10µm. 
 
 
Figure 4. ATIP3 is not a +TIP 
(A). RPE-1 cells transfected with low amounts of GFP-ATIP3 were fixed and 
stained with anti-GFP (green) and anti-EB1 (red) antibodies. Insets show that EB1 
comet-like structures at plus ends are not stained by GFP-ATIP3. Magnification 
100X. Scale bar, 10µm.  
 
(B). Time-lapse images of HC7 (MCF-7 cell clone stably expressing GFP-ATIP3 at 
endogenous levels, described in Rodrigues-Ferreira et al., 2009). GFP-ATIP3 
stains the MT lattice and the ends of shrinking MTs (arrowheads) in living cells, 
indicating backtracking properties. Scale bar, 10µm. 
 
Figure 5. In situ interaction between ATIP3 and EB1  
(A). Proximity Ligation Assays were performed in RPE-1 cells transfected with 
GFP-tagged constructs and deletion mutants as indicated on the left. Molecular 
complexes were analyzed using rabbit anti-GFP and mouse anti-EB1 primary 
antibodies and corresponding secondary DUO-LINK antibodies. In situ molecular 
interaction is revealed by red bright signals of rolling circle amplification products 
(RCP) stained with cy5-labeled oligonucleotide probe. Shown are merge pictures 
of GFP (green), RCP (red) and nuclei (DAPI, blue) staining. Scale bar 10µm.  
 
(B). Quantification of the number of RCP signals per square (100 µm2 area). 
Number of squares analyzed is under brackets. *** p<0.0001.  
 
(C). Enlarged portions of selected areas in (A) are shown in the insets. 
Arrowheads illustrate alignment of RCP signals along the MT lattice. 
 ͵Ͳ
 
(D). Proximity Ligation Assays revealing in situ molecular interaction between 
endogenous ATIP3 and EB1 in HeLa cells transfected with control siRNA (SiCtrl), 
ATIP3-specific siRNA (siATIP3) or EB1-specific siRNA (siEB1) as indicated. 
Endogenous complexes were analyzed using rabbit anti-MTUS1 and mouse anti-
EB1 primary antibodies and corresponding secondary DUO-LINK antibodies. Cells 
were stained with anti-tubulin F2C antibodies and secondary antibodies 
conjugated to Cy3. Shown are merge pictures of tubulin (green), RCP (red) and 
nuclei (DAPI, blue) staining. Scale bar 10µm. Inset shows enlarged portion of a 
selected area from siCtrl-transfected cell. The arrowhead illustrates alignment of 
RCP signals along the MT lattice.  
(E). Silencing efficiency was assessed by immunoblotting with anti-MTUS1 
(ATIP3) and anti-EB1 antibodies. Blots were reprobed using anti-tubulin antibodies 
for internal control.  
(F). Quantification of the number of RCP signals per square in PLA conditions 
shown in (D) (100 µm2 area). Number of squares analyzed is under brackets. *** 
p<0.0001. 
 
 
Figure 6. Effect of D2 deletion mutants on EB1 comet formation 
Anti-EB1 (green) and anti-tubulin (red) immunostaining of RPE-1 cells transiently 
transfected with GFP-D2 and GFP-tagged domains (A) and GFP-D2 deletion 
mutants (B). Insets show EB1 comet-like structures in enlarged portions of 
selected areas. Red arrowheads illustrate EB1 staining along the MT lattice. Right 
panels show distribution of EB1 (green) and alpha-tubulin (red) at the microtubule 
plus ends (linescans), quantification of comet length (scattered dot plot) and 
number of comets (per 62µm2 area). Number of comets analyzed is under 
brackets. Scale bar, 10µm. *** p<0.0001. 
 
 
Figure 7. Prognostic value of combined ATIP3 and EB1 expression levels in 
breast tumors.  
(A). Heat map and hierarchical clustering of 150 breast tumor samples based on 
the intensities of MTUS1 (212096_s_at; 212093_s_at; 239576_at) and MAPRE1 
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(200712_s_at ; 200713_s_at) probesets. Heat map illustrates relative expression 
profiles of MTUS1 and MAPRE1 (column) for each tumor sample (line) in 
continuous color scale from low (green) to high (red) expression. Dendogram of 
the four selected tumor groups is shown on the right. 
(B). Box plot comparison of MTUS1 (ATIP3) intensities (Raw Mas 5) in each of the 
four selected tumor clusters based from dendogram shown in (A). *p<0.05; 
***p<0.0001. 
(C). Box plot comparison of MAPRE1 (EB1) intensities (GCMRA) in each of the 
four selected tumor clusters based from dendogram shown in (A). ***p<0.0001. 
 
(D). Overall survival curves for patients with breast tumors classified into four 
groups based from dendogram shown in (A). p=0.0011 between clusters 3 and 4.  
 
(E). Overall survival (in months) for patients classified according to tumor groups 
shown in (D). Scattered dot plot and median values are shown for each tumor 
cluster. Number of patients is in brackets. *p<0.05; **p<0.001. 
 
(F). Percentage of patients remaining alive after 5 years with tumors classified into 
four groups as in (D). Number of patients is in brackets. 
 
 
Figure 8. Proposed mechanism for regulation of EB1 localization by 
interaction with ATIP3.  
In control cells, ATIP3-EB1 complexes are present in the cytosol and at the vicinity 
of the microtubule lattice and limit the binding of EB1 to MT plus ends. In ATIP3-
deficient cancer cells, free diffusion of cytosolic EB1 results in enhanced 
accumulation of EB1 at the plus ends of MTs and subsequent increase in MT 
dynamics at the growing ends. 
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Table I. Characterization of ATIP3 domains and deletion mutants 
Domain Positions (AA) 
Length  
(AA) 
EB1 
binding
MT 
localization 
Loss of 
EB1 comets
ATIP3 1-1270 1270 + + + 
D2 410-874 465 + + + 
D2N 410-634 225 - + nd 
D2C 705-874 170 + + + 
CN 705-816 112 + +/- + 
CC 817-874 58 - - - 
CN67 743-809 67 + - + 
CN45 755-799 45 + - + 
CN67delP [743-777]+[783-809] 61 - - - 
ATIP3delCN [1-704]+[817-1270] 1158 - + nd 
ATIP3delCC1 [1-816]+[869-1270] 1218 + nd nd 
ATIP3delCC2 [1-867]+[875-1270] 1263 + nd nd 
ATIP3delCTer 1-1240 1240 + nd nd 
D2delCN [410-704]+[817-874] 353 - + - 
D2delCC1 [410-816]+[867-874] 413 + nd nd 
 
AA: amino acids. Positions are according to accession number NP_001001924; nd: 
not determined. 
 ͵͵
 
Table II. ATIP3-EB1 expression levels in breast tumor clusters and overall survival of 
the patients. 

For each tumor cluster, shown is : number (nb) of tumors, median values for 
Affymetrix MTUS1 probeset 212093_s_at (raw mas5) and MAPRE1 probeset 
200713_s_at (GCMRA), corresponding expression levels for ATIP3 and EB1, 
median survival in months and percent of patients surviving after 5 years. 
Range values are in parenthesis. L: low; H: high; VH: very high. 
 
 
 
cluster 
nb of 
tumors 
median value 
MTUS1 
(212093_s_at)
median value 
MAPRE1 
(200713_s_at)
Expression 
ATIP3-EB1
median survival 
(months) 
5-y survival 
% patients 
(n) 
1 46 
473,2 
 (166,7 - 740,9)
811,8 
 (515,6 - 1201) L-L 
105,8 
 (4,43 - 180,6) 
60,8%  
(28/46) 
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809 
 (413 - 1541) H-L 
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71,4%  
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3 33 
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1399 
 (1010- 2539) L-H 
53,7 
 (19,53 - 145,3)
36,3%  
(12/33) 
4 21 
 1057 
 (603,1 - 1518) 
910,2 
 (526,4 - 1596) VH-L 
 126,5 
 (49,27 - 186,1)
76,2%  
(16/21) 
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Manuscript Title : ATIP3 interacts with End Binding protein EB1 to limit its 
accumulation at the microtubule plus ends 
 
 
 
Expanded View Material and Methods 
 
Human breast cancer cell lines  
Triple-negative breast cancer cell lines expressing (MDA-MB-468) or not (MDA-MB-
231-D3H2LN) endogenous ATIP3 were described previously (Rodrigues-Ferreira et 
al., 2009; Molina et al., 2013). HCC1143 and CAL-120 breast cancer cell lines were a 
kind gift of Dr. S. Alsafadi (Institut Gustave Roussy, Villejuif, France). All cell lines 
were tested for absence of mycoplasma contamination using MycoAlert Assay 
detection kit (Lonza, France), used at passages 2 to 20 after thawing and grown as 
described by the provider.  
 
Proximity Ligation Assay 
In situ PLA detection was carried out using DUOLINK II In Situ Far Red kit (Sigma-
Aldrich, St Louis, USA). RPE-1 cells stably expressing EB1-GFP were transfected for 
24 hrs with Cherry-ATIP3 construct as described in the Materials and Methods. Cells 
were fixed with ice-cold methanol and incubated for 1h at room temperature with 
rabbit anti-Cherry (1:500) and mouse anti-GFP (Roche, 1:200) antibodies diluted in 
PBS-0.2% BSA as a blocking solution. Incubation with PLA probes and RCP analysis 
was performed as described in the Materials and Methods. 
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Legends to Expanded View Figures  
 
Expanded View Figure E1. ATIP3 interacts with EB1 
(A). Co-immunoprecipitation of Cherry-ATIP3 or Cherry and/or indicated constructs 
(EB1-GFP, GFP-EB3, EB3-GFP or GFP) transfected in MCF-7 cells, using anti-GFP 
antibodies. Western blots were probed with anti-GFP and anti-MTUS1 antibodies as 
indicated on the right, to reveal EB1/3-GFP (55 KDa) and Ch-ATIP3 (210 KDa), 
respectively.  
(B). GST pull-down analysis showing interaction between GFP-ATIP3 and GFP-D2 
mutants as indicated and purified GST-EB1 agarose beads. Blots were probed with 
anti-GFP antibodies.  
(C). GST-EB1 pull-down assays as in B, performed on MCF-7 cell lysates expressing 
indicated GFP-ATIP3 or GFP-D2 deletion mutants described in Fig.2A and Table I. 
(D). Amino acid sequence alignment of EB1-binding domains of ATIP3 (CN45) and 
TIP150. Basic residues are highlighted in red and underlined. The SxIP motif (RPLP) 
is boxed. Stars indicate identical residues. Gaps have been introduced to maximize 
homology.  
(E). Amino acid sequence alignment of ATIP3 polypeptides from different species. 
The RPLP motif is boxed and stars indicate conserved residues. Hs, Homo sapiens, 
Bt, Bos taurus, Rn, Rattus norvegicus, Mm, Mus musculus.  
 
 
Expanded View Figure E2. ATIP3 is not a +TIP 
Images from fluorescent microscopy of MRC5 living cells co-transfected with Cherry-
ATIP3 (Ch-ATIP3) and EB3-GFP. Note that EB3 is enriched at the plus ends and 
weakly stains the MT lattice. Inset shows that ATIP3 is along the MT lattice and does 
not accumulate with EB3 at the plus ends. Scale bar 10 µm. 
 
 
Expanded View Figure E3. In situ interaction between ATIP3 and EB1 
(A). Proximity Ligation Assays were performed in RPE-1 cells transfected with GFP-
ATIP3 or GFP-D2 as indicated on the left. Molecular complexes were analyzed using 
rabbit anti-GFP and/or mouse anti-EB1 primary antibodies (as indicated above) and 
corresponding secondary DUO-LINK antibodies. In situ molecular interaction is 
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revealed by red bright signals of rolling circle amplification products (RCP) stained 
with cy5-labeled oligonucleotide probe. Shown are merge pictures of GFP (green), 
RCP (red) and nuclei (DAPI) staining.  
(B). PLA assay in RPE-1 cells transfected with GFP-ATIP3 in the presence or not of 
EB1-specific siRNA as indicated above. Shown are merge pictures as in A.  
(C). PLA assay in RPE-1 cells transfected with GFP and analyzed as in B.  
(D). PLA assay in RPE-1 cells stably expressing EB1-GFP and transfected with 
Cherry-ATIP3. Molecular complexes were analyzed using rabbit anti-Cherry (Ch) 
and/or mouse anti-GFP primary antibodies and corresponding secondary DUO-LINK 
antibodies as indicated on the left. In situ molecular interaction is revealed by red 
bright signals of rolling circle amplification products (RCP) stained with cy5-labeled 
oligonucleotide probe. Shown are merge pictures of Cherry (yellow), RCP (red) and 
nuclei (DAPI) staining.  
(E). PLA assay in RPE-1 cells transfected with GFP-D2C, D2N, CN and CC 
constructs.  
(A-E) Magnification x100. Scale bar 10µm. 
 
 
Expanded View Figure E4. Endogenous interaction between ATIP3 and EB1 
(A). Western blot analysis of endogenous ATIP3 expression in non-tumoral human 
mammary epithelial cells (HMEC), HeLa cells and non-transformed MCF10A cells, 
using anti-MTUS1 antibodies, and reprobed with anti-tubulin antibodies for internal 
control.  
(B). Proximity Ligation Assays performed in non transfected HeLa cells using rabbit 
anti-MTUS1 and mouse anti-EB1 primary antibodies, or anti-MTUS1 antibodies alone 
as negative control. Endogenous molecular interaction is revealed by red bright 
signals of rolling circle amplification products (RCP) stained with cy5-labeled 
oligonucleotide probe. Shown are merge pictures of RCP (red) and nuclei (DAPI, 
blue) staining. Scale bar 10µm. 
(C). Western blot analysis of endogenous ATIP3 expression levels in human breast 
cancer cell lines using anti-MTUS1 antibodies (upper panel) and reprobed with anti-
tubulin antibodies (lower panel).  
(D). PLA assays performed using rabbit anti-MTUS1 and mouse anti-EB1 primary 
antibodies as in (B), showing endogenous ATIP3/EB1 interaction in ATIP3-positive 
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MDA-MB-468 and HCC1143 breast cancer cell lines but not in ATIP3-negative MDA-
MB-231 and CAL-120 cell lines. MDA-MB-231 cells were previously demonstrated to 
be ATIP3-negative (Rodrigues-Ferreira et al., 2009). Shown are merge pictures of 
RCP (red) and nuclei (DAPI, blue) staining. Scale bar 10µm. 
 
 
Expanded View Figure E5. Rescue of ATIP3-silenced phenotype 
(A). Western blot analysis comparing expression of GFP-ATIP3 with that of 
endogenous ATIP3. HeLa cells were either left non-transfected (NT), or transfected 
for 72hrs with ATIP3-specific siRNA and for 24 hrs with plasmids encoding GFP (0.5 
µg) or GFP-ATIP3 (2 µg) as indicated. Blots were probed with anti-MTUS1 antibodies 
to reveal endogenous ATIP3 (180 KDa) and transfected GFP-ATIP3 (210 KDa), and 
then reprobed with anti-tubulin antibodies for internal control. 
(B). ATIP3-silenced HeLa cells were transfected with GFP-ATIP3 plasmid (2 µg) as 
in (A), then labeled with anti-GFP (green) and anti-EB1 (red) antibodies. Insets show 
EB1 comet-like structures in enlarged portions of selected areas (insets 1 and 2 show 
non-transfected and transfected cells, respectively). Right panel : Quantification of 
comet length (scattered dot plot) and number of comets (per 62µm2 area). Fifty 
comets were analyzed for each condition. Scale bar, 10µm. *** p<0.0001. 
(C). ATIP3-silenced HeLa cells were transfected with plasmids encoding GFP-ATIP3 
(2 µg), GFP-D2 (2 µg), GFP-D2delCN (1µg) or GFP-CN (0.5 µg) as indicated. 
Fluorescence intensity of GFP immunostaining indicates similar levels of expression 
for all fusion proteins. Scale bar : 10 µm.  
(D). ATIP3-silenced HeLa cells were transfected for 24 hrs with indicated plasmids in 
conditions of moderate expression as shown in (C), then labelled with anti-GFP 
(green) anti-EB1 (red) antibodies. Insets show EB1 comet-like structures in enlarged 
portions of selected areas as in (B). Scale bar, 10µm. 
(E). Quantification of comet length (scattered dot plot) and number of comets (per 
62µm2 area) in HeLa cells transfected with control siRNA (left) or ATIP3-specific 
siRNA (right panel) then transfected with GFP fusion proteins at levels close to 
endogenous as in (C). Number of comets analyzed is under brackets. *** p<0.0001. 
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Legends to Expanded View Movies 
 
Movies 1 and 2. Time-lapse microscopy of MRC5-SV cells co-transfected with 
Cherry-ATIP3 and EB3-GFP 
EB3-GFP (left) and Cherry-ATIP3 (right) MRC5-SV-coexpressing cells were imaged 
by spinning disk confocal microscopy (60X lens).Time-lapse series of 100 images 
were acquired in a stream mode and shown at 15 frames per second. 
 
Movies 3 and 4. Time-lapse microscopy of MRC5-SV cells co-transfected with 
Cherry-ATIP3 (red) and EB3-GFP (green). Inset. 
Cherry-ATIP3 (red) and EB3-GFP (green) MRC5-SV-coexpressing cells were imaged 
by spinning disk confocal microscopy as for movies 1 and 2. A zone of 1900 µm2 at 
the cell periphery is shown. 
 
Movies 5 and 6. Time-lapse microscopy of MCF-7 cells stably expressing 
moderate levels of GFP-ATIP3. 
Stably transfected GFP-ATIP3 cells were analyzed by time-lapse TIRF microscopy 
(100X lens). Time-lapse series of 500 images were acquired in a stream mode and 
shown at 30 frames per second. 
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Expanded View Table E2. Oligonucleotides used for PCR-amplification of 
ATIP3 domains (A) and site-directed mutagenesis (B). 
 
 
Expanded View Table E2.A 
Name Primers (5’   3’) Number Size 
(bp) 
D2 F : CCGCTCGAGGA CTGACTTGGGATGCAAATGAT 
R : CGGGGTACCTCATGCATTAAGAGCTGTAAATAA 
C 206 
C 208 
1395 
D2N F : CCG CTCGAGGACTGACTTGGGATGCAAATGAT 
R : CGGGGTACCTCAAAACAACGCAGAAACGGACCCGGT 
C 206 
C 304 
675 
D2C F : CCGCTCGAGCAACCACCTCAGGTAGGAATATATCC 
R : CGGGGTACCTCATGCATTAAGAGCTGTAAATAA 
C 306 
C 208 
510 
CN F : CCGCTCGAGCAACCACCTCAGGTAGGAATATATCC 
R : CGGCGGGGTACCTCAATTGTTGCTGTAAGTGCTCAGCTC 
C 746 
C 791 
336 
CC F : GGCCCGCTCGAGGATCTGGTAATGCCGCTGTCATC 
R : CGGGGTACCTCATGCATTAAGAGCTGTAAATAA 
C 793 
C 208 
174 
CN67 F : GCCCCGCTCGAGGAAGAAATCCCAGTGCTGATCGAGCC 
R : CGGCGGGGTACCTCACTCACTGTGGGTGCTGGCTATTGA    
C 987 
C 988 
201 
CN45 F : GGCCCGCTCGAGGAAGGATCAGGCGTGTGTCCAG 
R : CGGCGGGGTACCTCAGCTTCCTGTCCTCCGCAGCGC 
C 1022 
C 1023 
135 
F : Forward ; R : Reverse 
 
Expanded View Table E2.B 
Name Primers (5’   3’) Number Size 
(bp) 
CN67 
delP 
F : GCACAGTCGTCATGGGTGAATAAATCCAAAGCATCTTTG   
R : CAAAGATGCTTTGGATTTATTCACCCATGACGACTGTGC 
C 1030 
C 1031 
183 
ATIP3 
delCN 
F : GGGCTCTGCTTCAAAAACAACGTCTGGTAATGCCGCTGTC 
R : GACAGCGGCATTACCAGACGTTGTTTTTGAAGCAGAGCCC 
C 928 
C 929 
3474 
ATIP3 
delCC1 
F : AGCTGAGCACTTACAGCAACAATGGTCCTTCGAGA 
R : TCTCGAAGGACCATTGTTGCTGTAAGTGCTCAGCT 
C 724 
C 725 
3654 
ATIP3 
delCC2 
F : GATGAAAACTCCTCCAAAAGTTGAAAAGAGCAGGCAAAAG 
R : CTTTTGCCTGCTCTTTTCAACTTTTGGAGGAGTTTTCATC 
C 91 
C 92 
3789 
ATIP3 
delCTer 
F : CCGCTCGAGCCATGACTGATGATAATTCAGATG 
R : CGGGGTACCTCAACACAGGTCCCCATTGTGCAG 
C 70 
C 209 
3721 
D2 
delCN 
F : GGGCTCTGCTTCAAAAACAACGTCTGGTAATGCCGCTGTC 
R : GACAGCGGCATTACCAGACGTTGTTTTTGAAGCAGAGCCC 
C 928 
C 929 
1059 
D2 
delCC1 
F : AGCTGAGCACTTACAGCAACAATGGTCCTTCGAGA 
R : TCTCGAAGGACCATTGTTGCTGTAAGTGCTCAGCT 
C 724 
C 725 
1239 
F : Forward ; R : Reverse 
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Unpublished Results 
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1. New ATIP3 interacting partners 
  
1.1. ATIP3 interacts with MCAK and regulates its localization at the MT 
plus-ends 
As mentioned in the introduction, microtubules are highly dynamic structures whose 
regulation depends (at least in large part) on the plus-end tracking proteins (+TIPs). A 
potent MT destabilizer is the EB1-interacting protein MCAK. MCAK (Mitotic Centromere-
Associated Kinesin) is a MT plus-end tracking kinesin able to change MT plus-end structure 
to induce its depolymerization.  
Our previous results have shown that ATIP3 regulates MT dynamic instability possibly by 
its interaction with EB1. However, whether ATIP3 participates in a complex with other MT 
regulators is an unknown question. Of note, the ATIP3 paralog TIP150, which also interacts 
with EB1, is able to associate with MCAK to form a complex (together with EB1) that will 
accumulate at the MT plus-ends (Jiang K et al. 2009). Additionally, the ATIP3 Xenopus 
ortholog ICIS also associates with MCAK to stimulate its MT-destabilizing activity (Ohi R et 
al. 2003). Given this information we hypothesized that ATIP3 could interact with MCAK to 
regulate MT dynamics. 
In order to define whether ATIP3 interacts with MCAK, co-immunoprecipitation assays 
were performed in ATIP3-deficient MCF7 cells co-transfected with Myc-MCAK 
(Unpublished Figure 1A) and full-length ATIP3. As shown in Unpublished Figure 1B, GFP-
ATIP3 and positive control EB1-GFP, and not GFP, are able to co-precipitate with Myc-
MCAK (lines 1, 2 and 3). To get further insight into the ATIP3-MCAK interaction, ATIP3 
deletion mutants were also tested for an interaction with MCAK. Interestingly, EB1-
interacting domains of ATIP3 (D2, D2C, D2CN) interact with the kinesin (Unpublished 
Figure 1B lines 4, 5 and 6). This indicates that ATIP3 interacts with MCAK via the CN 
domain, which is the same domain of interaction with EB1. 
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Unpublished Figure 1. ATIP3 interacts with MCAK. (A) Schematic representation of MCAK protein. EB1 domain (dark 
gray) contains the EB1 binding site; CC domain (gray) the coiled-coil motifs. Amino acids are shown on the top. (B) Co-
immunoprecipitation of Myc-MCAK and GFP, EB1-GFP or GFP-ATIP3 indicated constructs (GFP-ATIP3, GFP-D2, GFP-D2C 
or GFP-D2CN) transfected in MCF7 cells, using anti-Myc antibodies. Western blots were probed with anti-GFP and anti-
Myc antibodies as indicated on the right. Molecular weights are indicated in KDa on the left. (C) GST pull-down analysis 
in HeLa cells non-transfected or transfected with control siRNA (siCtrl), ATIP3-specific siRNA (siATIP #1 and siATIP #2) or 
MCAK-specific siRNA (siMCAK) as indicated, using GST-EB1 agarose beads. Blots were probed with anti-ATIP (MTUS1) 
and anti-MCAK antibodies. (D) Immunostaining (anti-EB1, anti-GFP antibodies) of siRNA-silenced HeLa cells transfected 
with GFP-MCAK or GFP-CLIP170. Insets: EB1, MCAK and CLIP170 comet-like structures in ATIP3-positive (siCtrl) and 
ATIP3-negative (siATIP#1) cells. Distribution of EB1 (red), α-tubulin (blue) and GFP-MCAK or GFP-CLIP170 (green) at the 
MT plus-end (linescan) is shown. Scale Bar, 10 µm. 
 
  
99 
Given that ATIP3 interacts with MCAK and EB1 through the CN domain, and that ATIP3 
and MCAK interact with the C-terminal portion of EB1, two possibilities can be extracted 
from the results concerning the interaction domains. Either, ATIP3, EB1 and MCAK are in 
the same macromolecular complex and cooperate to maintain the interaction or 
conversely ATIP3-EB1, MCAK-EB1 and ATIP3-MCAK interactions are independent and 
compete for the interaction with each other. In order to test a possible competition 
between these proteins, ATIP3-depleted or MCAK-depleted HeLa cells lysates were 
incubated with GST-EB1 and pull-down experiments were performed. Unpublished Figure 
1C shows that silencing of ATIP3 does not alter the interaction of MCAK with EB1; as well 
as MCAK silencing does not change ATIP3 interaction with EB1. Thus, neither ATIP3 nor 
MCAK compete to interact with EB1. 
Previous results indicate that ATIP3 interacts with EB1 and delocalize it from the MT 
growing ends. As ATIP3 also interacts with MCAK, the localization of this +TIP was then 
evaluated by immunofluorescence imaging. HeLa cells co-transfected with control or 
ATIP3-specific siRNAs and GFP-MCAK were then stained with anti-GFP and anti-EB1 
antibodies. Unpublished Figure 1D (top panels) revealed that MCAK does not accumulate 
at the plus-ends and rather it stays diffuse in the cytosol when ATIP3 is expressed. 
Conversely, in ATIP3-silenced cells, MCAK comet-like structures were detected, as wells as 
EB1’s. These results suggest that ATIP3 impairs EB1 and EB1-interacting proteins 
accumulation at the MT growing end. To test this hypothesis, HeLa cells co-transfected 
with siRNAs (control or ATIP3-specific) and GFP-CLIP170 were stained with anti-GFP and 
anti-EB1 antibodies (as for MCAK experiment). Interestingly, unlike EB1 and MCAK, 
CLIP170 accumulates at the plus-end, in a comet-like fashion, independently of ATIP3 
expression (Unpublished Figure 1D, lower panels). Of note, CLIP170 binds EB1 via a CAP-
Gly domain and not via an SxIP motif as MCAK. 
All these data provide evidence that ATIP3 interacts with MCAK via the CN domain. 
However, the elucidation of a macromolecular complex would be necessary to explain if 
the delocalization effect seen for EB1 and MCAK is specific to these proteins or if it is 
rather a consequence of EB1 delocalization. 
 
1.2. ATIP3 interacts with APC 
The importance of stable MTs for cell migration was shown for the first time by Wen Y et 
al. (2004). In this study, they demonstrated that EB1 and APC worked as a capture 
complex to stabilize MT ends near the cell cortex. 
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Given that ATIP3 is a stabilizing MAP, that its expression is related to a higher content of 
acetylated (stable) MTs and a reduction of cell migration, we sought to investigate if the 
effects of ATIP3 were due to a possible complex with APC and EB1, as demonstrated for 
mDia. Thus, to examine if ATIP3 interacts with APC, pull-down experiments were 
performed using GST-APC deletion mutants comprising either the MT and EB1 binding 
domains (APC-EZ), the MT binding domain (APC-basic) or the EB1 binding domain (APC-C) 
(Unpublished Figure 2A). These three fusion proteins were incubated with GFP, GFP-ATIP3 
or GFP-D2 transfected MCF7 cell lysates and GST-pull-down experiments were analyzed by 
western blot. 
As shown in Unpublished Figure 2B, ATIP3 strongly interacts with APC-EZ and weakly with 
APC-C and APC-basic. Similarly, the central D2 domain of ATIP3 was able to interact both 
with APC-EZ and APC-C, and with less affinity to APC-basic. 
Altogether, these results indicate that ATIP3 interacts with APC via its central domain D2, 
which is the functional domain of ATIP3, also involved in EB1 interaction. 
 
Unpublished Figure 2. ATIP3 interacts with APC. (A) Schematic representation of APC proteins and deletion mutants 
APC-EZ, APC-basic and APC-C. Basic domain (gray) contains the MT binding region; EB1 domain (dark gray) EB1 binding 
site. (B) Pull-down analysis of GFP, GFP-ATIP3 and GFP-D2 using GST, GST-APC-C, GST-APC-EZ or GST-APC-basic agarose 
beads. Blots were probed with anti-GFP antibodies. Molecular weights are indicated in KDa on the left. 
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2. ATIP3 role in ciliogenesis 
 
Given that ATIP3 associates with MTs and regulates its dynamics, an interesting question 
that must be addressed is, does ATIP3 has a role in the assembly or in the function of MT-
based structures, such as the primary cilium? 
The primary cilium is an antenna-like structure (composed by stable MTs) which is 
anchored to the cell by the basal body (which develops from a centriole) in a manner that 
is regulated within the cell cycle. This structure works as a sensory organelle which 
receives signals from the environment and transmits them to the nucleus. Few studies 
have investigated the involvement of primary cilia in cancer cells, but most of them have 
associated a decrease in the incidence of primary cilia with multiples types of cancer (Yuan 
K et al. 2010). Recently, Emoto K and coworkers (2014) showed that primary cilia can be 
detected in human pancreatic cell lines and in cancer cells of pancreatic ductal carcinoma 
patients. Interestingly, they correlated the presence of the primary cilia with a higher 
frequency of lymph node metastasis and decreased overall survival, considering the 
presence of primary cilia as a prognostic indicator.  
As ATIP3 stabilizes MTs, we hypothesize that it will decorate the primary cilium, as VHL 
protein. RPE1 cells, which are a suitable model for ciliogenesis, were growth until 
confluence before transfection with GFP, GFP-ATIP3 and GFP-D2 constructs. 
Immunostaining with anti-acetylated tubulin, anti-EB1 and anti-GFP was performed. Wide 
field images revealed that in ATIP3- and D2-expressing cells the incidence of primary cilia 
was markedly reduced (Unpublished Figure 3). Same results were obtained by staining 
another component of the cilium, the GTPase Arl13B, suggesting that ATIP3 could regulate 
the ciliogenesis. 
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Unpublished Figure 3. ATIP3 impairs primary cilia formation. Immunostaining (anti-acetylated tubulin, anti-EB1 and anti-
GFP) of RPE1 cells transiently transfected with GFP, GFP-ATIP3 and GFP-D2. Upper insets, merge, acetylated tubulin and 
EB1; lower insets, merge (acetylated tubulin and GFP) and GFP images near the basal body. Arrows indicate GFP-ATIP3 
and GFP-D2 transfected cells. Scale bar, 10µm. 
 
Whether ATIP3 inhibits or delays ciliogenesis from the basal body, as well it decreases MT 
regrowth from the centrosome, should be investigated. For this aim, a cell model capable 
to assemble cilia and which expresses ATIP3 should be used and transfected with control 
and ATIP3-specific siRNA in order to quantify and compare the number of ciliated cells and 
the size of the cilia in ATIP3-expressing and depleted cells. 
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3. MTUS1 gene mutations in breast cancer 
 
Previous mutational analysis of MTUS1 performed in the laboratory, in a series of 30 
primary breast carcinoma and 10 breast carcinoma cell lines, identified five non-
conservative nucleotide alterations. Amino acid replacements were located on positions 
T186S, M418R, P503R, K644Q and R1003Q. Of note, variations T186S, M418R, P503R, 
K644Q reside in exon 1 and consequently are specific for ATIP3. More precisely, M418R, 
P503R, K644Q are located in D2 (Colasson H and Kheddache S, unpublished results). 
Transfections of GFP-ATIP3 constructs carrying these alterations were performed in RPE1 
and D3H2LN cells in order to analyze EB1 accumulation and wound healing time-lapse 
images, respectively. As shown in Unpublished Table 1, ATIP3-mutations did not differ 
from the wild-type protein in both EB1 accumulation, and migration directionality.  
Unpublished Table 1. Characterization of ATIP amino acid sequence variations. 
Domain MT localization Loss of EB1 comets Directionality coefficient* 
ATIP3 + + 0.39 
T186S + + 0.49 
M418R + + 0.51 
P503R + + 0.55 
K644Q + + 0.49 
R1003Q + + 0.60 
* GFP transfected cells had a coefficient of directionality of 0.85 
 
These results, along with previous data showing that ATIP3 mutations did not alter MT-
association and co-sedimentation, neither the ability to inhibit cell proliferation (Colasson 
H, unpublished results) nor the capacity to interact with EB1 (Velot L, unpublished results), 
suggest that the five alterations may be passenger mutations that are not essential for 
tumoral development. Interestingly, a mutational analysis of MTUS1 gene in 
hepatocellular carcinoma identified five different nucleotide alterations, of which four are 
located in ATIP3 exons (Di Benedetto M et al. 2006b). However, no functional experiments 
were performed to verify the importance of these mutations on cancer progression. 
Further in vitro experiments, as MT dynamics measurements, as well as an extensive 
mutational DNA analysis using different patient cohorts or data bases as the TCGA (the 
cancer genome atlas) would be of relevance to investigate the presence of driver 
mutations implicated in the carcinogenesis process that would confirmed the tumor 
suppressor function of ATIP3.  
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III. CONCLUSIONS 
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Based on previous data from the laboratory showing ATIP3 as a novel Microtubule-
Associated Protein (MAP) which is down-regulated in invasive and metastatic breast 
tumors, and with inhibitory effects on breast cancer cell proliferation in vitro and tumor 
growth in vivo, one of the goals of this thesis was to elucidate whether ATIP3 was involved 
in breast cancer metastasis and if, besides tumor cell proliferation, this tumor suppressor 
was also impairing some other steps of the metastatic process such as invasion, migration, 
extravasation and colonization. 
Using three independent patient cohorts it was possible to demonstrate that ATIP3 is a 
prognostic marker for survival of the patients with breast cancer. Furthermore, we 
showed that ATIP3 may be an indicator of metastatic progression and high risk of fatal 
complication because its low expression correlates with reduced overall survival of 
patients with metastatic disease.  
The role of ATIP3 on breast cancer metastasis was then evaluated by means of a 
bioluminescence-based experimental mouse model for cancer metastasis. Results show 
that restoration of ATIP3 in highly invasive D3H2LN breast tumor cells decreases the 
metastatic colonization (time course and the number and size of metastatic foci). Analysis 
of the different steps of the metastatic process indicate that ATIP3 reduces cell migration 
and transendothelial migration (extravasation), and increases adhesion to endothelial cells 
and to collagen. Analysis of GFP and GFP-ATIP3 migrating stable clones show that the 
tumor suppressor reduces cell velocity and cell directionality during wound-induced 
migration. These data indicate that ATIP3 limits early (growth) and late (dissemination) 
phases of metastasis development. 
As cell migration is a process that somewhat depends on microtubule (MT) network and 
MT dynamics, a second objective of this work was to determine whether ATIP3 may be 
able to modulate MT dynamics, as described for almost all MAPs. Different experimental 
data let to the conclusion that ATIP3 is a stabilizing MAP that increases the acetylation 
content of interphase MTs, preventing MT depolymerization induced by cold or 
nocodazole treatment and reducing MT regrowth after nocodazole washout. Moreover, 
time-lapse analysis of EB1-GFP showed that loss of ATIP3 increases MT dynamic instability 
by increasing MT growth rate and MT growth episodes and decreasing MT time spent in 
pause and MT catastrophe frequency. 
The asymmetric distribution of stable microtubules is suggested to be amongst the initial 
events that occur in response to migration signals. The effect of ATIP3 on MT dynamic 
instability parameters leads to a marked reduction of polarized MTs. Thus, in ATIP3-
deficient cells MTs near the cell cortex were radially organized with their plus-ends 
anchoring at the cell margin, while in ATIP3-expressing cells MT plus-ends do not reach 
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the cell edge, due to MTs bending before reaching the cell cortex. Furthermore, analysis of 
acetylated tubulin (marker of stable MT) indicated that ATIP3 induces a global stabilization 
of MTs that will result in the absence of cell polarization. 
ATIP3 can be divided in three regions according to the isoelectric point of each of these 
parts: D1, the N-terminal part of the protein is characterized by its acidic behavior; D2, the 
central domain of the protein is rich in basic residues; and D3, the C-terminal region, has a 
neutral charge and is involved in protein dimerization due to the presence of four coiled-
coil domains. Experiments conducted in order to identify the functional domain of the full-
length protein revealed that D2, and not D1 or D3, was able to co-sediment with tubulin 
and to localize with MTs after immunofluorescence staining. Besides binding to MTs, 
clonogenicity experiments and wound-healing tests confirmed D2 as the functional 
domain of ATIP3. D2 reduces cell proliferation in vitro and impairs directionality during 
migration, just like ATIP3. This indicates that the central part of the protein (D2) contains 
the MT binding domain and the functional properties of full-length ATIP3. 
Microtubule dynamics are accurately regulated by MAPs. EB1, the core of +TIPs functions, 
has an important role in MT dynamics. Immunostaining images of mCherry-ATIP3 
indicated a reduction of EB1 localization at the MT growing end, that is restored once 
ATIP3 is not expressed. The aim of this part of my thesis was to investigate if ATIP3 
interacts with EB1 to impair its localization at the plus-ends. 
Sequence analysis of the ATIP3 polypeptide reveals three possible EB1 interacting motifs: 
one SxIP (SAIP) located in the C-terminal region of the protein and two SxIP-like (KNIP and 
RPLP) located in the central domain D2. By means of GST pull-down and co-
immunoprecipitation, we showed that ATIP3 interacts with EB1. Detailed analysis of EB1 
interaction domains of ATIP3 show that only the RPLP (located in a region termed CN) 
directly interacts with the C-terminal domain of EB1. 
A large number of studies have shown that SxIP-containing proteins accumulate at the MT 
growing end together with EB1. In spite of evidence suggesting that ATIP3 may be a new 
plus-end tracking protein via EB1 interaction, immunostaining and time-lapse imaging of 
ATIP3 and EB1 demonstrate that ATIP3 does not accumulate at the growing end of the 
MTs. ATIP3 rather remains attached to the MT lattice and surprisingly, tracks shrinking MT 
ends. 
By means of Proximity Ligation Assay (PLA) experiments using endogenous ATIP3 and EB1 
antibodies, the in situ interaction between these two proteins was revealed: they mostly 
interact in the cytosol. Interestingly, some complexes were also detected along the MT 
lattice. This last localization is coherent with immunofluorescence images showing a 
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reduction at plus-end but a partial MT lattice localization of EB1 in ATIP3-expressing cells. 
Subsequent experiments, indicated that that impaired accumulation of EB1 at the MT 
growing end was correlated with the presence of the EB1-interacting domain (CN) and 
was independent of the association with MTs. Together these results indicate that ATIP3 
interacts with EB1 and that it may retain EB1 at the cytosol and MT lattice, decreasing the 
free available cytosolic pool of EB1 that can accumulate at the plus-ends.  
Clinical relevance of this interaction was then evaluated by the analysis of MTUS1 (ATIP3 
gene) and MAPRE1 (EB1 gene) expression levels in a cohort of 150 breast cancer patients, 
followed by the comparison with clinicopathologic data. Results showed that relative 
expression levels of both proteins in breast tumors are related with patient clinical 
outcome. Indeed, among tumors with low levels of ATIP3 and high levels of EB1 a reduced 
overall survival of patients was found. Inversely, a better clinical outcome resulted from 
tumors with low levels of EB1 and high or very high ATIP3 expression levels. These last 
results highlight the importance of coordinated ATIP3 and EB1 expression levels in breast 
cancer progression and clinical outcome. 
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IV. DISCUSSION AND FUTURE 
DIRECTIONS 
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Major achievements in this work include the identification of ATIP3 as a new biomarker of 
metastasis in breast cancer patients and a regulator of MT dynamics which reduces MT 
dynamic instability. Although a remarkable progress has been done in understanding 
ATIP3’s effects in essential cellular functions, there is still much more to explore.  
 
1. ATIP3 decreases MT dynamic instability 
Evidence that ATIP3 reduces EB1 accumulation at the MT growing ends was provided in 
this work. EB1 reduction at the plus-end has been usually recognized as a hallmark of MT 
dynamics reduction. However, future TIRF time-lapse videomicroscopy experiments using 
mCherry-tubulin stable clones transfected with low levels of GFP-ATIP3 (or GFP-D2) and 
GFP-ATIP3delCN (or GFP-D2delCN), which does not interact with EB1, should be 
performed to measure dynamic instability parameters that would elucidate the 
importance of EB1-ATIP3 interaction in MT dynamics. 
How does ATIP3 reduce EB1 accumulation at the MT plus-ends? Reduction may be due to 
(i) EB1 degradation, (ii) post-translational modifications of EB1 that reduces its affinity for 
the plus ends, (iii) reduction of the free available cytoplasmic EB1, (iv) induction of a 
conformational change of the MT dynamic end and (v) suppression of the MT growing 
events.  
To date our data have excluded the hypothesis of EB1 degradation induced by ATIP3. 
Additionally, a conformational change of the MT growing ends by ATIP3 is very unlikely 
given that association with MTs is independent to the reduction of EB1 accumulation 
(concerns different protein binding domains). However it should be interesting to evaluate 
if ATIP3 expression or depletion causes a change in the tubulin-GTP cap (using for example 
anti-GTP-tubulin antibodies (Dimitrov A et al. 2008) or electronic microscopy images of 
the MT plus-ends).  
Thus, EB1 post-translational modifications and cytosolic EB1 retention are the most 
probable hypotheses that may explain EB1 reduction at the MT growing ends by ATIP3. 
Recently, Rovini A and coworkers suggested that alteration of the C-terminal tyrosine of 
EB1 may affect its accumulation at the growing ends, as well as its functions in MT 
dynamic regulation (Rovini A et al. 2013). Additionally, they demonstrated that migration 
was increased in cells containing detyrosinated EB1, suggesting a potential role of EB1 
detyrosination in cancer progression. EB1 tyrosination/detyrosination cycle will be 
evaluated using anti-tyrosinated and anti-detyrosinated EB1 antibodies (Bosson A et al. 
2012).  
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Even if it has not been demonstrated that acetylation of EB1 reduces its accumulation at 
the plus-ends, evaluation of this post-translational modification would be interesting in 
ATIP3-depleted cells given that persistent acetylation of EB1 perturbs chromosome 
alignment in metaphase (Xia P et al. 2012). 
An alternative option is the possible retention of EB1 by ATIP3. Considering that a 
diffusible cytosolic pool of EB1 is necessary to allow the dynamic accumulation at the 
growing end (Dragestein KA et al. 2008), ATIP3 interaction with EB1 may limit its dynamic 
turnover and thus, a reduction of EB1 at the growing end would be observed. In 2003 
Tortosa E and coworkers proposed a model for the classical MAP MAP1B. They showed 
that MAP1B directly interacted with EB3 in the cytosol, reducing its accumulation at the 
MT plus-ends and consequently regulating MT dynamics. In line with this model and due 
to the direct interaction of ATIP3 with EB1, one might think that ATIP3 would retain EB1, 
decreasing the free available pool that can accumulate at the plus-ends. Thus, in ATIP3-
deficient cells, more EB1 would accumulate at the growing end, therefore increasing MT 
dynamics, +TIPs interactions, and consequently cell proliferation and cell migration. 
However, experiments to evaluate this model are necessary. For instance, comparison of 
EB1-GFP turnover dynamics at the plus-ends in ATIP3-expressing and depleted cells could 
be measured through FRAP (Fluorescence Recovery After Photobleaching) 
videomicroscopy experiments. 
Additionally, a comparative and quantitative global proteomic approach (Deracinois B et 
al. 2013) to identify the amount of ATIP3 and EB1 in a normal epithelial cell would be 
important to elucidate if there is enough ATIP3 proteins to retain EB1 in the cell. 
 
2. ATIP3 molecular complexes 
Results from this work showed that ATIP3 interacts with MCAK. Whether this interaction 
requires EB1 is still unknown, but so far it has been elucidated that CN domain of ATIP3 
interacts with C-terminal EB1, as well as with MCAK; and that MCAK interacts with the 
same C-terminal domain of EB1, suggesting a possible macromolecular complex. 
Co-immunoprecipitation assays using ATIP3 and MCAK deletion mutants that do not 
contain the EB1-interacting domain (ATIP3delCN or D2delCN on ATIP3 and MCAK-3E or 
MCAK-NN on MCAK (Honnappa S et al. 2009)), as well as EB1-specific siRNA transfection 
must be performed to revealed if the interaction of ATIP3 with MCAK involves EB1. 
Additionally, if ATIP3, MCAK and EB1 form a complex, should be demonstrated if they are 
cooperating to stabilize the interaction. With this aim, GST-EB1 pull-down experiments 
should be performed using increasing amounts of GFP-ATIP3 or increasing amounts of 
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GFP-MCAK, to elucidate if interaction of MCAK or ATIP3 increases when the concentration 
of the other protein also increases. 
In line with increased EB1 accumulation at the growing ends in ATIP3-depleted cells, 
observation of GFP-MCAK revealed the same effect for this +TIP. The question that arises 
is whether ATIP3 is indirectly impairing the accumulation of all EB1-interacting partners at 
the plus-end. Immunostaining analysis of GFP-CLIP170 revealed that this protein 
accumulates at the plus-ends independently of ATIP3 expression, suggesting that loss of 
ATIP3 does not increase dynamics of all MTs, but just a subset where possibly EB1 and 
MCAK are localized. Of note, CLIP170 contains a CAP-Gly domain that allows to tip-track 
by hitchhiking on EB1, but as well by MT end recognition and/or by copolymerization with 
tubulin. Future experiments analyzing other SxIP-containing proteins that do not interact 
with ATIP3 would help to answer this question and clarify if the effect of ATIP3 on MCAK 
localization is specific or a direct consequence of EB1 delocalization. 
Interaction of ATIP3 with EB1 and MCAK may be involved in MT dynamics regulation given 
that these two proteins have a key role in MT dynamic instability, being EB1 involved in 
the polymerization and MCAK in the depolymerization of MTs. Interestingly, the Xenopus 
ortholog of ATIP3, ICIS also interacts with MCAK to stimulate its MT-depolymerizing 
activity supporting our hypothesis describing a MT regulatory complex. 
ATIP3 also interacts with APC. APC and ATIP3 share a large number of characteristics since 
both are members of the MATSP superfamily of tumor suppressor proteins that bind and 
regulate MT dynamics. In addition, ATIP3 and APC interact with EB1 and MCAK. It has 
been reported that interaction of APC with EB1 plays an important role in cell migration 
(Wen Y et al. 2004), whereas its interaction with MCAK is relevant for cell proliferation 
(Bahmanyar S et al. 2009). 
Weak interaction of ATIP3 with APC was found in the absence of EB1 binding domain 
(APC-basic), suggesting that EB1 may be not required for this interaction but for the 
stabilization. Nevertheless, additional GST pull-down experiments should be performed to 
confirm this hypothesis using EB1-specific siRNA or ATIP3 or D2 deletion mutants lacking 
the CN domain. In addition, further experiments aiming to determine ATIP3 domain of 
interaction with APC should be performed. Deletion of this domain from full-length 
protein must be tested in functional assays, such as cell migration to define if the effect of 
ATIP3 on MT polarity and thus cell polarity and migration are due to its interaction with 
APC. 
Where is the interaction between ATIP3 and APC happening? As APC is an SxIP-containing 
protein, its localization (in ATIP3-expressing and depleted cells) is important to verify 
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whether an accumulation at the MT plus-ends of APC is induced by the loss of ATIP3, as 
observed for EB1 and MCAK. Furthermore, considering that Louie RK et al. (2004) showed 
that APC and EB1 co-localize at the mother centriole, and that ATIP3 also localized at the 
centrosome, super resolution images should be taken to determine the exact position of 
ATIP3 and to define if it co-localizes with EB1 and APC complexes. 
In addition, PLA experiments aiming to identify the in situ localization of ATIP3 and APC 
(and as well ATIP3 and MCAK) should be performed to characterize the interaction 
between these proteins. Finally, and as for MCAK, it should be investigated if ATIP3, APC 
and EB1 form a complex to regulate MT behavior during cell migration. 
 
3. ATIP3 is not a +TIP 
In 2009, Honnappa S and coworkers revealed that some +TIPs contain repeated SxIP 
motifs (such as mammalian CLASP2) and show enhanced affinity for MT growing ends, 
suggesting that multiple SxIP motifs may cooperate to enhance MT tip tracking (Honnappa 
S et al. 2009). Considering that ATIP3 contains three SxIP motifs and that it interacts with 
three +TIPs (EB1, MCAK and APC), this strongly suggest that ATIP3 is a MT plus-end 
interacting protein (+TIP). However, ATIP3 does not track the end of growing MTs but 
instead the MT lattice and the end of shrinking MTs. 
In 2012, Jiang K and coworkers identified some SxIP-containing proteins that interacted 
with EB1 but did not showed tip-tracking behavior. Two interesting proteins were tastin 
and DDA3. By means of time-lapse videomicroscopy, these two proteins were described 
as back-tracking proteins, similar to ATIP3. Nevertheless, nothing is known about the 
mechanism by which these two proteins track depolymerizing MT ends. Backtracking 
proteins have been described in budding yeast (Salmon ED, 2005), Drosophila (Mennella V 
et al. 2005) and in humans (Langford KJ et al. 2006). In Drosophila, KLP59C (KIF2C/MCAK 
ortholog) remains associated with shrinking MTs and perpetuates their depolymerization 
by suppressing rescue. Although the mechanism by which this protein is retained at 
depolymerizing MT ends remains unclear, it has been suggested that differential affinity 
for the MT lattice versus the ends may be involved in KLP59C backtracking behavior (Sharp 
DJ et al. 2005). Of interest, APC was also described as a backtracking protein; however, no 
mechanism of action was associated with this localization (Langford KJ et al. 2006). 
How does ATIP3 track the end of a depolymerizing MT? A possible explanation for ATIP3 
accumulation and tracking of shrinking MTs may be a strong interaction of this protein 
with the MT lattice that will result in the slow dissociation of ATIP3 and the apparent 
accumulation at the depolymerizing end. However, future experiments like FRAP analyses 
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to measure the dynamics of GFP-ATIP3 association/dissociation with tubulin at the MT 
lattice would be interesting to test this hypothesis. 
 
4. ATIP3 impairs cell polarity and cell migration 
Several studies have shown that coupling of MTs at the front edge is relevant to sustain 
cell polarization and involves MTs plus-ends tracking proteins (+TIPs) such as EB1, APC, 
mDia, CLIP170, CLASP1, CLASP2, MACF/ACF7 and IQGAP. As mentioned above ATIP3 
interacts with EB1 and APC, but the role of this interaction on cell migration must be 
evaluated.  
It has been reported that cell polarization through APC includes the activation of Par 
proteins, especially Par6, the atypical PKCζ and GS3Kβ (Etienne-Manneville S et al. 2005). 
Evaluation of the activation of these proteins in ATIP3-expressing and depleted cells will 
allow to elucidate the effect of ATIP3 in the pathways that mediates MT and cell 
polarization. 
Cell polarity mostly depends on actin rearrangement which in turn depends on activation 
of Rho GTPases. In accordance, the relevance of Rho pathway in ATIP3 effects should be 
tested using Rho inhibitors (as the toxin B or the C3 exoenzyme) or Rho Kinases (ROCK) 
inhibitors (like Y-27632). Additionally, actin dynamics in ATIP3-expressing and depleted 
cells during migration can be elucidated by means of TIRF (Total Internal Reflection 
Fluorescence) time-lapse videomicroscopy and will provide some clues to unravel the 
molecular mechanism of ATIP3 in cell polarity. 
Impaired MT polarization results in a defect on cell polarity and subsequent cell migration. 
Tracking of phase contrast time-lapse images revealed an alteration of cell directionality 
that was accompanied with a difference in cell morphology. While highly invasive D3H2LN 
GFP cells formed a clear lamellipodium in the front of the cell near the wound and a 
trailing edge at the rear, ATIP3-positive cells exhibited various protrusions in different 
directions that do not persist over time. This unsustained cell shape during migration 
results in the failure of ATIP3-expressing cells to develop a polarized morphology that is 
instrumental for migration of adherent cells.  
Time-lapse images also revealed a difference in the way GFP- or GFP-ATIP3-expressing 
cells migrate. D3H2LN GFP-expressing cells exhibit a collective cell migration where 
confluence cells remain attached and the cell monolayer moves coordinately to close the 
wound. Conversely, ATIP3-expressing cells do not form a compact monolayer and single 
cells move independently of their neighbors without a direction, confirming the defect on 
cell polarity. The change in morphology observed raises the hypothesis that loss of ATIP3 
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might induce a mesenchymal-epithelial transition (MET), where spindle-shaped cells 
become an array of polarized cells. Even if little is known about the role of MET in cancer 
and metastatic progression, it has been reported that it participates in the establishment 
and the stabilization of distant metastasis by allowing cancerous cells to regain epithelial 
properties and integrate into distant organs (Thiery JP, 2002; Brabletz T et al. 2005). 
This observation should be verified by immunostaining of E-cadherin and N-cadherin, β-
catenin, APC, intermediate filaments and other proteins involved in the transition, in both 
ATIP3-expressing and depleted cells. Additionally, ATIP3 introduction at low levels in cysts 
to evaluate a possible disruption of the structure, loss of polarity, and a switch between 
epithelial to mesenchymal markers would be important. This experiment should be 
performed as well with ATIP3-expressing cells where the protein will be silenced using 
specific siRNAs. 
 
5. Clinical relevance of ATIP3 
At the clinical level, this work allowed the identification of a new prognostic marker of the 
clinical outcome and an indicator of metastatic progression and high risk of fatal 
complication. Interestingly, two independent studies have shown that low expression of 
MTUS1 is associated with low overall survival of patients with bladder cancer (Xiao J et al. 
2012) and oral tongue squamous cell carcinoma (Ding X et al. 2012). The identification of 
ATIP3 as the MTUS1 splice variant down-regulated in these two human cancers will permit 
the extrapolation of our results in human tumors other than breast cancer. Additionally, 
the evaluation of ATIP3 status in those cancers where MTUS1 expression levels have been 
reported as reduced (pancreas, ovary, colon, head-and-neck, bladder and gastric) it would 
be of importance.  
This work provides evidence that the combined evaluation of ATIP3 and EB1 gene 
expression profiles predicts the clinical outcome of breast cancer patients. Reduction of 
EB1 accumulation at the MT growing ends and alteration of its functions will depend on 
the relative expression levels of EB1 and ATIP3. In normal conditions, combined EB1/ATIP3 
levels will maintain the equilibrium between the oncoprotein functions and the tumor 
suppressor functions. In contrast, an increase of EB1 or a decrease of ATIP3 will end in a 
deregulation of the balance, thus tumors with high levels of EB1 or low levels of ATIP3 
may have an increase MT dynamics, tumor growth, tumor metastasis and consequently 
patients would have a worst prognosis. 
It will be interesting to extend this first analysis including more patients’ cohorts or using 
data bases (as the Kaplan-Meier plotter) to confirm the result obtained, and to evaluate 
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the clinical importance of a group that was not present in this first gene expression 
analysis: high levels of both proteins. Furthermore, the evaluation of ATIP3 relative 
expression levels in those human cancers where EB1 has been reported as overexpressed 
(Fujii K et al. 2005; Nishigaki R et al. 2005; Wang Y et al. 2005; Orimo T et al. 2008; 
Stypula-Cyrus Y et al. 2014) will allow to extend the correlation seen in breast cancer. 
Additionally, the implement of PLA experiments (using anti-MTUS1 and anti-EB1 
antibodies in tumor and normal tissue) as clinic test may be of diagnostic value. 
How could we translate these results in an ATIP3 targeted therapy? Different strategies 
(such as nanoparticles, cell-penetrating peptides or CPPs, or injection of naked DNA) have 
been reported as options for a personalized treatment (Bolhassani A et al. 2011; Sanchez 
C et al. 2014; Bu X et al. 2014; Fioretti D et al. 2014). However, given that ATIP3 is a large 
protein (1270 amino acids) is difficult its introduction in cancer cells. Which is why, the 
identification of a functional domain is important. D2 (465 amino acids) seems a good 
candidate as it retains all the full-length functions. Subsequent reduction of this domain 
showed that D2C and CN (170 and 112 amino acids, respectively) retained all of the 
functions tested as the interaction with EB1, the co-localization with MTs (CN with less 
affinity) and impairment of EB1 localization at the MT growing end. Future experiments 
should validate the effect of D2 deletion mutants in cellular processes, such as cell 
proliferation and cell migration, and metastatic progression to determine if these domains 
are fully functional and suitable for further use as a targeted therapy. 
Results from this work allowed the identification of patients with high risk of fatal 
complication. The design and modelization of peptides that mimic the effects of ATIP3 and 
impede the accumulation of EB1 at the plus-ends (CN, par example), should be considered 
as an important therapeutic tool, against tumors that have lost ATIP3 and overexpress 
EB1, that has to be still developed. 
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> Les microtubules, formés de l’assem-
blage dynamique de dimères d’alpha et 
de bêta-tubuline, jouent un rôle essen-
tiel dans l’homéostasie cellulaire. Dans 
les cellules en interphase, le cytosque-
lette de microtubules intervient dans le 
maintien de l’architecture cellulaire, la 
migration et le trafic intracellulaire de 
protéines et d’organites ; en mitose, il se 
réorganise pour former le fuseau mitoti-
que qui permet une répartition correcte 
des chromosomes [1]. La dynamique de 
polymérisation des microtubules, essen-
tielle à leur fonction, est sous le contrôle 
d’un ensemble de protéines agissant de 
concert : les MAP (ie_nkpq^qha)]ook)
_e]pa`lnkpaejo) dont l’activité est fine-
ment régulée dans l’espace et le temps 
[1, 2]. Les altérations de la structure 
ou de la régulation des MAP peuvent 
avoir des répercussions considérables 
dans de nombreuses situations physio-
pathologiques, comme c’est le cas par 
exemple pour la protéine APC (]`ajk)
i]pkqolkhulkoeo_khe) dans le cancer du 
côlon, ou la protéine Tau dans la maladie 
d’Alzheimer.
ATIP3, un régulateur de mitose 
associé aux microtubules
Notre équipe a récemment mis en évidence 
une nouvelle protéine associée aux micro-
tubules dénommée ATIP3 $=P.)ejpan]_pejc
lnkpaej/% [3], codée par le gène candidat 
suppresseur de tumeurs IPQO- (ie_nkpq)
^qha)]ook_e]pa`pqiknoqllnaookn )1 [4, 
5]. La molécule ATIP3 est localisée au 
centrosome et le long des microtubules 
dans les cellules en interphase. Au cours 
de la division cellulaire, elle s’associe au 
fuseau mitotique à tous les stades de la 
mitose et au pont intercellulaire lors de 
la cytokinèse $Becqna-%. En accord avec 
1 Le gène IPQO- a initialement été nommé iepk_dkj`ne]h
pqiknoqllnaookn , sur la base des résultats de Seibold ap
]h. [11]. En 2010, lorsqu’il s’est avéré qu’ATIP3, ICIS et 
TIP150, produits des gènes IPQO- et IPQO.( sont associés 
aux microtubules [3, 7, 8], le comité de nomenclature de 
la base de données NCBI (J]pekj]h_ajpanbkn^ekpa_djkhkc u
ejbkni]pekj) a renommé IPQO- : ie_nkpq^qha)]ook_e]pa`
pqiknoqllnaookn.
cette localisation particulière, nos travaux 
ont montré un effet régulateur d’ATIP3 sur 
la mitose. En effet, ATIP3 freine la proli-
fération cellulaire et prolonge le temps 
de division en maintenant les cellules au 
stade métaphase [3].
L’étude moléculaire de la protéine ATIP3 
revêt un intérêt fondamental quand on 
sait que son expression est diminuée 
dans le cancer du sein, et ce de façon 
d’autant plus marquée que la tumeur est 
plus agressive et de grade histologique 
élevé, métastatique ou du sous-type 
triple négatif, pour lequel il n’existe pas 
à ce jour de thérapie ciblée. Ainsi ATIP3 
constitue un nouveau biomarqueur des 
tumeurs de sein de mauvais pronostic. 
De plus, ses effets antimitotiques ej
repnk et antitumoraux ejrerk en font une 
cible privilégiée pour l’élaboration de 
nouvelles thérapies moléculaires contre 
le cancer du sein [3].
Bien que les mécanismes d’action d’ATIP3 
demeurent inconnus à ce jour, des études 
récentes réalisées sur deux protéines (ICIS 
et TIP150) qui lui sont structuralement 
apparentées, ouvrent des perspectives 
intéressantes dans le domaine du cancer. 
La protéine ICIS (codée par le gène ortho-
logue IPQO- de Xénope) a été décrite 
comme une nouvelle MAP localisée aux 
Figure 1. Localisation de la protéine ATIP3 aux 
microtubules dans les cellules de carcinome 
pulmonaire SK-MES en interphase (à gauche) 
et en mitose (à droite). L’image d’immuno-
fluorescence est obtenue après immuno-
 marquage de la protéine ATIP3 endogène (en 
vert) et de l’alpha-tubuline (en rouge).
Interphase Mitose
Article disponible sur le site http://www.medecinesciences.org ou http://dx.doi.org/10.1051/medsci/2011273244
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kinétochores [6], structure qui relie les 
centromères aux microtubules lors de 
la mitose $Becqna.%. ICIS interagit avec 
la kinésine MCAK (iepkpe__ajpnkiana)
]_per]pejcgejaoej) et contribue à la 
dépolymérisation des microtubules et 
donc à la dynamique du fuseau mitotique 
essentiel à la ségrégation des chromoso-
mes [6]. Plus récemment, la mise en évi-
dence d’une interaction entre ICIS et une 
autre kinésine 13 (Kif2A) conforte le rôle 
de cette protéine dans la dépolymérisa-
tion des microtubules [7]. D’autre part, 
la protéine TIP150 (produit du gène para-
logue IPQO.) a récemment été identifiée 
comme une MAP interagissant avec EB1 
(aj`^ej`ejclnkpaej-) et MCAK aux bouts 
« plus » des microtubules $Becqna.% pour 
favoriser leur dépolymérisation [8]. Ainsi, 
par analogie avec ses homologues ICIS 
et TIP150, on peut avancer l’hypothèse 
d’un rôle d’ATIP3 dans la dynamique des 
microtubules re] l’activation de  kinésines 
de la famille MCAK.
Fonctions 
des autres membres de la famille ATIP
Qu’en est-il des autres membres de la 
famille ATIP ? L’épissage alternatif du gène 
IPQO- génère en effet deux autres pro-
téines - ATIP1 et ATIP4 - identiques à 
ATIP3 dans leur portion carboxy- terminale 
[4, 5, 9] mais dont le lien avec le cytos-
quelette de microtubules n’a pas encore 
été évalué. ATIP1, initialement identifié 
comme partenaire d’interaction du récep-
teur AT2 de l’angiotensine II - ce qui lui a 
d’ailleurs valu son nom d’=P.na_alpkn)ej)
pan]_pejclnkpaej- est un acteur privilégié 
des voies de signalisation de ce récepteur, 
impliqué dans l’inhibition de la proliféra-
tion cellulaire, la différenciation  neuronale 
et le remodelage vasculaire [4].
Outre son rôle central dans la signali-
sation de l’AT2, ATIP1 contribue aussi 
à l’adressage du récepteur à la mem-
brane [10]. De façon intéressante, ATIP1 
a été décrite comme étant localisée 
dans les mitochondries [11] ou le Golgi 
[10], deux compartiments cellulaires 
étroitement associés aux microtubu-
les. La colocalisation d’ATIP1 avec ces 
deux organites et ses effets sur le trafic 
intracellulaire du récepteur AT2 suggè-
rent qu’ATIP1 pourrait interagir avec les 
microtubules et s’associer à des moteurs 
moléculaires pour permettre le transport 
intracellulaire d’organites ou de récep-
teurs. Bien que purement spéculative, 
cette hypothèse mérite d’être examinée.
La protéine ATIP4 n’a pas encore été 
isolée à ce jour. Au-delà de son domaine 
d’interaction avec le récepteur AT2, cette 
protéine présente deux caractéristiques 
particulières - la présence d’un domaine 
transmembranaire et un profil d’expres-
sion exclusivement restreint au système 
nerveux central - qui en font un média-
teur potentiel des effets de l’AT2 dans 
le cerveau [4]. On peut noter que les 
400 acides aminés carboxy-terminaux 
d’ATIP4 sont identiques à ceux d’ATIP1 
et ATIP3 et fortement conservés dans les 
séquences des protéines ICIS et TIP150, 
ce qui pose la question de l’association 
potentielle d’ATIP4 avec le cytosque-
lette de microtubules re] son domaine 
 carboxy-terminal  intracellulaire.
En conclusion
Les protéines de la famille ATIP ont 
récemment été impliquées dans diverses 
fonctions, allant de la différenciation 
neuronale au remodelage vasculaire et 
à la prolifération tumorale. Cette revue 
pose l’hypothèse selon laquelle ces pro-
téines pourraient, avec leurs analogues 
structuraux ICIS et TIP150, constituer 
une nouvelle superfamille de protéines 
associées aux microtubules. Localisées 
dans différents compartiments intra-
cellulaires, les protéines ATIP pourraient 
contribuer aux fonctions essentielles de 
la cellule (mitose, trafic, signalisation) 
en régulant la dynamique des microtu-
bules. L’étude moléculaire des membres 
de cette superfamille devrait permettre 
de révéler de nouveaux aspects du rôle 
des microtubules aux niveaux cérébral, 
cardiovasculaire et tumoral. ‡
ATIP, a novel superfamily of microtu-
bule-associated proteins
Figure 2. Localisation cellulaire des protéines 
ATIP et de leurs analogues structuraux ICIS 
et TIP150. Schéma représentant l’association 
d’ATIP3, ICIS et TIP150 avec les microtubules 
dans une cellule en interphase (à gauche) ou 
en mitose (stade métaphase, à droite). En 
interphase, ATIP3 (en rose) est localisée tout 
le long des microtubules alors que TIP150 (en 
vert) est exclusivement présente aux extrémi-
tés des microtubules (bout +). ATIP1 (en bleu) 
est localisée au Golgi. Dans une cellule en 
mitose, on retrouve ATIP3 (en rose) le long des 
microtubules du fuseau mitotique et ICIS (en 
jaune) au niveau des kinétochores. Golgi
ATIP1
Interphase Mitose
Microtubules
ATIP3
Bout +
TIP150
Kinétochores
ICIS
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La chromatine et ses dérivés
Depuis son apparition en 1882 [1], le 
terme « chromatine » a changé de défi-
nition à de nombreuses reprises. Ces 
définitions ont toutes eu pour fonction 
de mettre un nom sur un objet dont la 
nature, la structure, les propriétés et les 
fonctions n’ont jamais été parfaitement 
comprises. Par exemple, la dichotomie 
entre euchromatine et hétérochroma-
tine, initialement établie par micros-
copie électronique, désignait l’hétéro-
chromatine comme la fraction compacte 
du matériel nucléaire d’une cellule en 
interphase. La définition actuelle obéit 
aux exigences de la génomique : l’hé-
térochromatine est volontiers définie 
par sa nature répétitive ou l’absence 
d’expression des gènes qui y sont codés. 
Ainsi, chacune des deux définitions 
élude les mécanismes fondamentaux de 
la propriété sur laquelle elle est basée.
Malgré la nature éminemment floue du 
concept de chromatine, la communauté 
scientifique ne fait preuve ni de dogma-
tisme, ni de naïveté quant à son usage. 
Le terme garde son aspect indéfini avant 
tifier $Becqna-%. Donnant des résultats 
comparables à ceux de la précipitation 
de la chromatine (ChIP), la technologie 
DamID jouit d’un avantage : elle peut 
être appliquée de façon systématique 
sans recours au développement d’an-
ticorps spécifiques, ce qui permet une 
augmentation conséquente du débit. Les 
cartes de liaison à haute résolution de 
ces 53 protéines nous ont permis de don-
ner le premier aperçu de la chromatine à 
cette échelle dans une cellule eucaryote.
Hétérogénéité et simplicité 
de la chromatine de drosophile
La première surprise de cette étude est 
l’hétérogénéité de la chromatine de 
drosophile. On pourrait s’attendre à une 
répartition plus ou moins uniforme des 
évènements de liaison sur la molécule 
d’ADN. Or, la majeure partie du génome 
est liée par un petit nombre de protéi-
nes très abondantes, telles que l’his-
tone H1, alors qu’une petite fraction du 
génome est liée par un très grand nom-
bre de protéines différentes. La seconde 
surprise est la faible complexité de la 
tout pour des raisons expérimentales. 
Il est clair depuis plus d’une quinzaine 
d’années que la dichotomie naïve entre 
euchromatine et hétérochromatine est 
le fruit de l’inefficacité des méthodes 
utilisées pour interroger les propriétés du 
matériel nucléaire ejrerk . Il n’est donc 
pas surprenant que les termes chan-
gent à nouveau de sens avec l’essor des 
 analyses ejrerk à l’échelle du génome.
Grâce aux technologies récentes, nous 
avons cartographié les sites de liaison 
de 53 protéines de la chromatine sur le 
génome de la drosophile [2]. Pour cela 
nous avons utilisé un modèle uniforme 
de cellules en culture et une méthode 
de cartographie ejrerk  appelée DamID. 
Le principe de la méthode repose sur 
l’activité de l’enzyme Dam (@J=]`a)
jejaiapduhpn]joban]oa). Dam dépose une 
empreinte sur l’ADN, absente des géno-
mes eucaryotes, qui peut être détectée 
par des enzymes de restriction. En fusion-
nant une protéine à Dam, il est possible 
de restreindre la méthylation de l’ADN 
aux sites de liaison de cette protéine ej
rerk, ce qui permet ensuite de les iden-
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1066CX Amsterdam, 
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Abstract
Breast cancer metastasis is a leading cause of death by malignancy in women worldwide. Efforts are being made to further
characterize the rate-limiting steps of cancer metastasis, i.e. extravasation of circulating tumor cells and colonization of
secondary organs. In this study, we investigated whether angiotensin II, a major vasoactive peptide both produced locally
and released in the bloodstream, may trigger activating signals that contribute to cancer cell extravasation and metastasis.
We used an experimental in vivo model of cancer metastasis in which bioluminescent breast tumor cells (D3H2LN) were
injected intra-cardiacally into nude mice in order to recapitulate the late and essential steps of metastatic dissemination.
Real-time intravital imaging studies revealed that angiotensin II accelerates the formation of metastatic foci at secondary
sites. Pre-treatment of cancer cells with the peptide increases the number of mice with metastases, as well as the number
and size of metastases per mouse. In vitro, angiotensin II contributes to each sequential step of cancer metastasis by
promoting cancer cell adhesion to endothelial cells, trans-endothelial migration and tumor cell migration across
extracellular matrix. At the molecular level, a total of 102 genes differentially expressed following angiotensin II pre-
treatment were identified by comparative DNA microarray. Angiotensin II regulates two groups of connected genes related
to its precursor angiotensinogen. Among those, up-regulated MMP2/MMP9 and ICAM1 stand at the crossroad of a network
of genes involved in cell adhesion, migration and invasion. Our data suggest that targeting angiotensin II production or
action may represent a valuable therapeutic option to prevent metastatic progression of invasive breast tumors.
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Introduction
The occurrence of distant metastasis is a critical event that limits
the survival of patients with breast cancer. While targeted
molecular therapies have considerably improved the management
of primary breast tumors, these remain poorly effective for the
treatment of distant metastases. The identification of molecular
agents that may contribute to breast cancer cell dissemination is
therefore essential for future development of new anti-metastatic
therapeutic strategies.
Metastasis is an inefficient process. Among the large number of
cancer cells that detach from the primary tumor and invade
adjacent tissues to reach the bloodstream, most remain quiescent
or die in the circulation [1–3]. Only few circulating tumor cells are
able to cross the blood barrier and colonize distant organs to form
micrometastases [3–5]. There is increasing evidence that, in
addition to intrinsic metastasis gene signatures that predict the
ability of tumor cells to colonize distant tissues [6], close
interactions between circulating tumor cells and the host
microenvironment are critical to the establishment of cancer cells
at secondary sites [7–9]. Diffusible molecules such as cytokines or
chemokines (CXCL12, CCL2) play a seminal role in breast cancer
metastasis [10,11]. We reasoned that other small molecules such as
vasoactive peptides, either produced locally or released in the
blood flow, may trigger activating signals contributing in an
autocrine or paracrine manner to cancer cell extravasation,
colonization and metastasis.
Angiotensin II (AngII) is the biologically active peptide of the
renin-angiotensin system (RAS) involved in blood pressure control,
tissue remodeling and angiogenesis as well as in vascular and
inflammatory pathologies. Of interest, major functions attributed
to AngII (inflammation, angiogenesis and migration) are also
related to cancer progression [12,13]. Most components of the
RAS including angiotensinogen, angiotensin converting enzyme
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35667
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(ACE) and angiotensin receptors are expressed locally in a wide
variety of tumors, including in breast tumors [13–15]. Local
production of AngII in gastric cancer has been shown to facilitate
tumor progression and lymph node metastasis [16,17]. Further-
more, blockers of the RAS (either ACE inhibitors or angiotensin
receptor blockers ARBs) were shown to efficiently reduce tumor
growth, angiogenesis and metastasis in mouse experimental
models in vivo [12,13,18,19]. However, anti-metastatic properties
of RAS inhibitors were mainly associated with effects on the host
microenvironment, including infiltration of tumor-associated
macrophages or tumor-related angiogenesis [20,21], and to date
there has been no report on potential metastatic effects of AngII
through direct cancer cell activation.
In this study, we aimed to investigate whether AngII may act
directly on tumor cells to modify their metastatic properties. We
demonstrate that pre-treatment of breast cancer cells by AngII
triggers rapid development of metastatic foci at secondary sites in
an experimental mouse model in vivo and potentiates cancer cell
motility and transendothelial migration.
Results
Angiotensin II accelerates the development of
metastases in vivo
An experimental mouse model of cancer metastasis was
developed to investigate the effects of AngII on the metastatic
potential of breast cancer cells in vivo. Highly metastatic human
breast cancer cells D3H2LN (an in vivo-selected subclone of MDA-
MB-231 cells expressing luciferase [22]) were exposed to AngII
(100 nM) for 24 hrs (or vehicle for control group) and injected
intra-cardiacally into the bloodstream of nude mice in order to
recapitulate the late and essential steps of cancer metastasis, i.e.
extravasation and colonization [22,23]. Such strategy allowed us
to evaluate the effects of AngII on cancer cells while avoiding any
direct effect of the peptide on the host microenvironment.
The establishment of tumor micrometastases in various organs
was evaluated every two days by intravital bioluminescent imaging
on anesthetized animals. Fourteen mice injected with AngII-
treated cells were compared to 15 control mice, in two
independent experiments. As shown in Fig. 1A, mice from both
groups showed detectable micrometastases as early as day 7 post-
injection and all of them harbored metastases at day 19,
illustrating high aggressiveness of the D3H2LN cell line. However,
tumor cells exposed to AngII acquired a more aggressive behavior,
showing at least one metastatic site in 50% (7/14) of the animals at
day 7 as compared to 26,7% (4/15) of control mice. At day 9 of
the experiment, 86% (12/14) of the mice that received AngII-
treated cells presented at least one detectable metastatic nodule,
compared to 40% (6/15) for control mice (Fig. 1A). Notably,
AngII pre-treatment not only increased the percentage of mice
with metastasis, but also increased the number of detectable
metastatic foci per mouse (Fig. 1B) as well as the total number of
tumor cells disseminated in the whole body, as assessed by
quantification of bioluminescence (Fig. 1C). Ex-vivo analysis of
bioluminescence in isolated organs (not shown) and subsequent
histological analysis (Fig. 1D) on the last day of the experiment
confirmed the presence of tumor cells in the brain, lung and bone
samples that had been identified as luciferase-positive in the whole
animal.
The most significant differences between AngII-pretreated and
control groups were observed shortly after cell injection, as
illustrated by pictures of 5 representative mice taken at (Fig. 1E).
Indeed, breast cancer cells treated with AngII developed three
times more metastatic foci per mouse at day 9 compared to
control cells (Fig. 1B, Fig. S1A). In agreement, the number of
disseminated cancer cells was significantly increased in the AngII-
treated group as compared to control (median 1.155 and
0.5256106 of photons/s respectively, at day 9 post-injection)
(Fig. 1C, Fig. S1B). Our results thus indicate that invasive
D3H2LN breast cancer cells exposed to AngII show increased
metastatic potential in vivo and are more prone to rapidly establish
at distant organs.
Angiotensin II increases breast cancer cell adhesion and
migration
Metastatic dissemination of circulating cancer cells involves
several sequential steps, among which tumor cell adhesion to the
vascular endothelium, migration across the endothelial barrier and
subsequent invasion across the extracellular matrix to reach a
secondary site. In order to evaluate the consequences of AngII
activation on cancer cell adhesion and migration, the properties of
MDA-MB-231 and D3H2LN breast cancer cells were analyzed in
vitro following pre-treatment with AngII. As shown in Fig. 2A,
AngII stimulation for 24 hrs significantly increased (1.7 fold) the
adhesion of cancer cells to a monolayer of human endothelial cells.
Cancer cell adhesion following AngII stimulation was also
increased (2 fold) when endothelial cells were pre-activated for
24 hrs with pro-inflammatory cytokines (IFNc and TNFa). To
note, short-term exposure (30 min or 6 hrs) of breast cancer cells
to AngII was not sufficient to promote increased adhesion to the
endothelial monolayer (data not shown), suggesting that AngII-
increased cancer cell adhesion may involve transcriptional
regulation of target genes rather than activation of intracellular
trafficking or signaling pathways – that generally occur within
minutes.
We next evaluated the effects of AngII on breast cancer cell
migration. As shown in Fig. 2B, pre-treatment of breast cancer
cells with AngII for 24 hrs significantly increased (1.5 fold) their
ability to migrate in Boyden chamber assays using FCS as
chemoattractant. Similar results were obtained in invasion assays
using filters coated with matrigelH that mimics the extracellular
matrix (Fig. 2C). The pro-migratory effects of AngII on breast
cancer cells were further confirmed in wound healing assays
(Fig. 2D, E) showing significant increase (1.64 fold) in cell
migration and wound closure at 16 hrs following pre-treatment
with AngII. To note, AngII-pre-treatment had no significant effect
on cell proliferation (Fig. S2), ruling out the possibility that
increased cell number may account for increased wound closure.
Finally, exposure of breast cancer cells to AngII induced a 2.7 fold-
increase in trans-endothelial migration, i.e. the ability to migrate
through a monolayer of human endothelial cells (Fig. 2F), which is
a hallmark of cancer cell extravasation in vitro.
Thus, AngII contributes to each step of breast cancer cell
extravasation including tumor cell adhesion to endothelial cells,
motility, invasion and trans-endothelial migration.
Angiotensin II regulates a panel of connected target
genes
To get further insight into the mechanisms by which AngII
increases breast cancer cell migration and metastasis, we searched
for downstream molecular targets that may be regulated following
exposure of MDA-MB-231 cells to AngII for 24 hrs. Comparative
DNA microarray (Affymetrix U133A) studies revealed a panel of
123 differentially expressed genes (more than 1.4-fold, p,0.05).
Among those, 102 genes (63 up-regulated and 39 down-regulated)
were associated with known functions (Tables S1 and S2)
including cell proliferation and apoptosis (32%), cell adhesion
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and migration (27%) and inflammation (18%) (Table S3).
Accordingly, these genes were found to contribute to intracellular
protein kinase pathways (21%) or small GTPase signaling (17%)
(Table S4). Of interest, a large number of differentially regulated
genes (25%) were also related to cell metabolism, a finding that
opens new areas of investigation regarding the effects of AngII in
cancer cells.
Except for one up-regulated gene (encoding anti-apoptotic
molecule ATAD3A), differential regulation by AngII at 24 hrs did
not exceed a factor of 3 (Table S1), suggesting that AngII may
induce fine-tuned modulation of a wide number of genes involved
in various signaling pathways, rather than strong activation or
inhibition of a restricted set of specific genes. Ingenuity Pathway
Analysis (IPA) software revealed a network of genes centered
around angiotensinogen (AGT), the precursor of AngII (Fig. 3A).
Remarkably, two main groups of regulated genes could be
distinguished, one being related to MAP kinase (MAPK1) a major
effector of cell proliferation and inflammation (comprising
MAPK1, MAP2K7, MKNK2, PAWR, ARHGEF12, IGF1R,
RASGRF1 and DOK1), the other one being connected to matrix
metalloproteases MMP2 and MMP9 (also comprising ICAM1,
ITGB2, BSG, CDKN1, ANAPC10, SMAD2, RASGRF1 and
DOK1), well-known mediators of cell invasion and matrix
remodeling (Fig. 3A). Notably, RASGFR1 and DOK1 belong to
both groups of connected genes.
To note, microarray studies indeed revealed an increase in
MMP2 and MMP9 expression levels in response to AngII
stimulation, although results did not reach significance due to
heterogeneity of probesets hybridization. The pivotal position of
these genes within the network of AngII-regulated targets
prompted us to further investigate their differential expression by
RT-PCR. As shown in Fig. 3B and 3C, AngII dose-dependently
increases the mRNA levels of MMP2 (2-fold) and MMP9 (3-fold)
but not MMP3 nor MMP1 (not shown). Lipopolysaccharide (LPS),
as well-known potent inducer of MMPs expression and activity,
was used as a positive control for AngII efficiency. Dose-dependent
activation of MMP9 enzymatic (gelatinase) activity, reaching a 2-
fold increase at 100 nM AngII, was further confirmed by
zymography analysis (Fig. 3D). Of interest, Intercellular Adhesion
Molecule (ICAM-1), a major player in cell-cell adhesion and trans-
endothelial migration, also stands at the crossroad between AGT,
MMPs and integrins (Fig. 3A). In agreement with gene array
studies showing up-regulation of ICAM-1 mRNA (1.48 fold) by
AngII (Table S1), FACS analyses (Fig. 3E) further confirmed up-
regulation (1.8-fold) of ICAM-1 protein levels at the plasma
Figure 1. AngII increases the time-course, incidence and number of metastases in an experimental model in vivo. (A). Percentage of
mice showing at least one detectable metastasis over time after intracardiac injection of D3H2LN cells treated with AngII (red dotted line, n = 14) or
vehicle (black line, n = 15). (B). Number of metastases per mouse at indicated days. Results are mean +/2 SEM of 15 control (white bar) and 14 AngII-
treated (black bar) groups. (C). Number of photons/s per mouse at indicated days. Results are expressed as in B. (D). Histological analysis of
metastases developing at the brain (left panel), the lung (middle panel) and the bone (right panel), obtained from 3 mm sections of formalin-fixed,
paraffin-embedded tissue blocks stained with hematoxylin/eosin. Arrows indicate tumor cells. Magnification, 200x. (E). Representative pictures of 5
mice taken at day 9 after injection of control cells (upper panel) or AngII-treated cells (lower panel). * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0035667.g001
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membrane of MDA-MB-231 cells following 24 hrs treatment with
AngII.
Discussion
Pro-metastatic effects of AngII in various experimental models
in vivo have been attributed to its actions on the host
microenvironment [12,13,20,21]. We show here for the first time
that direct exposure of breast cancer cells to AngII contributes to
increased tumor-endothelial cell adhesion, trans-endothelial mi-
gration and motility, and accelerates metastatic progression in an
experimental mouse model in vivo. AngII is a potent vasoactive
peptide that can be both released in the bloodstream and
generated locally by endothelial, stromal and/or cancer cells.
We propose that autocrine or paracrine effects of AngII, either
present in the circulation or in the microenvironment of secondary
tissue, may trigger an activating signal facilitating the dissemina-
tion and establishment of micrometastases in target organs.
Cancer cell extravasation and metastatic colonization are rate-
limiting steps that involve reciprocal interactions between tumor
cells and the host stroma [24]. Extravasation requires cancer-
endothelial cell adhesion and subsequent trans-endothelial migra-
tion. Colonization in turn necessitates remodeling of the
extracellular matrix to invade and adapt to the new microenvi-
ronment [25], as well as activation of pro-survival pathways that
allow maintenance of cancer cells and their growth as microme-
tastases [24,26]. Data presented here provide evidence that AngII
transcriptionally modulates a wide range of coordinated genes that
contribute to cell adhesion/migration and proliferation/survival
through connection to matrix metalloprotease and MAP kinase
pathways, respectively. These observations are in support of the
functional studies reported here and suggest that AngII may
contribute to both extravasation and colonization of metastatic
breast cancer cells.
At the molecular level, previous studies have extensively
documented AngII-mediated regulation of MAP kinase pathways
in various cell types, in relation with mitogenic and anti-apoptotic
effects of the peptide [27]. We show here that AngII up-regulates
MMP2 and MMP9 gene expression and enzymatic activity in
breast cancer cells, in agreement with studies conducted in the
gastric cancer cell line MNK-28 [28]. Notably, we also report here
that AngII up-regulates the expression of Intercellular Adhesion
Molecule ICAM-1 at the mRNA and protein level. ICAM-1 is
well-known to trigger leukocyte adhesion to the endothelium and
Figure 2. AngII increases breast cancer cell adhesion and migration. (A). MDA-MB-231 breast cancer cell adhesion to HCMEC/D3 endothelial
cells monolayer following exposure of cancer cells to AngII (100 nM) for 24 hrs. Results are means +/2 SEM of 7 independent experiments performed
in quadruplicate, and expressed as fold increase of untreated cells (control, Ctrl). *p,0.05. (B, C). Boyden chamber assays of tumor cell migration
across 8 mm-pore filters either non coated (B) or coated with matrigel to mimic cell invasion (C). Results are means +/2 SEM of 3 separate
experiments performed in triplicate, and expressed as fold increase of control. *p,0.05. (D, E). Wound healing assay. Results are from 2 independent
experiments performed in quintuplicate, and expressed as fold increase of wound closure at time 16 hrs (T16) compared to control (vehicle-treated
cells). *p,0.05. (E). Representative pictures of wounds from control and AngII-treated cells (100 nM, 24 hrs) at T0 and T16. Magnification, 100x. (F).
Trans-endothelial migration. Results are mean +/2 SEM of 3 independent experiments performed in triplicate, and expressed as fold increase of
control. *p,0.05.
doi:10.1371/journal.pone.0035667.g002
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subsequent diapedesis, and its expression in endothelial cells has
been shown to be increased by AngII in inflammatory situations
[29]. Our results show for the first time that ICAM-1 is up-
regulated in breast tumor cells in response to AngII treatment.
Relevance of this finding to human disease is supported by a
recent report showing that increased levels of ICAM-1 in breast
tumors are associated with a more aggressive phenotype [30], and
by studies highlighting the importance of vascular cell adhesion
molecules in the establishment of breast cancer cells at the
secondary site [31]. Other genes encoding adhesion molecules
Figure 3. AngII transcriptionally regulates a panel of connected genes. (A). Gene networks differentially regulated by AngII. Up- and down-
regulated genes related to angiotensinogen (AGT) are indicated in red and green, respectively. Filled lines indicate direct interactions, filled and
dashed arrows indicate direct and indirect regulations, respectively. Note two groups of connected genes centered around MAPK1 and MMP2/9,
respectively. (B). RT-PCR analysis of MMP9, MMP2 and MMP3 mRNA expression in MDA-MB-231 cells treated for 24 hrs with increasing doses of AngII
as indicated, or LPS (Lipopolysaccharide, 100 ng/ml) as a positive control. GAPDH amplification was used as internal control. Shown is one out of 3 to
5 independent experiments performed in duplicate. (C). Quantification (Image J software) of PCR amplification of MMP9, MMP2 and MMP3 relative to
GAPDH and normalized to expression levels in cells treated with 1 nM AngII. (D). Gelatin-based zymography analysis of MMP9 activity in conditioned
medium of cells treated as in B. Shown is one representative out of 3 independent experiments (Upper panel). Quantification (ImageJ software) of
results normalized to the quantity of proteins in cell lysate and expressed relative to control (lower panel). (E). FACS analysis of ICAM-1 expression at
the plasma membrane of MDA-MB-231 cells treated with AngII (100 nM) or vehicle for 24 hrs. Results are means +/2 SEM of 3 independent
experiments and expressed as fold-increase of the control. **p,0.01.
doi:10.1371/journal.pone.0035667.g003
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(ITGB2) or metabolic pathways (FUT4) were also significantly up-
regulated by AngII (1.5 and 1.7 fold, respectively) (Table S1). Of
interest, FUT4 encodes fucosyltransferase which is involved in the
synthesis of sialyl-Lewis X, a well-known ligand of selectins
adhesion molecules, suggesting an indirect effect of AngII on the
selectin–selectin ligand axis.
We propose here a model in which direct stimulation of
circulating cancer cells by locally-produced AngII may regulate a
set of genes that ultimately influence the host microenvironment to
facilitate cancer cell extravasation, adaptation to the soil and
subsequent metastatic colonization. This model supports the
notion that targeting AngII production or action using ACE
inhibitors or ARBs, respectively, may represent an interesting
therapeutic option to prevent metastatic progression of invasive
breast tumors. In patients however, the question of whether RAS
blockers may have beneficial effects in cancer remains contradic-
tory [12,13,32–35], a finding that might reflect tumor heteroge-
neity in terms of RAS expression and local levels of AngII
production. Future prospective studies analyzing expression of
RAS components and AngII production in breast cancer may lead
to the identification of a subpopulation of tumors that respond to
ACE inhibitors and/or ARBs. Such agents being largely used in
the clinics as antihypertensive agents with mild side effects may
constitute a major breakthrough for personalized therapy of
metastatic breast tumors.
Materials and Methods
Cell lines
MDA-MB-231-Luc-D3H2LN luciferase-positive breast cancer
cells (referred here as D3H2LN) were obtained from Caliper Life
Science (Xenogen, MA, USA) and grown as described previously
[23]. These cells were derived from a spontaneous lymph node
metastasis of the MDA-MB-231 adenocarcinoma cell line
expressing luciferase, as described [22]. Metastatic MDA-MB-
231 breast tumor cells were obtained and grown as described
previously [36]. Human vascular endothelial HCMEC/D3 cells
were immortalized from brain microcapillaries and grown as
described [37].
Animal studies
Intracardiac experimental mouse model of metastasis in vivo was
conducted as described [22,23]. Briefly, female nude mice of 8–
0 weeks (Janvier, France) were anesthetized by intraperitoneal
injection of 120 mg/kg ketamine and 6 mg/kg xylazine. D3H2LN
cells expressing luciferase were pre-treated with 100 nM AngII
(Sigma, France) or vehicle in serum-free medium for 24 hrs prior
to injection (100.000 cells in 100 ml sterile PBS) into the left
ventricle of the heart by non surgical means. Anesthetized mice
were placed in the IVISTM Imaging System (Xenogen, Caliper
Life Science, MA, USA) and imaged from both dorsal and ventral
views five minutes after intraperitoneal injection of D-luciferin
(Caliper Life Science). A successful intracardiac injection was
indicated on day 0 by systemic bioluminescence distributed
throughout the animal. Only mice with evidence of successful
injection were included in the experiment. Assessment of
subsequent metastasis was monitored by imaging using the
IVISTM Imaging System (Caliper Life Science), every 3–4 days
for up to 24 days on mice anesthetized by exposure to 1–3%
isoflurane. Experiments were carried out with the approval of the
De´partement d’Expe´rimentation Animale, Institut d’He´matologie,
Hoˆpital St-Louis ethical committee, and were performed twice on
7 to 8 mice per group.
For ex-vivo analysis, organs highlighted by bioluminescence in
whole mice were removed surgically after sacrifice of the animals
and rapidly incubated with D-luciferin before imaging using the
IVIS system. For histological analyses, sections (3 mm) of
metastatic organs were cut from formalin-fixed, paraffin-embed-
ded tissue blocks, counterstained with hematoxylin-eosin and
examined under an inverted microscope.
Tumor cell adhesion to endothelial cells and trans-
endothelial migration
For endothelial cell adhesion assay, tumor cells were pre-treated
with AngII (100 nM) or vehicle in serum-free medium for 24 hrs
prior to labeling using green fluorescent cell tracker CMFDA
(Molecular Probes) as recommended by the manufacturer.
Fluorescent tumor cells (100.000/well of 96-well plates) were
added for 30 min at 37uC to a monolayer of human endothelial
cells (HCMEC/D3) either left untreated or pre-treated for 24 hrs
with pro-inflammatory cytokines IFNc (200 U/ml) and TNFa
(100 U/ml). After extensive washing, adherent cells were lysed in
water and tumor cells were quantified in a fluorescent microplate
reader at wavelength 485/530 nm. Experiments were performed
in quadruplicate.
For trans-endothelial migration assay, endothelial HCMEC/D3
cells (20.000/well) were plated on collagen type I-coated Transwell
filters (8 mm pore filter) and grown to confluence. Serum starved
MDA-MB-231 cells (100.000/well) were pre-treated for 24 hrs
with AngII (100 nM) or vehicle prior to labeling with CMFDA cell
tracker as described before. Fluorescent tumor cells were added to
the endothelial monolayer in the presence of chemokine CXCL12
(100 ng/ml) in the lower compartment. After 24 hrs, cells
remaining in the upper chamber were removed with a cotton
swab and tumor cells having migrated through the endothelial
monolayer to the lower face of the filter were lysed with water and
quantified in a fluorescent microplate reader at wavelength 485/
530 nm. Experiments were performed in triplicate.
Cell migration
For Boyden chamber assays of cell migration, MDA-MB-231
cells (200.000/well) were pre-treated for 24 hrs with AngII
(100 nM) or vehicle and were then seeded on the upper chamber
of 8 mm-Transwell filters (Corning, NY, USA) either coated or not
with 10 mg/ml matrigel (BD Biosciences), and allowed to migrate
for 18 hrs in the presence of 10% FCS in the lower compartment.
Cells migrating to the lower face of the filters were fixed in
methanol, stained with crystal violet and counted under an
inverted microscope. Experiments were performed in triplicate.
For wound healing assays, D3H2LN cells were pre-treated for
24 hrs with AngII (100 nM) or vehicle and were then grown to
confluence in 24-well plates before cross-shape wounds were
performed in the monolayer using a sterile 10 ml pipette tip.
Wounds were registered by phase contrast microscopy immedi-
ately after scratching (T0) and after 16 hrs in serum-free medium
(T16), and quantified using ImageJ software (http://rsb.info.nhi.
gov/ij/). For each condition the ratio of wound closure at T16
relative to T0 was calculated.
Gene array studies
Total RNA from MDA-MB-231 cells treated for 24 hrs with
AngII (100 nM) or vehicle, was extracted using Trizol (Invitrogen)
and analyzed with the Affymetrix Human Genome U133 Plus 2.0
Gene Chips (a genome wide array with 54674 probe sets targeting
19418 transcripts) as described [38]. Gene expression levels were
normalized using the GC-RMA algorithm and flags were
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computed using MAS5. Quality assessment of the chips was
performed with affyQCReport R package (R project for Statistical
Computing [http://www.r-project.org/]). Each data set was
derived from triplicates of biologically independent samples and
compared using Student’s t test. To estimate the false discovery
rate the resulting p values were filtered at 5%. Microarray
experiments were performed according to the MIAME consor-
tium guidelines. Data have been submitted to MIAMEarray
express under accession number E-MEXP-3470 and the release
date is 2012-12-05. Data were submitted to Ingenuity Pathway
Analysis (IPA) to model relationships among genes and proteins
and to construct putative pathways and relevant biological
processes (http://www.ingenuity.com).
RT-PCR analysis
Total RNA was extracted from MDA-MB-231 cells treated as
indicated, and cDNA was reverse-transcribed using oligo-dT and
superscript RT (Invitrogen) as recommended by the manufacturer.
PCR amplification (35 cycles, annealing temperature 55uC) was
performed on 25 ng cDNA using oligonucleotide primers as
follows: MMP9-F 59AAG TAC TGG CGA TTC TCT GAG
GG;MMP9-R 59GGC TTT CTC TCG GTA CTG GAA GAC;
MMP2-F 59TTT TCT CGA ATC CAT GAT GG; MMP2-R
59CTG GTG CAG CTC TCA TAT TT; MMP3-F 59CCT
GCT TTG TCC TTT GAT GC; MMP3-R 59TGA GTC AAT
CCC TGG AAA GTC; GAPDH-F 59GGA GAA GGC TGG
GGC; GAPDH-R 59GAT GGC ATG GAC TGT GG.
FACS analysis
MDA-MB-231 cells were treated for 24 hrs with AngII
(100 nM) or vehicle and harvested in 1mM EDTA. Expression
levels of ICAM-1 at the cell membrane were evaluated by FACS
analysis using Cytomics TM FC500 (Beckman Coulter) after
labeling with anti-ICAM-1 antibodies (R&D system).
Gelatin zymography
For analysis of metalloprotease enzymatic activity, conditioned
medium of MDA-MB-231 cells treated for 24 hrs with increasing
concentrations of AngII, or lipopolysaccharide (LPS, 100 ng/ml)
as positive control, were collected and loaded on gelatin (1 mg/
ml)-containing SDS-PAGE run at 4uC (zymography gels) as
described [23]. MMP9 activity was visualised as a clear band at
90 kDa after coomassie blue coloration, and quantified using
ImageJ software.
Statistical analysis
Statistical analyses were conducted using JMP-7 software. Data
in bar graphs (mean +/2 SEM) were analyzed using Student’s t-
test. p,0.05 was considered statistically significant.
Supporting Information
Figure S1 (A). Quantification of the number of metastases per
mouse at day 9. Shown are pooled results from 2 independent
experiments, black squares and black triangles representing
control (n = 15) and AngII-treated (n= 14) mice, respectively.
(B). Quantification of the number of photons/s per mouse at
day 9. Results are expressed as in (A). * p,0.05, ***p,0.001.
(TIF)
Figure S2 MTT assay of D3H2LN cells proliferation
following 24 hrs- pre-treatment with AngII (100 nM) or
vehicle. Shown is one representative experiment out of 3
performed in quadruplicate.
(TIF)
Table S1 Shown are the 63 genes up-regulated by AngII
(100 nM, 24 hrs) by 1.4-fold or more (p,0.05). The genes
are listed in alphabetical order, together with their main
characteristics and known functions (description/ Gene pathway/
function column), differential regulation by AngII (fold column)
and p value. (a): Genes connected to Angiotensinogen pathway
AGT (as illustrated in Figure 3A) are indicated by an asterisk *.
(DOC)
Table S2 Shown are the 39 genes down-regulated by
AngII (100 nM, 24 hrs) by 1.4-fold or more (p,0.05). The
genes are listed in alphabetical order as indicated in Table S1. (a):
Genes connected to Angiotensinogen pathway AGT (as illustrated
in Figure 3A) are indicated by an asterisk *.
(DOC)
Table S3 Genes regulated by AngII are classified
according to their major functions namely Inflamma-
tion, Cell Proliferation and Apoptosis, Adhesion and
Migration, Metabolism. Genes with others functions appear
in the ‘‘others’’ section. Number of genes is indicated under
parenthesis. Up-regulated genes are indicated in bold whereas
down-regulated genes are indicated in standard font.
(DOC)
Table S4 Genes regulated by AngII are organized in
four major pathways related to protein kinase signaling,
small GTPases, Ubiquitin/proteasome and intracellular
traffic. Number of genes is indicated under parenthesis. Up-
regulated genes are indicated in bold whereas down-regulated
genes are indicated in standard font.
(DOC)
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Supplemental Table S1. List of genes up-regulated by AngII in MDA-MB-231 cells. 
Gene 
Symbol(a) Gene Name  Description / Gene pathway / Function fold 
p 
value 
ABCC10 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 10 
Transporter, Drug resistance, Metabolism 1.55 0.035 
AKT1S1 AKT1 substrate 1 (proline-rich) Protein kinase signaling, Apoptosis 2.15 0.025 
ALDH3B1 Aldehyde dehydrogenase 3 family, member B1 Enzyme, Metabolism, Inflammation 1.57 0.021 
ALS2CL ALS2 C-terminal like Exchange factor, Small GTPase signaling, Proliferation, Intracellular 
traffic 
2.02 0.044 
ARFGAP1* ADP-ribosylation factor GTPase activating 
protein 1 
Exchange factor, Small GTPase signaling, Intracellular traffic, Cell 
Adhesion/Migration 
1.60 0.022 
ARHGEF12* Rho guanine nucleotide exchange factor (GEF) 
12 
Exchange factor, Small GTPase signaling, Metabolism, Cell 
Adhesion/Migration 
3.03 0.034 
ARPC4 Actin related protein 2/3 complex, subunit 4 Actin binding protein, Small GTPase signaling, Intracellular traffic 
Cell Adhesion/Migration 
1.51 0.027 
ARRDC1 Arrestin domain containing 1 Arrestin-related trafficking, Cell Adhesion/Migration 1.82 0.041 
ATAD3A ATPase family, AAA domain containing 3A ATP binding protein, Apoptosis 4.55 0.032 
ATXN7L3 Ataxin 7-like 3 Zn finger, Trancriptional regulator, Histone ubiquitination 1.48 0.045 
BSG* Basigin (EMMPRIN) Receptor, Protein kinase signaling, Cell Adhesion/Migration, 
Inflammation, Metabolism 
1.81 0.042 
CARD10 Caspase recruitment domain family, member 10 Guanylate kinase family member, Protein kinase signaling, Cell 
Growth and Apoptosis, Cell Adhesion/Migration 
1.55 0.035 
CDKN1C* Cyclin-dependent kinase inhibitor 1C (p57, 
Kip2) 
Kinase, Proliferation, Actin dynamics, Neuronal differentiation, 
Tumor invasion and metastasis 
1.50 0.017 
CYB5R2 Cytochrome b5 reductase 2 Enzyme, NADH redox activity, Metabolism 1.81 0.015 
DDA1 DET1 and DDB1 associated 1 Autophagy, Ubiquitination, Tumor invasion and Metastasis 1.61 0.048 
DLGAP4 Discs, large (Drosophila) homolog-associated 
protein 4 
Guanylate kinase, Receptor interacting protein 1.44 0.040 
DOK1* Docking protein (downstream of tyrosine kinase 
1) 
Scaffold protein, Receptor tyrosine kinase signaling, Proliferation, 
Cell Adhesion/Migration 
2.06 0.004 
DOLK Dolichol kinase Kinase, Glycosylation, Metabolism 1.55 0.040 
EFNB3 Ephrin-B3 Receptor tyrosine kinase, Small GTPase and Protein kinase 
signaling, Cell Growth and Apoptosis, Cell Adhesion/Migration 
1.43 0.047 
EIF5A Eukaryotic translation initiation factor 5A Translation factor, Cell Growth and Apoptosis, Metabolism, Cell 
Adhesion/Migration 
1.73 0.048 
FBXL19 F-box and leucine-rich repeat protein 19 Enzyme, F-Box protein family, Ubiquitin/Proteasome pathway 2.04 0.037 
FMNL3 Formin-like 3 Actin binding protein, Small GTPase signaling, Cell 
Adhesion/Migration 
1.48 0.049 
FRMD4A FERM domain containing 4A Actin interacting domain, Small GTPase signaling, Actin dynamics, 
Epithelial polarity, Cell Adhesion/Migration 
1.43 0.027 
FUT4 Fucosyltransferase 4 (alpha (1,3), myeloid-
specific) 
Enzyme, Protein kinase signaling, Selectin-related interactions, Cell 
Adhesion/Migration, Inflammation, Metabolism  
1.82 0.043 
GNG7 Guanine nucleotide binding protein (G protein), 
gamma 7 
Protein G gamma subunit, GPCR signalling, Cell Growth 1.62 0.011 
HMG20B High-mobility group 20B Transcription regulator, DNA binding, BRCA2 interaction 1.87 0.018 
ICAM1* Intercellular adhesion molecule 1 Transmembrane cell adhesion molecule, Inflammation, Cell 
Adhesion/Migration 
1.43 0.050 
IGF1R* Insulin-like growth factor 1 receptor 
 
Receptor, Protein kinase signaling, Cell Growth and Apoptosis, 
Inflammation 
1.71 0.050 
IL17RA Interleukin 17 receptor A Receptor, Protein kinase signaling, Inflammation  1.60 0.047 
ITGB2* Integrin, beta 2 (complement component 3 
receptor 3 and 4 subunit) 
Receptor, Small GTPase signaling, Inflammation, Cell 
Adhesion/Migration 
1.50 0.032 
KDELR1* KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 1 
Receptor/Transporter, Protein kinase signaling, Small GTPase 
signaling, Intracellular traffic, ER stress response 
1.85 0.030 
MAN1B1 Mannosidase, alpha, class 1B, member 1 Enzyme, Metabolism, Intracellular traffic, Proteasome pathway  1.89 0.046 
MAP2K7* Mitogen-activated protein kinase kinase 7 Kinase, Protein kinase signaling, Cell Growth and Apoptosis, 
Inflammation 
 
 
 
 
MAP4K2 Mitogen-activated protein kinase kinase kinase 
kinase 2 
Kinase, Protein kinase signaling, Inflammation 2.20 0.046 
MKNK2* MAP kinase interacting serine/threonine kinase 
2 
Calcium/calmodulin dependent Protein kinase signaling,Translation, 
Metabolism, Cell Proliferation, Inflammation, Proteasome pathway 
1.89 0.022 
MRPS18A Mitochondrial ribosomal protein S18A Mitochondrial, ribosomal, Protein synthesis 1.77 0.040 
MYH11 Myosin, heavy chain 11, smooth muscle Actin binding protein, TGFbeta pathway, Motor activity, Cell 
Proliferation, Cell Adhesion/Migration  
1.66 0.024 
MYO1C* Myosin IC Actin based molecular motor, Cell Proliferation, Intracellular traffic, 
Cell Adhesion/Migration 
1.49 0.036 
NAT8L N-acetyltransferase 8-like (GCN5-related, 
putative) 
Enzyme, Nacetyl methyltransferase superfamily, Membrane-bound 
protein, neuron-specific, Metabolism 
1.74 0.045 
NEK8 NIMA (never in mitosis gene a)- related kinase 
8 
Kinase, Cell Cycle progression, Cell proliferation, Ciliogenesis 1.60 0.042 
OTUD5 OTU domain containing 5 Cysteine protease, Deubiquitinase, Innate immune response, 
Inflammation, Proteasome pathway 
1.55 0.046 
PCGF1 Polycomb group ring finger 1 Transcriptional regulator, Development, Ubiquitin/Proteasome 
pathway 
1.51 0.036 
PCTK1 PCTAIRE protein kinase 1 Cyclin dependent kinase Cdk16, Protein kinase signaling, 
Intracellular traffic, Exocytosis 
1.56 0.029 
PRIC285 Peroxisomal proliferator-activated receptor A 
interacting complex 285 
Zinc finger, Transcription regulator, DNA helicase, Metabolism, 
Inflammation 
1.56 0.004 
PYCR2 Pyrroline-5-carboxylate reductase family, 
member 2 
Enzyme, Metabolism  1.44 0.023 
RAB4B RAB4B, member RAS oncogene family Enzyme, Small GTPase signaling, Intracellular traffic, Glut4 
transport, Metabolism, Motility 
1.56 0.036 
RASGRF1* Ras protein-specific guanine nucleotide-
releasing factor 1 
Exchange factor, Small GTPase signaling, Protein kinase signaling, 
Cell Proliferation, Cell Adhesion/Migration 
2.90 0.001 
SEMA6B Sema domain, transmembrane domain (TM), 
and cytoplasmic domain, (semaphorin) 6B Transmembrane receptor, Axon guidance, Cell Adhesion/Migration 2.64 0.005 
SHB Src homology 2 domain containing adaptor 
protein B 
Adaptator protein, Protein kinase and Small GTPase signaling, Cell 
Growth and Apoptosis, Cell Adhesion/Migration, Inflammation 
1.50 0.026 
SIX2 SIX homeobox 2 Transcription factor, Cortisol Secretion, Metabolism 1.48 0.043 
SLC2A4RG SLC2A4 regulator Transcription factor, Glut4 enhancer, Metabolism 1.51 0.039 
SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 Small GTPase signaling, Neuronal Migration 2.03 0.047 
STX10 Syntaxin 10 SNAP receptor activity, Vesicular transport, Intracellular traffic 1.47 0.023 
TBC1D10A TBC1 domain family, member 10A Exchange factor, Small GTPase signaling, Intracellular traffic  1.83 0.020 
THRA Thyroid hormone receptor, alpha  Nuclear hormone receptor, Metabolism 1.51 0.022 
TNFRSF12A* Tumor necrosis factor receptor superfamily, 
member 12A 
Membrane receptor, Protein kinase signaling, Apoptosis, 
Inflammation 
1.86 0.045 
TRAF3IP2 TRAF3 interacting protein 2 TNF receptor pathway, Protein kinase signaling, Apoptosis, 
Inflammation, Proteasome pathway 
1.85 0.034 
TSPAN4 Tetraspanin 4 Transmembrane protein, Cell Growth and Apoptosis, Cell 
Adhesion/Migration 
1.98 0.034 
UBE2M Ubiquitin-conjugating enzyme E2M (UBC12 
homolog) 
Enzyme, Ubiquitin/Proteasome pathway, Cell Proliferation and 
Apoptosis 
1.78 0.032 
UBE2R2 Ubiquitin-conjugating enzyme E2R 2 Enzyme, Ubiquitin/Proteasome pathway, Cell Growth 1.50 0.024 
UBXN11 UBX domain protein 11 Small GTPase signaling, Cell Adhesion/Migration 
Ubiquitin/Proteasome pathway 
1.48 0.015 
VPS37D Vacuolar protein sorting 37 homolog D  Intracellular traffic  2.05 0.047 
WIZ Widely interspaced zinc finger motifs Zinc finger, Nuclear co-repressor, Histone methylation 2.06 0.025 
 
 
Supplemental Table S2. List of genes down-regulated by AngII in MDA-MB-231 cells. 
Gene  
Symbol (a) 
Gene Name Description / Gene pathway / Function fold p 
value 
ANAPC10* Anaphase promoting complex subunit 10 Enzyme, Cell Proliferation and Apoptosis, Ubiquitination  
 
-2.21 0.041 
ARL17 ADP-ribosylation factor-like 17 Metabolism -1.72 0.040 
B4GALT4 UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 4 
Enzyme, Membrane-bound protein, Metabolism 
 
-1.42 0.038 
BTBD3 BTB (POZ) domain containing 3 Interacts with PlexinB3 -1.42 0.035 
COG5 Component of oligomeric golgi complex 5 Transporter, Intracellular traffic -2.14 0.026 
DOCK5 Dedicator of cytokinesis 5 Exchange factor, Small GTPase signaling, Cell Adhesion/Migration -1.57 0.043 
DYRK2 Dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 2 
Kinase, Protein kinase signaling, Cell Proliferation,  -1.69 0.048 
EIF2S3 Eukaryotic translation initiation factor 2, subunit 3 
gamma, 52kDa 
Translation regulator, Protein synthesis, Cell Proliferation -2.08 0.024 
EXOC8 Exocyst complex component 8 Cell Adhesion/Migration, Intracellular traffic -1.52 0.032 
FBXO45 F-box protein 45 Ubiquitination -1.69 0.005 
FGFR1OP2 FGFR1 oncogene partner 2 Cell Proliferation, Cell Differentiation -1.75 0.045 
HCFC2 Host cell factor C2 Transcription regulator, Cell Proliferation -1.86 0.049 
IDH3A Isocitrate dehydrogenase 3 (NAD+) alpha Enzyme, Metabolism  -2.02 0.003 
IRAK3 Interleukin-1 receptor-associated kinase 3 Transmembrane receptor, Protein kinase signaling, Inflammation -1.81 0.037 
KIF1B Kinesin family member 1B Transporter, Intracellular traffic, Cell Adhesion/Migration -2.16 0.040 
KPNA1 Karyopherin alpha 1 (importin alpha 5) Transporter, Intracellular traffic, Inflammation -1.47 0.026 
MAP7D3 MAP7 domain containing 3 Microtubule associated protein 7, Cell Adhesion/Migration -2.51 0.029 
MAPK1* Mitogen-activated protein kinase 1 Kinase, Protein kinase signaling, Transcription regulation, Cell 
Proliferation 
-1.50 0.038 
MITF Microphthalmia-associated transcription factor Transcription factor, Cell differentiation, Cell Proliferation and 
Apoptosis 
-1.47 0.039 
MSRB2 Methionine sulfoxide reductase B2 Transcription regulator, Metabolism -1.76 0.021 
NDUFS1* NADH dehydrogenase (ubiquinone) Fe-S protein 
1, 75kDa (NADH-coenzyme Q reductase) 
Enzyme, Metabolism -1.39 0.013 
OSGEPL1 O-sialoglycoprotein endopeptidase-like 1 Enzyme, Metabolism -1.50 0.032 
PAG1 phosphoprotein associated with glycosphingolipid 
microdomains 1 
Transmembrane protein, Protein kinase signaling, Inflammation -1.66 0.038 
PAWR* PRKC, apoptosis, WT1, regulator Transcription regulator, Cell Proliferation and Apoptosis -1.99 0.011 
PTPN21 Protein tyrosine phosphatase, non-receptor type 
21 
Protein tyrosine phosphatase, Cell Proliferation and Apoptosis, Cell 
Differentiation 
-1.52 0.004 
RALB V-ral simian leukemia viral oncogene homolog B 
(ras related; GTP binding protein) 
Enzyme, Small GTPase signaling, Cell Proliferation and Apoptosis, 
Cell Adhesion/Migration 
-1.50 0.026 
RGS2* Regulator of G-protein signaling 2, 24kDa GTPase activating protein, Small GTPase signaling, Cell Proliferation 
and Apoptosis 
-1.49 0.023 
RNF144B Ring finger protein 144B Enzyme, Ubiquitination, Metabolism -1.46 0.009 
RTTN Rotatin Development  -1.90 0.015 
SFRS3 Splicing factor, arginine/serine-rich 3 Splicing factor, Gene expression -1.81 0.032 
SGMS2 Sphingomyelin synthase 2 Enzyme, Metabolism, Cell Growth and Apoptosis -1.50 0.045 
SLC40A1 Solute carrier family 40 (iron-regulated 
transporter), member 1 
Transporter, Metabolism -1.91 0.023 
SMAD2* SMAD family member 2 Transcription regulator, Cell Proliferation and Apoptosis -2.48 0.006 
SYNE1 Spectrin repeat containing, nuclear envelope 1 Nuclear membrane protein, Cytoskeletal anchoring, Differentiation, 
Cell Adhesion/Migration 
-2.70 0.013 
UBE2H Ubiquitin-conjugating enzyme E2H (UBC8 
homolog, yeast) Enzyme, Ubiquitination -1.77 0.025 
ZFP82 Zinc finger protein 82 homolog (mouse) Zinc finger protein,Transcription regulator -1.93 0.001 
ZNF354B Zinc finger protein 354B Zinc finger protein, Transcription regulator -2.36 0.041 
ZNF57 Zinc finger protein 57 Zinc finger protein, Transcription regulator  -2.24 0.022 
ZRANB1 Zinc finger, RAN-binding domain containing 1 Peptidase, Metabolism, Inflammation -1.40 0.034 
 
Supplemental Table S3: Genes regulated by AngII classified according to their functions 
 
 
 
Inflammation  
(18) 
ALDH3B1, BSG, FUT4, ICAM1, IGF1R, IL17RA, IRAK3, 
ITGB2, KPNA1, MAP2K7, MAP4K2, OTUD5, PAG1, 
PRIC285, SHB, TNFRSF12A, TRAF3IP2, ZRANB1 
Cell Proliferation and Apoptosis 
(32) 
AKT1S1, ALS2CL, ANAPC10, ATAD3A, CDKN1C, DOK1, 
DYRK2, EFNB3, EIF2S3, FGFR10P2, GNG7, HCFC2, IGF1R, 
MAPK1, MAP2K7, MITF, MYH11, MYOC1, NEK8, PAWR, 
PTPN21, RALB, RASGRF1, RGS2, SGMS2, SHB, SMAD2, 
TNFRSF12A, TRAF3IP2, TSPAN4, UBE2M, UBE2R2 
Adhesion and Migration 
(27) 
ARFGAP1, ARHGEF12, ARPC4, ARRDC1, BSG, DOK1, 
DOCK5, EXOC8, EFNB3, FMNL3, FRMD4A, FUT4, ICAM1, 
ITGB2, KIF1B, MAP7D3, MYH11, MYOC1, RAB4B, RALB, 
RASGRF1, SEMA6B, SHB, SRGAP1, SYNE1, TSPAN4, 
UBXN11 
Metabolism 
(25) 
ABCC10, ALDH3B1, ARHGEF12, ARL17, B4GALT4, BSG, 
CYBR5, DOLK, EIF5A, FUT4, IDH3A, MSRB2, NATL8, 
NDUFS1, OSGEPL1, PRIC285, PYCR2, RAB4B, RNF144B, 
SGMS2, SIX2, SLC2A4RG, SLC40A1, THRA, ZRANB1  
Others 
(23) 
ATXN7L3, BTBD3, COG5, DDA1, DLGAP4, FBXL19, 
FBX045, HMG20B, KDELR1, MAN1B1, MRPS18A, PCGF1, 
PCTK1, RTTN, SFRS3, STX10, TBC1D10A, UBE2H, 
VPS37D, WIZ, ZFP82, ZNFF354B, ZNF57 
Supplemental Table S4: Genes regulated by AngII classified according to their signaling 
pathways 
 
 
Protein Kinase Signaling  
(21) 
AKTS1, BSG, CARD10, DOK1, DYRK2, EFNB3, FUT4, 
IGF1R, IL17RA, IRAK3, KDELR1, MAPK1, MAP2K7, 
MAP4K2, MKNK2, PAG1, PCTK1, RASGRF1, SHB, 
TNFRSF12A, TRAF3IP2 
Small GTPase Signaling 
(18) 
ALS2CL, ARFGAP1, ARHGEF12, ARPC4, DOCK5, 
EFNB3, FMNL3, FRMD4A, ITGB2, KDELR1, RAB4B, 
RALB, RASGRF1, RGS2, SHB, SRGAP1, TBC1D10A, 
UBXN11 
Ubiquitin/Proteasome 
(13) 
ANAPC10, DDA1, FBXL19, FBXO45, MAN1B1, 
MKNK2, OTUD5, PCGF1, RNF144B, UBE2H, UBE2M, 
UBE2R2, UBXN11 
Intracellular Traffic 
(10) 
COG5, EXOC8, KDELR1, KIF1B, KPNA1, MAN1B1, 
PCTK1, RAB4B, STX10, VPS37D 

